sartorius stedim biotech group reference document 2013 order intake sale revenue underlying ebitda ebita million million 4099 4426 5002 5539 6149 752 859 996 1170 1356 4012 4329 4773 5440 5884 603 700 835 995 1142 700 160 600 120 500 80 400 40 300 0 2009 2010 2011 2012 2013 2009 2010 2011 20122 2013 order intake ebitda sale revenue ebita key figure figure given million according ifrs 20131 20121 20111 20102 20092 unless otherwise specified oder intake sale revenue earnings order intake 61491 55391 50021 44261 40991 1 1 1 1 sale revenue 5884 5440 4773 4329 40121 13 1 2 1 1 underlying ebitda 1356 1170 996 859 7521 13 1 2 1 1 underlying ebitda sale revenue 230 215 209 198 1871 13 1 2 1 1 underlying ebita 1142 995 835 700 6031 13 1 2 1 1 underlying ebita sale revenue 194 183 175 162 1501 1 2 1 1 ebit 1013 856 712 599 4861 1 2 1 1 ebit sale revenue 172 157 149 138 1211 1 1 1 1 net profit noncontrolling interest 663 568 431 385 2911 14 3 1 1 1 1 group net profit noncontrolling interest 752 646 534 452 3471 research development cost 3601 3182 2861 2781 2451 financial data per share earnings per share 4321 3701 2811 2391 1711 earnings per share 14 4901 4211 3491 2811 2041 dividend per share 1205 1101 1001 0906 0606 balance sheet balance sheet total 87121 79391 72081 65631 66791 equity 48181 43501 39561 36511 39321 equity ratio 5531 5481 5491 5561 5891 gearing ratio 031 031 031 031 021 financials capital expenditure excluding financial asset goodwill 3421 5001 3861 1671 1571 1 1 1 1 sale revenue 58 92 81 39 391 1 1 1 1 depreciation amortization 306 259 245 230 2271 1 1 1 1 net cash flow operating activity 901 489 606 728 9191 1 1 1 1 net debt 1300 1137 1001 1028 8761 13 1 1 1 1 ratio net debt underlying ebitda 10 10 10 12 121 total number employee december 31 32896 29861 28581 25811 23811 1 adjusted extraordinary item 2 restated see note financial statement pp 102 103 3 information ebitda ebita net profit underlying presentation please refer group business development chapter glossary 4 excluding amortization linked business combination 2011 2013 excluding fair value adjustment hedging instrument 5 amount suggested board director conseil dadministration subject approval annual general shareholder meeting 6 excluding tap biosystems 2013 sustainable growth 2 2 2 3 financial target fully achieved sartorius stedim biotech ssb posted double sale revenue earnings digit growth order intake well sale reve nue third consecutive year business 108 fueled singleuse product equipment biomanufacturing regional perspective 5884 asia led growth sale revenue increased 5440 19 ssb boosted earnings 158 proportionately mainly driven 1356 economy scale underlying ebitda margin 1170 230 surged 23 sale revenue earnings 2013 215 reached upper end guidance provided 2012 beginning fiscal 2013 ebitda margin acquisition partnership growth addition product development sartorius stedim biotech focus alliance bolton acquisition extend offering 2013 ssb acquired tap biosystems group plc added bioreactors early phase process development portfolio addition cell culture medium business taken ssb end 2012 fully inte 15 ml 250 ml 2 10 l 1 300 l 50 2000 l grated performed strongly first year new roof tap biosystems sartorius stedim biotech highly dedicated employee 2013 3480 employee worked 2008 sartorius stedim biotech good 47 2369 five year ago compared previous year 47 alone number employee increased 17 across ssb group new job created 2013 region first global employee engagement 3484 survey mirrored company success active people management response rate result clearly industry bench mark production capacity expanded sartorius stedim biotech constantly expands capacity accompany growth 2013 company significantly extended manufacturing area injection molding goettingen investment made headquarters aubagne yauco puerto rico increase production singleuse bag chinese site beijing cleanroom installed pre pare manufacture fluid management product market shanghai ssb opened new sale headquarters group asia stock moved sbf 120 index ssbs profitable growth also reflected development share price around 66 2013 outperformed french stock market result increased liquid sartorius stedim biotech share ity free float market capitalization ssb stock moved june 2013 sbf 120 index sbf 120 composed 120 active share paris stock exchange mission sartorius stedim biotech leading provider cuttingedge equipment service development quality assurance production process biopharmaceutical industry integrated solution covering fermentation filtration purification fluid management lab technology supporting biopharmaceutical industry around world develop produce drug safely timely economically nextgeneration process sartorius stedim biotech focus singleuse technology addedvalue service meet rapidly changing technology requirement industry serf strongly rooted scientific community closely allied customer technology partner company dedicated philosophy turning science solution reference document 2013 present original french document de référence section document included translated reference document filed interest investor covered autorité de marchés financier another part reference document february 27 2014 accordance article 212 13 règlement général may used copy present reference document connection offering security obtained following supplemented prospectus note dopération autorité de marchés financier issued sartorius stedim biotech sa endorsement reference document zi le paluds avenue de jouques made issuer engages responsibility c 91051 13781 aubagne cedex signatory group website wwwsartoriusstedimcom autorité de marchés financier website reference document incorporates reference wwwamffranceorg preceding reference document 13 0109 filed march 7 2013 d12 0137 filed march 8 2012 following information included reference present reference document year 2012 consolidated financial statement sartorius stedim biotech prepared using international accounting standard report statutory auditor relating statement group 2012 management report appearing page 90 130 18 52 respectively reference document filed autorité de marchés financier march 7 2013 number d13 0109 year 2011 consolidated financial statement sartorius stedim biotech prepared using international accounting standard report statutory auditor relating statement group 2011 management report appearing page 86 127 18 48 respectively reference document filed autorité de marchés financier march 8 2012 number d12 0137 01 shareholder 8 chairman message 10 executive committee 12 sartorius stedim biotech share 02 management report 18 sartorius stedim biotech 20 macroeconomic environment condition sector 24 group business development 32 sustainability report 45 statutory auditor report review environmental social societal information 47 net worth financial position 50 risk opportunity report 57 forecast report 61 financial statement parent company sartorius stedim biotech sa reference document contains statement concerning future performance sartorius stedim biotech sa statement based assumption estimate although convinced forwardlooking statement realistic cannot guarantee actually apply assumption harbor risk uncertainty could lead actual result diverging substantially expected one planned update forwardlooking statement translation original frenchlanguage reference document document de référence 2013 sartorius shall assume liability correctness translation original french reference document legally binding version furthermore sartorius stedim biotech sa reserve right responsible topicality correctness completeness quality information provided liability claim regarding damage caused use information provided including kind information incomplete incorrect therefore rejected throughout reference document difference may apparent result rounding addition content 03 corporate governance 05 nnual financial statement sartorius stedim biotech sa note 70 board director committee 77 executive committee 144 annual financial statement 78 hairmans report pursuant article c 158 statutory auditor report financial statement l 22537 french commercial code 85 r emuneration executive 93 nonexecutive member board tatutory auditor report prepared 06 supplementary information accordance article l 225235 160 information legal nature 94 independent auditor fee 170 pecial report statutory auditor related party agreement commitment 04 c onsolidated financial 171 esolutions submitted annual combined r shareholder meeting april 8 2014 statement note 191 information reference document annual financial report 98 statement profit loss 194 glossary comprehensive income 196 address 99 statement financial position 200 product highlight 2013 100 statement cash flow 101 statement change equity 102 note financial statement 117 note statement profit loss 120 note individual balance sheet item 140 disclosure 142 tatutory auditor report consolidated financial statement shareholder chairman message dear shareholder pleased report 2013 marked another year positive development also reflected progress sartorius stedim biotech group development share price soared 66 sale 108 operational profit 2013 outperformed french stock market margin 230 reached upper end result increased liquidity free float market guidance provided january 2013 capitalization ssb stock moved june third year succession posted doubledigit sbf 120 index composed 120 topline growth even slightly higher active share paris stock exchange expectation market rate also satisfied profit development however 2013 success company past five year able add one financial perspective also percentage point underlying ebitda margin operational viewpoint key element total year year whole see u well track solution provider strategy continuously add new achieve strategic 2020 plan defined two offering portfolio customer year ago product development alliance bolton acquisition satisfied cell culture medium geographic perspective asia led growth business started integrate 2013 share sale asian market first quarter 2013 performed strongly first meanwhile surpassed 20 mark see u fully year ssbs roof moreover yearend participating growth opportunity afforded able move forward acquisition region key u biotech market also tap biosystems group plc tap bringing steadily becoming stronger even though sale promising product line smallscale singleuse figure show moderate expansion 2013 bioreactors early phase process mainly due high comparables previous development concentrate year extraordinary performance finally europe extending global reach innovative still generate almost 50 sale technology regard partnership entered grew solid rate 10 alliance several company example field process analytical tool strong growth sale also resulted significant increase underlying earnings per year 2014 keep u busy share 421 490 based continue execute regional growth initiative positive result board director strive outpace market north submit proposal annual general shareholder america leverage market growth asia obviously meeting raise dividend 9 120 per integration tap agenda well share unlock synergy cell culture medium complementary product portfolio ensure properly structured keep achieved 2013 show potential growth also continue invest global behind company employee would like infrastructure capability decided initiate thank worldwide team outstanding multiyear investment program goettingen commitment accomplishment equally appreciate site involves expanding production capacity continued trust valued customer partner well demonstration application laboratory shareholder placed u active people development also remain priority company happy global building attractive business model track employee engagement survey showed aboveaverage record strength team cordially invite result category positive feedback inspires continue u road success u become even better employer example promoting crossfunctional cross regional career path enable staff fully develop potential sincerely financial standpoint set ambitious target aim increase sale revenue around 11 14 operational profit margin 235 also medium long term see excellent prospect business global pharma market continuing grow biotech remain innovation engine joachim kreuzburg pharma industry furthermore singleuse production chairman board ceo device made inroad major biomanufacturing step penetrating market high momentum strong advantage regard production cost flexibility driving change still considerable challenge remain jointly solved supplier user full scalability increased standardization single use device required innovation ssb one pioneer singleuse technology fully committed forefront deliver new solution executive committee joachim kreuzburg chairman board chief executive officer head finance human resource compliance legal affair corporate communication hold doctorate economics university degree mechanical engineering joachim kreuzburg also ceo ssbs parent corporation sartorius ag chairman sartorius group executive committee oscarwerner reif executive vice president research development manages group global research development unit hold doctorate chemical engineering studied chemistry molecular biology germany usa oscarwerner reif also member sartorius group executive committee volker niebel executive vice president operation responsible production supply chain management business process management information tech nology hold university degree business administration economics volker niebel also belongs sartorius group executive committee reinhard vogt executive vice president marketing sale service charge marketing sale service hold vocational diploma industrial business administration reinhard vogt also member executive board sartorius ag member sartorius group executive committee 12 shareholder sartorius stedim biotech share sartorius stedim biotech share fact share isin fr0000053266 liquidity provider gilbert dupont stock exchange euronext paris market segment local security compartment large cap index sbf 120 sbf 250 cac mid 60 cac share cac mid small 190 cac small cac health care number shares1 17042306 thereof sartorius ag 670 thereof free float 230 thereof treasury share 100 number share outstanding 12 15343596 thereof sartorius ag 744 thereof free float 256 voting rights1 28665315 voting right outstanding13 26966605 1 december 31 2013 2 number issued share minus number treasury share 3 number voting right minus number voting right connected treasury share stock market significantly strong share price development stock market around world developed strongly 2013 sartorius stedim biotech share price 2013 slow start year contributing performed better french stock market factor included historically low interest rate well whole close 7340 end 2012 expectation european economy share price rose 660 12185 end particular would increasingly return even keel 2013 sbf 250 example rose significantly share hit lowest closing price year course year reach alltime high 3267 7535 january 3 2013 rising sharply point november 18 ended year 3263 next month highest closing price point represents overall gain 2013 registered 12400 august 27 2013 buoyed 196 favourable business development improved overall forecast year ssb included sbf 120 index june 21 2013 sartorius stedim biotech included sbf 120 index euronext paris sbf 120 index composed 120 active stock paris stock exchange ie 40 component cac 40 index plus 80 stock quoted continuously euronext paris criterion admission index liquidity free float market capitalization shareholder sartorius stedim biotech share 13 sartorius stedim biotech share january 1 2013 december 31 2013 jan feb march april may june july aug sept oct nov dec 140 140 130 130 120 120 110 110 100 100 90 90 80 80 70 70 60 60 50 50 sartorius stedim biotech share sartorius stedim biotech share comparison sbf 250 cac mid small nasdaq biotechnology index indexed january 1 2013 december 31 2013 jan feb march april may june july aug sept oct nov dec 170 170 160 160 150 150 140 140 130 130 120 120 110 110 100 100 90 90 80 80 sartorius stedim biotech share sbf 250 cac mid small nasdaq biotechnology index 14 shareholder sartorius stedim biotech share market capitalization trading volume analyst reflecting increase sartorius stedim biotech recommendation financial analyst serve share price market capitalization surged 660 important foundation decision private course reporting year 11 billion institutional investor investing share december 31 2012 19 billion december 31 2013 currently following institution regularly prepare report update sartorius stedim biotech average number sartorius stedim biotech share share traded daily paris bourse reporting period 9011 thus substantially research coverage ahead previous year level 7464 total institute date recommendation trading volume euronext stock exchange portzamparc january 29 2014 add however increased 1061 million 2012 société générale january 29 2014 hold 2378 million 2013 oddo midcap january 28 2014 buy investor relation activity gilbert dupont january 28 2014 add investor relation work focus maintaining ongoing open dialog shareholder potential financial calendar 2014 investor financial analyst ensure highest possible level transparency provide share financial calendar 2014 holder interested general public alike agm 2014 april 8 2014 equal timely access information relevant 3 mo 2014 april 28 2014 share price reporting together provide regular hy 2014 july 22 2014 detailed insight strategy latest development 9 mo 2014 october 21 2014 business prospect 2013 provided regular information current business development via press release halfyear annual report addition quarterly telephone webcast conference stepped contact capital market including large number oneonone meeting plus confe rences road show main european financial center london paris frankfurt main zurich also new york elsewhere investor relation communication activity reporting year made particular point explaining current business performance corporate strategy well change portfolio ie acquisition area cell culture medium smallvolume singleuse bioreactors information publication relating company share may found internet page wwwsartoriusstedimcom sartorius stedim biotech investor relation team available private institutional investor well financial analyst wishing contact directly question relating group sartorius stedim biotech shareholder sartorius stedim biotech share 15 key figure sartorius stedim biotech share 2013 2012 2011 2010 2009 share price1 reporting date 12185 7340 4900 3770 2800 high 12400 7603 5489 4000 3170 low 7535 4673 3735 2800 1345 dividends2 120 110 100 090 060 total dividend paid2 million 184 169 153 138 102 payout ratio3 245 261 287 305 294 dividend yield4 10 15 20 24 21 market capitalization million 18696 11261 7510 5774 4752 average daily trading number share 9011 7464 7435 14965 10427 trading volume share million 2378 1061 852 1319 653 cac mid small million 8629 6812 5652 7195 6100 sbf 250 million 3263 2729 2344 2801 2789 1 daily closing price 2 2013 amount suggested board director subject approval annual general shareholder meeting 3 based underlying net result excluding amortization 4 dividend relation corresponding closing price year source euronext bloomberg dividend sartorius stedim biotech group applies dividend based underlying net profit policy intended ensure shareholder adequately information underlying net profit please refer rewarded company sustained success glossary dividend payout ratio would dividend accordingly determined basis 245 compared 261 previous year underlying net profit year definition see would result dividend yield relation p xx sartorius stedim biotech endeavor principle closing price share december 31 2013 distribute 25 30 underlying 12185 10 previous year 15 net profit dividend fiscal 2013 well board director plan enable shareholder participate adequately company success therefore annual general 060 090 100 110 120 140 shareholder meeting april 8 2014 board director submit proposal pay dividend 120 per share net profit 209 million 105 reported sartorius stedim biotech sa would represent gain 91 previous year 070 figure 110 therefore total profit distributed would increase 169 million year ago 035 184 million 000 2009 2010 2011 2012 20131 1 amount suggested board director subject approval annual general shareholder meeting 16 shareholder sartorius stedim biotech share shareholder structure sartorius stedim biotech sa issued capital amounted 104 million reporting date divided 17042306 share calculated par value 061 share convey double voting right result total 28665315 voting right reporting date completion share buyback program 2010 sartorius stedim biotech sa hold 10 share reporting date furthermore sartorius ag hold 67 share approxi mately 85 outstanding voting right around 23 share 15 outstanding voting right free float outstanding 15343596 share treasury share deducted sartorius ag owns 74 free float account remaining 26 shareholding structure share capital sartorius ag 67 treasury share 10 free float 23 shareholding structure voting right sartorius ag 85 free float 15 management report 18 management report sartorius stedim biotech sartorius stedim biotech strategy sartorius stedim biotech provides integrated solution global leader field process core process step biopharmaceutical production filtration fermentation fluid management technology total solution provider strategy extensive membrane chromatography cell culture range technology product service help offer range conventional lab product customer manufacture medication vaccine biopharmaceutical laboratory safely efficiently using biological method integrated product service along customer process chain management report sartorius stedim biotech 19 extensive singleuse portfolio sector expanding product portfolio specialize providing singleuse product besides realizing organic growth potential biopharmaceutical production process singleuse intend expand position sartorius stedim product account around three quarter biotech group also strategic alliance sale revenue provide biopharmaceutical customer acquisition acquisition cell culture medium innovative alternative conventional reusable business swiss life science group lonza stainless steel system cost timesavings december 2012 added another important element offer particularly attractive also reduce product portfolio risk contamination dispose extensive portfolio singleuse technology also completed acquisition british company sector also able offer integrated singleuse tap biosystems group plc december 16 2013 system variety process step service move enhances fermentation range tailor specifically requirement especially early phase process development individual application comprehensive technical consulting give u additional edge competition organization sartorius stedim biotech group organized total solution provider strategy strictly function worldwide company offer great potential accordingly controlled core operating function marketing sale distribution service sartorius stedim biotech continuing execute research development operation finance etc solution provider strategy proven successful responsibility various function higher past decade focus biopharma tier management assigned global level ceutical market regard highly attractive hence span site country stable betterthanaverage growth potential global functional organization creates aim capitalize strong position effective platform central strategic control already enjoy core technology target fast efficient collaboration within group achieve continued significant organic growth also make easier company realize future regionally prioritize north america total solution provider strategy position world leading biopharmaceutical market effectively respect global customer rapidly expanding pharmaceutical market asia 20 management report macroeconomic environment condition sector macroeconomic environment condition sector macroeconomic environment forecast indicate slight improvement french economy expected grown 02 global economy expanded 29 2013 2013 period growth previous previous year 32 according international year economic activity france suffered result monetary fund imf slightly less 31 significant fall corporate investment rate still forecast middle year imf suggests effect gradual recovery southern eurozone country remained economic activity industrialized country recession second year succession partially offset weakening impetus growth rate 18 previous year 24 italy emerging country thirdlargest economy eurozone 13 spain previous year 16 confirming another period recession global development gdp 2009 2013 07 51 38 32 29 gross domestic product eu 6 05 02 13 18 13 09 00 16 24 12 4 1 2 0 0 1 2 2009 2010 2011 2012 2013 2 source international monetary fund 3 germany france spain italy nether economic output industrialized country rose land 12 overall reporting year according 2013 2012 imf figure previous year 15 performance source international monetary fund varying enormously country country rate growth u economy likely economic growth asia china india indonesia reached 16 well short 2012 figure malaysia philippine thailand vietnam 28 reporting year due declining export impacted weak start year especially significantly reduced government spending china eventually reached almost level result country automatic budget cut previous year 63 2012 64 however still short midyear forecast 69 economic activity eurozone whole declined slightly growth rate 04 previous imf put likely rate growth economic year 06 german economy eurozones output japan around 20 2013 largest continued expand rate growth previous year growth fueled largely slowed 05 previous year 09 private government expansionary fiscal policy consumption public consumption investment prompted rising consumer spending corporate building equipment provided momentum investment economic stimulus program effect offset weak start year upturn export following devaluation yen negative net export figure also helped management report macroeconomic environment condition sector 21 gross domestic product region interest rate trend 29 04 16 20 63 32 06 28 20 64 average global interest rate fell historic low reporting year ecb example cut base rate 9 twice reporting year 075 record low 025 3month euribor rate rate 6 interest fixedterm deposit denominated euro interbank business still low level 3 03 december 31 2013 previous year 02 0 source international monetary fund world economic outlook october 2013 vwd ecb deeuriborrateseu 3 global eurozone u japan asia1 sector condition 2013 2012 sartorius stedim biotech serf customer mainly 1 asia china india asean5 indonesia malaysia biopharmaceutical industry make philippine thailand vietnam business particularly sensitive development source international monetary fund industry exchange rate trend stable growth pharmaceutical market important currency sartorius group besides international market research institute ims health euro include especially u dollar well expects global pharmaceutical market grow currency like chinese yuan indien 33 2013 follows growth 26 rupee previous year eurous dollar exchange rate slipped low principal factor influencing global year 127 u dollar end march pharmaceutical industry remained unchanged result uncertainty surrounding economic reporting year demographic change development europe euro strengthened improved access healthcare especially u dollar finish year emerging market featuring among key 137 u dollar december 31 2013 driver growth availability new drug remained high 30 approval u market world largest reporting development eur u dollar january 1 2013 december 31 2013 period positive factor countered effect austerity measure notably 15 healthcare system industrialized nation expiration patent 14 13 12 11 source bloomberg 22 management report macroeconomic environment condition sector growth regional pharma market 300 monoclonal antibody undergoing clinical deve lopment phase iiii 2012 represents 21 30 1114 36 912 significant increase previous year 08 10 128 00 109 15 pronounced move singleuse system 10 biopharmaceutical production 5 biotech production method much complex traditional method far also proved 0 costintensive manufacturer supplier consequently engaged intensive effort 5 develop efficient production technology europe north asia japan latin singleuse product require significantly less america africa america capital expenditure reduce cleaning validation australia cost minimize downtime crucial role 2013 2012 play singleuse product deliver greater flexibility help bring development source ims health market faster thanks particular cost efficiency singleuse product become well established large number process step according ims growth strongest region asia africa australia latin america amongst others expansion budget consolidation affect statefunded healthcare provision higher public research sector consumer spending medicine fueled market growth proportion demand laboratory product come publicsector research research budget many country unchanged slightly biotechnology market growth average compared previous year knock effect economic crisis reporting year global market pharmaceutical manufactured consequently brought slight yearonyear fall using biotech method grew around 8 demand public research sector according reporting year outperforming global data frost sullivan pharmaceutical market whole attributable particular launch many new biopharmaceutical drug last year competition expanded indication existing medicine proportion sale revenue accounted primary mean company medication manufactured using biotech method biotechnology market differentiate doubled ten year 2013 stand competitor innovative prowess quality around 21 22 therapeutic protein play performance product biotechnology important role treatment condition including sector constantly discovering new area diabetes chronic anemia still make largest application expects supplier equally fast category active ingredient produced using biotech moving creative developing new equipment method importance monoclonal antibody manufacture biotech product new supplier used application including particular seek exploit opportunity inherent treatment cancer hiv autoimmune disease environment gain foothold market multiple sclerosis rheumatoid arthritis carefully targeted niche product also continues grow according study established supplier meanwhile expanding boston consulting group product range continuously management report macroeconomic environment condition sector 23 generate round 85 sale revenue validated process replacing product production cycle expensive receive high proportion followup repeat business particular strength sartorius stedim biotech lie integrated process solution investigation development substance lab production end product offer broadest range industry strategic focus singleuse product give u another edge competition sartorius stedim biotech occupies strong position market worldwide field bioprocess filtration fermentation fluid management membrane chromatography competitor multinationals based usa merck millipore pall general electric healthcare among main rival process area thermo fisher merck millipore key player laboratory field also face competition smaller company applikon atmi individual segment source boston consulting group medizinische biotechnologie deutschland 2013 medical biotechnology germany 2013 ims health market prognosis june 2013 evaluate pharma world preview 2018 june 2013 frost sullivan 2012 annual forecast analysis global market laboratory product icis market outlook 24 management report group business development group business development order intake sale revenue period customer required time transition contribution sale revenue approx sartorius stedim biotech group adopted 2 pct point slightly forecast however slight change reporting structure result earnings business consolidated fiscal 2013 change relate amortization full year please refer page 102 103 tax since shown functional sale revenue region1 expense change cost allocation impact group net profit ensure europe 488 comparability business figure 2012 restated see consolidated financial statement north america 256 note moreover underlying ebitda used key performance indicator since beginning 2013 instead underlying ebita however profit figure continue reported asia pacific 214 order intake sale revenue million market 42 4099 4426 5002 5539 6149 4012 4329 4773 5440 5884 1 acc customer location 700 600 group strong performance supported region europe region generated highest 500 revenue accounted around 49 business posted gain 103 cc driven 400 particularly strong demand singleuse product 300 north america earned around 26 total 2009 2010 2011 2012 2013 sale revenue whereas sale revenue order intake significant doubledigit rate previous year sale revenue growth moderate 44 cc reporting period given high yearearlier base sartorius stedim biotech group reported strong asia pacific region 2013 accounted growth order intake reporting year around 21 total sale revenue developed 6149 million order intake 137 constant dynamically yet region recorded currency cc compared yearearlier figure gain sale revenue 190 cc growth 5539 million considerable increase fueled strong demand singleuse driven high demand singleuse product well product equipment special growth impulse form large equipment order sale revenue grew 108 cc 5440 million 5884 million thus reached upper end 8 11 growth guidance cc provided outset year organic sale revenue growth 89 cc ahead expectation cell culture medium business acquired december 2012 showed strong operating performance reporting management report group business development 25 sale revenue1 region fiscal 2013 earnings sartorius stedim million unless otherwise specified biotech group developed better expected 2871 1508 1258 247 beginning year given excellent sale revenue 2618 1492 1124 205 growth thus underlying ebitda increased 320 proportionately 158 1356 million respective margin improved 215 230 240 compared initial forecast 225 inclusion full earnings cell culture 160 medium business corresponding sale revenue recognized pro rata contributed increase 80 margin turn currency fluctuation slightly negative impact underlying ebita rose 148 0 1142 million corresponding margin increased 183 194 europe north asia america pacific market 2013 underlying ebitda ebita 2012 million 752 859 996 1170 1356 603 700 835 995 1142 sales1 growth growth2 million 160 group 5884 82 108 120 europe 2871 97 103 north america 1508 11 44 80 asia pacific 1258 119 190 market 247 200 200 40 1 acc customer location 2 currencyadjusted 0 2009 2010 2011 20122 2013 ebitda earnings ebita sartorius stedim biotech group earnings interest tax depreciation amortization ebitda used key profitability measure addition report ebita profit figure context amortization refers exclusively purchase price allocation ppa intangible asset acquired specified ifrs 3 provide complete transparent presentation group profitability report earnings adjusted extraordinary item underlying ebitda underlying ebita information definition please refer glossary page 195 underlying presentation reconciled ebitda key indicator see glossary following page 26 management report group business development underlying ebitda1 ebita margin underlying earnings per share 187 198 209 215 230 204 281 349 421 490 150 162 175 183 194 500 24 375 18 250 12 125 6 0 0 20091 20101 20112 20122 20132 2009 2010 2011 20122 2013 1 excluding amortization ebitda 2 excluding amortization excluding fair value adjustment ebita hedging instrument 1 adjusted extraordinary item 2 restated see note consolidated financial statement page 102 103 reconciliation underlying presentation ebitda key indicator extraordinary item amounted 37 million million 2013 20121 previous year 59 million essentially cover underlying ebitda 1356 1170 onetime expense various corporate project including extraordinary item amortization depreciation 213 175 group ebit see glossary rose 856 million underlying ebita 1142 995 1013 million respective margin increased amortization 92 80 157 172 extraordinary effect 37 59 relevant underlying net profit group surged ebit 1013 856 646 million year ago 752 million fiscal extraordinary effect 37 59 2013 profit figure calculated adjusting amortization ifrs 3 92 80 extraordinary item eliminating noncash financial result 69 37 amortization 92 million previous year valuation hedging instrument 03 19 80 million fair value adjustment hedging income tax 2013 29 2012 30 312 282 instrument well corresponding tax effect underlying net result 764 657 item corresponding earnings noncontrolling interest 12 11 per share 490 421 year earlier underlying net result excluding amortization ifrs 3 non controlling interest 752 646 underlying earnings per share 490 421 1 restated see consolidated financial statement note page 102 103 see glossary definition total listed management report group business development 27 appropriation profit research development board director submit proposal sartorius stedim biotech group stepped annual general shareholder meeting april 8 2014 research development activity reporting payment dividend 120 per share fiscal year increasing spending area 133 2013 110 previous year total 360 million previous year 318 million profit distributed would accordingly increase 91 respective ratio rd cost sale revenue also 169 million year earlier 184 million higher 61 58 year earlier relation closing price share 12185 december 31 2013 would result dividend research development cost yield 10 previous year 15 million 245 278 286 318 360 40 35 30 25 20 2009 2010 2011 20121 2013 1 restated see note consolidated financial statement page 102 103 research development ratio sale revenue 61 64 60 58 61 10 8 6 4 2 2009 2010 2011 20121 2013 1 restated see note consolidated financial statement page 102 103 protect knowhow pursue targeted intellectual industrial property right policy systematically monitor compliance right review cost benefit viewpoint whether necessary continue maintain individual right 28 management report group business development number application intellectual control unit order implement new operating industrial property right filed 2013 amounted 87 concept standard bioreactors technical compared 135 previous year result upgrade give user option operating application submitted past year issued bioreactor either reusable disposable system 120 patent trademark previous year 127 balance sheet date total 1592 patent sartorius stedim biotech developed new package trademark portfolio previous year 1641 process analytics software continuous control fermentation process software allows 2013 2012 additional sensor linked capture number patent trademark considerably process data previous option application 87 135 paving way particularly efficient cell culture registered patent trademark 120 127 process customer development new cell culture medium lonza brandnew membrane virus removal prefiltration 2013 worked development new cell culture medium suitable cultivating cell line rd priority reporting year included used manufacture vaccine moreover development new filter membrane already optimized initial group culture design size round existing product line medium specific customer enhanced medium one highlight new virosart hf hollowfiber provide optimal growth condition cell ensure membrane used purification process high yield target biological active ingredient biopharmaceutical medium developed virus removal collaboration one partner product performance data set new benchmark market also successfully completed development new prefilter cartridge extended line sartopore platinum sterilizinggrade filter membrane adding new version biostat str bioreactor 2000liter version novel plastic film singleuse bag project develop 2000liter model successful biostat str range singleuse bioreactors completed successfully reporting year rounding range enabling u offer customer attractive alternative conventional stainless steel bioreactors productionscale process singleuse bag new bioreactor designed largescale cell cultivation first feature novel polyethylene film developed collaboration one partner notably robust film particularly wellsuited application involving cell culture microbial fermentation application use wide range new product fermentation fluid management new controller standard bioreactors innovative process analytics software reporting year developed brandnew software solution continued extend system management report group business development 29 marketing sale distribution service strong demand validation maintenance service beyond supplying product existing production process sartorius stedim biotech make particular provide comprehensive range service priority working customer starting right designed around often complex manufacturing earliest phase process development process customer biopharmaceutical company accordingly market product directly industry result offering clearly set u apart field sale representative key competition validation service account additionally supported global key consulting expertise enjoyed strong demand account management organization collaborates reporting year particularly customer asia closely direct sale team sartorius stedim business maintenance service also made biotech activity focus particular new project excellent progress ensure keep pace solution deployed feature burgeoning demand sophisticated service large proportion singleuse product offer future well conducted training program 2013 large number service employee sale initiative europe china new sale marketing headquarters asia acquisition tap biosystems alliance forged launched sale initiative usa still world largest pharmaceutical market continued extend leading market 2012 reorganize strengthen sale position fermentation technology acquiring tap activity extended initiative region biosystems british company specializes southern central europe china developing multiparallel bioreactors smallscale reporting year objective initiative cell culture volume marketleading mini achieve international harmonization sale bioreactor system called ambr 15 provide marketing analyzing optimizing activity biopharma industry equipment solution also spurred continued growth china early phase process development asian country established new sale marketing headquarters shanghai also stepped sartorius stedim biotech entered global sale marketing sale distribution activity partnership german gas measurement specialist latin america another attractive growth region bluesens 2013 expand portfolio area sartorius process analytics addition company forged sale development alliance welsh company aber instrument highly specialized cell culture medium join product portfolio supplier sensor technology acquisition cell culture medium business swiss life science group lonza december 2012 added important component sartorius product portfolio like bioreactors singleuse bag container cell culture medium key cell cultivation process making ideal complementary product range assumed global marketing sale distribution activity cell culture medium reporting period therefore offer customer fully integrated product solution single source moreover integrated former lonza employee team application specialist 30 management report group business development product another product equipped new single use sensor additional accessory sartorius stedim biotech range product includes univessel su singleuse bioreactor designed process large number singleuse product development optimization task manufacture active pharmaceutical ingredient operated different controller pre upstream downstream application company sterilized readytouse singleuse system offer extensive lineup singleuse filter flexible alternative conventional glass bioreactors membrane plus singleuse reusable bioreactors singleuse bag tubing connector container cell culture medium range also includes filtration enhanced process efficiency safety reliability system filter integrity testing equipment sophisticated service reporting year added introduced special sensor offgas analysis complementary product many product line 2013 facilitate continuous control unveiled series new equipment generation monitoring fermentation process readily integratable bioreactors size sensor allows bioprocesses monitored real time new filtration product key parameter determined helping make process significantly efficient product launch 2013 included introduction increasing yield result secondgeneration crossflow filtration system purifying vaccine monoclonal antibody new sartocheck 4 plus bag test system enables recombinant protein designed efficient purification customer check integrity singleuse bag small batch compact modular system installed bioreactor ability used development process smallscale detect even slightest damage bag help production operation filtration system feature make process safer reliable new control unit large selection filter element provide even greater flexibility reporting year saw unveiling new expanded fluid management portfolio virosart hc filter membrane designed specifically purification proteinrich medium year review sartorius stedim biotech blood plasma virosart hc used remove viral expanded array singleuse bag plastic contaminant also added new filter element tubing connector equipment fluid sartopore xlm sartobran filter membrane management application example introduced product line 2013 new product cultibag line singleuse bag cell cultivation launched new generation mobile mixing system biopharmaceutical medium bioreactors additional feature extended capability system sterile disconnection plastic tubing cell cultivation included additional feature biostat cplus bioreactor used microbial well cell culture application result specifically customconfigured according user special need management report group business development 31 production supply chain management sartorius stedim biotech operates well developed global production network largest site plant goettingen germany aubagne france followed production facility bangalore india yauco puerto rico guxhagen germany advanced production facility support efficient manufacturing process short lead order processing time need maintain competitive edge around world completed number significant capacity expansion project goettingen guxhagen yauco previous year implemented series small mediumscale project reporting year extend manufacturing capacity goettingen site april 2013 opened new building manufacturing plastic part use product like singleuse filter bag substantially expanded production area provides ample space installation additional injection molding machine first commissioned reporting year also hired employee expand production capacity significantly new plant puerto rico response persistently high demand singleuse bag pharmaceutical industry elsewhere acquired building directly adjacent aubagne facility order increase space available site producing singleuse bag plan move additional machinery mid2014 moreover chinese site beijing installed cleanroom intend manufacture fluid management product local market initial preparatory step taken installation casting machine goettingen site provide greater capacity flexibility filter membrane manufacturing operation work install machine scheduled commence 2014 32 management report sustainability report sustainability report sustainability one core value firmly following report provides overview embedded sartorius stedim biotech corporate key indicator activity project culture ever since company established three area sustainable corporate management sustainable development company ecological sustainability contributing society major objective primary business responsibility offer methodological note attractive product solution customer innovation well strategic operational personnel indicator regarding health excellence key meeting objective u safety reported refer entire group sustainability context mean pursuing indicator referenced range business objective take longterm broadly global scope scope consolidation indicated based view also specifically includes social separately environmental indicator refer ecological interest take responsibility sartorius stedim biotech production site toward various stakeholder seriously believe located aubagne lourdes mhamdia goettingen longterm relation deliver benefit guxhagen stonehouse tagelswangen yauco party involved accordingly regard active bangalore represent 8410 group total management social ecological task workforce compensation business activity rather one success factor line approach regard essential comply legal ethical standard manufacture ecological responsibility keep en vironmental impact mind developing product innovation likewise hr policy aimed preserving right interest employee actively using developing potential global workforce company site around world employer contractor take active part developing regional environment increasing attractiveness supporting cultural social project since 2012 sartorius stedim biotech reporting key personnel environmental indicator metric compliance french grenelle ii environmental law indicator oriented towards general standard thus permit comparison company internally figure provide basis defining reviewing controlling environmental personnel target enhanced groupwide recording reporting environmental personnel data 2013 sartorius stedim biotech base recording greenhouse gas emission greenhouse gas protocol also introduced number new performance indicator 2013 including general absence rate total amount carbon total consumption chemical example addition international environment health occupational safety steering group established harmonize continuously improve process three area worldwide management report sustainability report 33 sustainable corporate management organization ilo united nation global compact furthermore reject form detailed information economic dimension compulsory labor child labor respect sustainability sartorius stedim biotech provided special need protect young employee sartorius page 18 19 24 31 explain stedim biotech employee required adopt strategy measure use achieve profitable taskoriented open friendly fair approach growth interacting colleague employee third party thereby helping create atmosphere respectful cooperation tolerate employee compliance legal ethical standard discriminated disadvantaged harassed excluded based gender ethnic origin life activity based corporate value philosophy race religion age disability appearance sustainability openness enjoyment value sexual preference identity origin political govern treat customer business partner position uphold freedom association investor well work together within right individual fairly represented labor company time corporate value organization choosing pursuant local law guide u direction intend develop company future code conduct help ensure operate highest level integrity binding sartorius stedim biotech conduct business employee anticorruption guideline accordance legal regulation individual measure intended help employee act country globally accepted ethical standard ethically accordance law daily action follow principle responsible work employee around globe required corporate governance control focused complete training course us fictitious sustainable value added includes compliance example train deal ethically legally legal groupinternal regulation consideration problematic situation whistleblower portal stakeholder interest transparent corporate telephone hotline enable employee supplier communication appropriate risk management customer partner report dubious conduct proper accounting auditing sartorius stedim biotech complies rule recommendation remuneration paid sartorius stedim biotech afepmedef corporate governance code regular working hour overtime compensation information provided chairman report hour worked excess contract regular work chapter starting page 70 reference schedule either meet case exceeds document industry standard legal minimum wage depending particular country germany instance compliance system intended ensure compensation paid according pay rate set member executive body manager employee trade union ig metall stand industrial comply legal regulation code internal union metalworker guideline designed preemptive nature aim prevent misconduct prevent financial loss many employee covered remuneration damage company image important pillar system include variable well fixed compliance system based code compensation component level variable conduct anticorruption code code component linked progress comprise minimum standard legally compliant company attainment personal target ethical behavior defined employee respective manager annual target agreement adhere set principle defined code conduct sartorius stedim biotech support business partner adhere highest respect principle human right defined standard business ethic compliance respect united nation universal declaration human supplier subcontractor partner right convention international labor request respect human right 34 management report sustainability report complying code conduct applicable employee function december 31 2013 human right law regulation also ensuring compliance throughout production 627 supply chain marketing sale service 245 employee number employee reported following research development 79 include staff member except vocational trainee intern employee extended leaf administration 49 absence participating early retirement plan number recorded head count ie employee counted regardless whether work full part time december 31 2013 sartorius stedim biotech number employee function show group employed total 3289 people figure production area directly linked production yet include approximately 200 employee accounted largest share 2063 people british company tap biosystems sartorius company total workforce reporting year stedim biotech acquired end reporting previous year 1793 active recruitment response year compared workforce 2986 sustained strong demand singleuse product reporting date year earlier equates accounted yearonyear increase increase 102 151 total 807 people quarter company total workforce work marketing sale distribution service function previous employee region year 768 number people employed december 31 2013 research development unit increased 34 europe 647 259 previous year 251 head count administrative function include finance north america 150 human resource little changed 161 previous year 175 figure include additional administrative function performed asia pacific 143 sartorius corporate administration gmbh part sartorius stedim biotech group market 60 employee age 2013 16 20 05 21 30 247 31 40 308 41 50 266 head count region sartorius stedim biotech employed twothirds total workforce 51 60 155 2127 people europe december 31 2013 61 19 previous year 1962 represents increase 84 compared end 2012 reported head count 2013 rose 414 492 188 sartorius stedim biotech employed 1268 woman north america 453 472 2021 men december 31 2013 therefore woman asia pacific region make 386 total workforce men 614 largest group employee age 31 40 category 1013 people average employee age across entire workforce virtually unchanged reporting period 393 year previous year 395 year management report sustainability report 35 new hire attrition rate average seniority represented second management level absenteeism vice president intend continue striving international lineup management level 2013 2012 medium term new hire 634 563 another priority diversity strategy ensure redundancies1 36 na 2 woman adequately represented management attrition rate 100 131 position succeeded increasing proportion average seniority year 83 87 woman total head count slightly 1 year year 386 2012 377 trend redundancy companydriven dismissal layoff first reporting year recorded mirrored management level number group whole post held woman two tier management 2 express number people leaving company immediately executive board rising year percentage average head count 2013 316475 year 250 december 31 2013 previous year includes terminated contract retirement 243 reason employee leaving company reporting period sartorius stedim biotech attrition rate express number employed 91 people registered disabled people leaving company percentage 21 work france 66 germany average head count fell 100 group represents yearonyear increase 11 whole reporting year previous year 131 attrition rate generally subject regional variation therefore also applies sartorius stedim biotech developing potential rate reporting year 81 europe employee worldwide 96 north american region 117 asia pacific region adjusted figure 2013 grow successfully dynamic market environment excluding resignation employee terminated need competent qualified employee contract amount group whole 74 therefore endeavor continuously enhance 2012 105 attrition rate 31 previous appeal employer internally year 39 site germany employ externally providing employee good 414 people 61 previous year 61 opportunity continuing personal development france central effort 2013 sartorius stedim biotech provided total 155360 hour training absence rate express proportion planned site france tunisia puerto rico working time lost due general absence corresponds average 160 hour training rate stood 43 group whole average training cost 31110 per employee reporting year average period missed due illness amounted 79 day per employee 2013 employee annual performance review 2012 70 day include time lost due structure assessment criterion longterm health condition statutory maternity standardized cover development opportunity entitlement day missed result workrelated well target performance ultimate accident objective expand human resource program cover whole global operation appropriate expedient harmonize applying different perspective throughout group multicultural company diversity sartorius stedim biotech fill management vacancy market business region customer also largely within rank accordingly reflected workforce setting team develops promotes employee management therefore ensure different perspective potential international level conduct background combined productively also special program help junior manager develop filling management vacancy aim achieve mix refine management skill specific culture gender age group manager project directly related company business germany france usa india example sartorius stedim biotech also provides separate 36 management report sustainability report development program experienced management leonardo da vinci scheme international staff designed reference management vocational education connection many guideline program promotes establishment year support intern number way common management culture example enabling take part training initiative thanks alliance kedge structured expert career path program business school marseille france intern introduced throughout group reporting aubagne site instance able attend year run alongside existing management master business administration course offered program new addition enables sartorius stedim biotech provide specific development opportunity scientist engineer rd function sartorius bioscience scholarship program raise profile expert within meanwhile supporting talented student outside company graduate scientific technical field financially also technically personally managing change process successfully issue provision mentor within everincreasing importance company sartorius organization reporting year selected stedim biotech operates strategic change manage first group participant india ment system help employee implement change scholarship program successfully sustainably managementlevel staff worldwide received training area sartorius stedim biotech continued develop reporting year international link research institution university 2013 highlight area included sartorius college offer wide range training alliance école nationale supérieure de continuing personal development opportunity technologie de biomolécules de bordeaux number language employee help granted scholarship first time improve language methodological skill reporting year value selling course example teach field sale representative application specialist worldwide strategic skill necessary provide freedom flexibility work firstclass customer advisory service added new elearning platform technical training program sartorius stedim biotech set employee demanding 2013 provides interactive way employee task delegate responsibility early stage marketing sale service function leaf freedom arrange daily work prepare individually subsequent facetoface importance enabling flexible work practice training session widely recognized across company number parttime employee 137 2012 128 equates train production staff cleanroom working 42 total head count 2012 43 accordance uniform standard method working time model give employee german special training program offered ssb site option scheduling working hour aubagne yauco focus building developing flexibly instance flextime parttime work technical skill 2013 total 85 employee teleworking received 140 hour training program aubagne site example encouraging social dialog finding developing talented young staff sartorius stedim biotech place great importance communication employee interoffice memo sartorius stedim biotech offer young people newsletter employee magazine inform opportunity work within company order staff example change within company enhance professional knowledge skill goal economic situation first global experience company making use employee survey took place 2013 achieved corresponding european union funding program participation rate 60 question posed covered including marie curie scheme young scientist company respondent personal working management report sustainability report 37 condition result particularly good recorded 48 workrelated accident site plan repeat employee survey regular around world reporting period previous interval future enable u identify change year 82 great majority minor nature time investigate significance number day lost due work accident 2013 consequently considerably lower france well germany sartorius stedim previous year 858 compared 1139 2012 biotech staff represented three employee 23 accident largest production site council employee council hold regular staff goettingen germany reporting year meeting 2013 eight collective agreement previous year 21 seven occurred signed french site eight german company premise rather employee location cover particular pay level travel home work review working time integration young employee effectiveness accident prevention measure retention elderly employee deployment regularly reference accident analysis industrial camera production personnel development signed one collective agreement environment health safety issue ehs 2013 statistic accident work 2013 germany occupational integration management 2013 employee returning work relatively long number work accident 48 illness france agreement concluded 1 number day lost due work accident 858 area harmonization health insurance frequency rate 2 87 severity rate3 1556 employee health safety 1 measured calendar day 2 represents number accident per 1000000 theoretical sartorius stedim biotech corporate health working hour theoretical working hour 2013 55151006 management policy covering physical 3 represents number day lost accident per psychosocial element health order enhance 1000000 theoretical working hour employee performance motivation reduce cost associated illness sartorius stedim biotech also promotes awareness personal health among ecological sustainability employee special action day individual site offer vice president sustainable production ecological product germany annual medical checkup selected innovation important basis longterm partner clinic financial success sartorius stedim biotech design manufacturing process conserve sartorius stedim biotech strive improve resource offer customer product technical organizational working condition efficient safe also provide ecological continuously order bring benefit planning operation look reduction jobrelated medical condition risk beyond immediate use resource health potential cause industrial accident understand entire lifecycle product well providing regular training employee including customer process supplier area occupational health safety also required meet specification green environmental protection site germany approach growth coupled underproportionate provided 2995 hour total training ehs issue use natural resource goal sartorius 2013 continuously adapt job safety work stedim biotech implement various level organization condition line applicable information environmental protection adopted law regulation connection sartorius stedim biotech employee described responsive concern employee page 38 42 aubagne site example operate special program preventing potential health hazard implement specific improvement suggested employee 38 management report sustainability report high standard quality environmental improved emission monitoring protection taking greenhouse gas protocol ghg global sartorius stedim biotech certified according standard recording greenhouse gas internationally recognized standard quality emission guide sartorius stedim biotech iso 9001 environment iso 14001 two expanded reach greenhouse gas emission management system ensure comply recording reporting year significantly quality requirement manufacture increased level detail captured emission product prudent use resource categorized three broad scope scope 1 record minimize environmental risk manufacturing co2 emission caused directly production site site certified compliance iso 9001 scope 2 determines indirect emission arise series international standard apart tagels course power generation external energy wangen switzerland employ around 40 staff supplier scope 3 considers co2 emission member environmental management system associated factor manufacture pre already certified compliance iso 14001 cursor product distribution operation sartorius sartorius stedim india sartorius stedim already report scope 1 scope 2 emission biotech gmbh goettingen latter intends gradually integrate scope 3 emission sartorius stedim biotech plastic goettingen co2 accounting right along value chain site guxhagen additionally introduced energy management system 2013 specified application ghg accounting method mean iso 50001 intend energy manage beginning 2013 consider report ment system certified 2014 two environmental co2 equivalent co2eq emission co2 standard today set benchmark inter gas relevance climate change national site respective company data previous year converted organizational unit ensure law accordingly order make yearonyear com regulation relating environmental protection parisons meaningful observed technical possibility reducing environmental risk identified strive continuously improve existing management system working toward gradual rollout production site appropriate expedient overall environmental risk identified require company make specific provision annual financial statement sartorius stedim biotech supply product directly end consumer rather manufacturer pharmaceutical food chemical also research development laboratory ensure product satisfy stringent quality requirement employ rigorous quality check advanced manufacturing method process cleanroom technology manufacturing method process subject constant review continuous improvement process moreover refined appropriately requirement evolve successful completion host annual audit customer accreditation iso 9001 iso 13485 together document high standard quality achieved sartorius stedim biotech product process respond rapidly product defect minimize adverse consequence sartorius stedim biotech established traceability system enables u recall entire product batch immediately necessary management report sustainability report 39 greenhouse gas emission sartorius stedim introduced energy management system two biotech sa developed follows 2013 goettingen site nearby guxhagen site enables u identify strategic opportunity reduce energy consumption intend energy consumption greenhouse gas certified energy management system specified 2013 20121 iso 50001 2014 overall energy consumption goettingen site increased much slower total energy consumption mwh 68952 61110 rate sale revenue last year electricity 38400 33460 adoption modern technology including energy natural gas 27434 26294 efficient combined heat power chp plant fuels2 2685 997 compressed air center controlling production energy source 433 359 machine brought reduction annual carbon total greenhouse gas emission dioxide emission around 5600 metric ton use co2eq3 24543 21358 intelligent control system enabled u realize scope 14 6834 6015 additional energy saving 1300 mwh scope 2 17709 15232 reporting year sartorius stedim biotech key indicator commissioning second combined heat power co2eq emission per employee 92 85 plant goettingen site early 2014 co2eq emission per sale revenue tmio 417 393 international site well sartorius stedim 1 figure 2012 corrected ex post biotech continuously develops manufacturing inconsistency process enhances building facility 2 data range cover diesel consumption electricity conserve resource particularly new building generator increasing proportion renewable energy 3 emission co2eq calculated university source energy mix plant yauco applied science art goettingen using emission factor listed professional software called gabi cover estimated 9 energy consumption 4 scope 1 excluding fuel consumption car fleet requirement site solar energy furthermore guxhagen factory germany source part energy need local photovoltaic plant scope 2 emission consumption electricity make use geothermal energy account almost three quarter company total emission represent main source whole strategy supplying local emission sartorius stedim biotech market far possible directly local quarter attributed largely combustion production facility help shorten transportation fossil fuel scope 1 route thus lower carbon dioxide emission total amount carbon released solvent emission occur principally filter production reducing climate change goettingen yauco site stood 50 metric ton reporting year share since 2010 sartorius stedim biotech figure relevance term greenhouse gas measuring scope 3 well scope 1 scope 2 emission taken account calculating co2 emission main production site singleuse equivalent figure bag aubagne using bilan carbone method also measure total emission carbon dioxide greenhouse gas process efficient use energy upstream downstream production operation analysis 2012 found business sartorius stedim biotech strives adapt workrelated travel employee account consequence climate change lower around 22 environmental footprint greenhouse gas emission finding way improve source co2 include raw material obtained company energy efficiency one main sartorius stedim biotech supplier 19 approach reducing carbon dioxide largest freight transport 18 packaging 10 group site goettingen account approximately threefourths energy consumption newly 40 management report sustainability report drawn plan action make cut amount waste site co2 emission based finding 2013 2013 1 2012 example set employee working site aubagne moving plan encourage total amount waste 2949 2972 carpooling public transportation waste recycling 1499 1869 waste disposal 1460 1104 nonhazardous waste 2399 2285 sustainable use water hazardous waste 560 687 waste per employee 111 118 water sartorius stedim biotech recycling rate 51 63 consumes used rinsing process proportion hazardous waste 19 23 manufacture filter membrane according 1 precipitation bath method advanced casting machine regarding waste indicator india group implemented working group order improve reliability data help ensure efficient use water site reported goettingen germany bangalore india company operates water treatment system thus contributing sustainable use raw organic solvent sartorius stedim biotech material according estimate yauco need manufacturing membrane filter sartorius stedim biotech reduces usage drinking cartridge recovered recycled goettingen water approximately 85 compared facility account solvent use conventional plant based low water solvent reprocessing plant site strategy implemented inside new building solvent used recovered fed back plant india achieve reduction production operation without ever leaving measure including intelligent solution premise way maintain closed material making use rain water cycle minimize transport requirement reduce quantity water used volume waste water produced conducting research water consumption development also achieved overall reduction amount solvent required 2013 2012 membrane manufacture order reduce water consumption cbm 280705 297450 consumption polyethylene packaging sartorius water consumption per employee cbm 105 118 stedim biotech switched delivery polypropylene waste water sack silo manufacture injectionmolded biological oxygen demandbod1 175 175 component required singleuse product 1 contaminated wastewater without sanitary wastewater return recyclable material sartorius stedim biotech strives reduce amount waste generated using waste sorting system contribute toward enabling reusable material recycled proportion waste stored landfill lowered moreover company safely disposes hazardous waste management report sustainability report 41 supplier pharmaceutical industry sartorius building council leed initiative goettingen stedim biotech currently prohibited regulatory invested particular energyefficient air requirement using recycled plastic conditioning system ventilation equipment ground product safety yet consistently send use energysaving led lighting guxhagen site plastic waste recycling disposed substantially reduce consumption fossil fuel environmentally responsible way name using geothermal solar energy example 2013 approximately 91 waste manufacturing plant mostly situated industrial produced french site aubagne lourdes area noise pollution resident relevant tunisian site mohamdia recycled issue company care biodiversity energyrich composite plastic waste resulting estimate impact biodiversity low bag manufacture used generate therefore consider action necessary energy incineration special power plant area time larger proportion polymer waste separated collected according type material polyamide polyethylene reused secondary sustainable product innovation material reporting year reduced paper consumption site mentioned 10 effort optimize environmental performance returned waste paper recycling disposal product production method begin environmentally responsible manner research development stage wherever safety functionality permit increase proportion sartorius stedim biotech complies european renewable raw material used reduce packaging directive waste electrical electronic sartorius stedim biotech also work partner equipment weee site germany industry scientific community sustainable using electronic signature hazardous product solution efficient use raw material material caustic solution oil since 2010 instance explore possibility obtaining result document production hazardous polymer membrane capsule renewable waste provide digital proof proper recovery raw material recycled substance determine andor disposal ensuring waste fully green house gas emission released tracked end end manufacture filter cartridge environmentally friendly expansion use raw material according infrastructure legal regulation expanding infrastructure sartorius stedim sartorius stedim biotech established material biotech line local regulation practice management system test safety raw land use inside new building extended material use compliance environmental production facility integrate advanced ecological protection occupational safety regulation utility technology eg regarding energy europe include international rohs directive consumption preventing waste limiting noise pollution restriction use certain hazardous reducing scrap resulting manufacturing substance electrical electronic equipment process often exceed european reach regulation registration requirement imposed u local environmental evaluation authorisation chemical well protection regulation sartorius stedim biotech comparable international standard customer site yauco expanded 2012 serve informed safety data sheet product safety central manufacturing logistics site information warning alert operating north american market meet highest u instruction hazardous substance present standard green resourcesaving efficient product construction 2012 became first pharmaceutical industry supplier worldwide achieve platinumlevel certification u green 42 management report sustainability report sartorius stedim biotech intends gradually integrated solution sartorius stedim introduce various new indicator raw material use biotech flexact product range example next year began reporting approach beyond ecological benefit year quantitative data chemical group generally offered singleuse technology flexact purchased 2955 metric ton worldwide 2013 solution reduce need stationary installation use manufacturing product equipment thus quantity material consumed versatile central control unit flexact instance used number different highperformance product improve customer biopharmaceutical process environmental footprint technical refinement membrane filter series singleuse product becoming increasingly enabled sartorius stedim biotech slash consumption widespread manufacture innovative effective ultrapure water wetting rinsing medication practical membrane around 95 filter significantly economic aspect also provide ecological benefit lower adsorption lessens amount highvalue compared conventional equipment made steel protein solution lost result pharmaceutical glass singleuse product eliminate need manufacturer substantially reduce quantity resourceintensive cleaning process ultrapure resource use recovering higher yield water well subsequent wastewater processing study shown singleuse service unit assist customer adapting product made plastic far superior complex solution optimally requirement site reusable system consumption energy always analyze customer process whole water chemical product lifecycle identify potential financial ecological expert compared approach based primarily improvement way contribute making reusable material approach based process customer efficient predominantly singleuse material across various environmentally compatible scenario including typical industrial manufacturing 1 process monoclonal antibody result clear sinclair lindsay l et al environmental impact cut manufacturer employing mostly singleuse disposable technology biopharm int november 2 2008 wwwbiopharmservicescomdocsenvironmentimpactdisposabl solution consume around 87 less water 30 espd rawlings b pora h environmental impact less energy addition expert found singleuse reusable bioprocess system bioprocess int deployment singleuse solution reduces size february 2009 18 25 production unit manufacturer said require 30 less space thus also saving energy material research confirmed energy required sterilization cleaning material process based singleuse product around half conventional processes1 although singleuse product clear ecological benefit regarding energy water consumption use generates waste yet consistent reuse recycling could improve environmental performance well ultrapure plastic use manufacture various singleuse product contain around 80 90 energy pure crude oil thus valuable secondary raw material high energy content polymer example mean reused fuel heat power generation management report sustainability report 43 contributing society local subsidiary involved alongside representative political industrial social business activity many positive effect community initiative strengthen progress city community competitiveness respective region focus sartorius stedim biotech based many year area directly indirectly related instance often one largest local business activity infrastructure logistics private employer contractor area environmental protection education maintain main manufacturing site consequently play open constructive dialogue various significant role helping increase local growth local stakeholder inform promptly purchasing power together cooperation comprehensively activity partner sartorius stedim biotech actively help shape development affect concern economic social environment providing financial support project sphere standard function maintenance education culture social affair sport machine building plant security cafeteria contribute toward making region operation use service provided various operate attractive current future subcontractor local site contract sartorius stedim biotech employee alike service awarded according standardized transparent bidding procedure company social outreach activity targeting area beyond mostly locally based sustainability criterion play role home region concentrate field supplier assessment code conduct connection core business fostering research supplier subcontractor sartorius stedim education supporting event scientific biotech drew 2013 requires comply community remain chief priority recognized quality environmental standard supplier evaluation program currently preparation sartorius stedim biotech work contributing toward regional employment approximately 19 subcontractor french site development 11 provider recruitment training service site germany long relatively large production facility sartorius standing relationship 22 subcontractor stedim biotech aubagne yauco goettingen among key industrial employer respective promoting sustainable development longterm region instance headquarters aubagne cooperation reliable partnership key tenet city 40000 inhabitant provide policy aubagne collaborated many attractive longterm job good 400 people year local community goettingen member large french employer organization actively participate several initiative network medef sartorius stedim biotech collaborates closely including local climate protection initiative national local institute help improve reduce carbon dioxide emission sartorius stedim job market situation expanded yauco plant biotech help enhance education provides employment almost 300 people directly granting scholarship assisting career sartorius stedim biotech another guidance fund charitable work non approximately 100 people local service provider governmental organization example supplier sartorius stedim biotech one goettingen company operates industrial larger private employer university town partner several high school university goettingen local workforce 1000 people goettingen yauco cooperate several also major force local economy public school award 20 scholarship rural region surrounding nearby guxhagen excellent student student low income family sartorius stedim biotech also support cultural event one group sponsor behind cultural program presented 2013 part marseille year european capital culture 44 management report sustainability report supporting student graduate sartorius stedim biotech ensures gain young talent dedicated program alliance international bioscience scholarship provides financial technical personal support student graduate scientific technical discipline program intended attract appropriately qualified young people particularly global growth market company enhance international project activity sartorius stedim biotech group headquarters aubagne collaborate several school university including école dingénieurs marseille give recently qualified biotechnology engineer opportunity gain professional experience application engineer marketing 2013 entered new partnership école nationale supérieure de technologie de biomolécules providing scholarship student choice also extended collaboration école nationale supérieure de art métiers student opportunity attend company workshop reporting year helping young people lowincome family gain access scientific technical career another priority activity year review sartorius stedim biotech supported california nonprofit organization biotech partner organizes internship opportunity disadvantaged young people sponsoring event scientific community addition maintaining longterm alliance scientific institution sartorius stedim biotech regularly take part symposium convention annual conference example 2013 included number scientific event bioprocess industry covering subject development antibody vaccine sartorius also supported annual conference usbased parenteral drug association pda various pda convention including event singleuse system microbiological analysis management report statutory auditor report review environmental social societal information 45 statutory auditor report review environmental social societal information statutory auditor report review environmental social societal information published management report free translation english original report paragraph article r 225 105 french issued french provided solely convenience commercial code attestation completeness english speaking reader csr information year ended december 31 2013 express limited assurance fact taken whole csr information presented fairly attention shareholder material aspect accordance adopted reporting criterion reasoned opinion capacity statutory auditor sartorius fairness csr information stedim biotech designated independent thirdparty entity whose request accreditation work carried threeman team deemed admissible french national january 28 february 7 ie period accreditation body cofrac hereby present around two week assist u conducting work report social environmental referred corporate responsibility expert societal information presented management report prepared year ended december 31 2013 conducted following procedure accordance hereinafter csr information pursuant professional standard applicable france article l225 102 1 french commercial code order may 13 2013 determining methodology code du commerce according independent third party entity conduct assignment1 regard responsibility company fairness opinion isae international standard assurance engagement 30002 board director sartorius stedim biotech responsible preparing management report including csr information provided article 1 attestation completeness csr r 225 105 1 french commercial code information prepared accordance reporting criterion used sartorius stedim biotech reporting based interview management familiarized criterion presented throughout group sustainable development management report available request strategy regard social environmental company registered office impact company business societal commitment appropriate resulting independence quality control action programs3 independence defined regulatory text compared csr information presented profession code ethic well provision management report list set forth set forth article l 822 11 french article r 225 105 1 french commercial code commercial code furthermore set quality control system includes documented event omission4 certain consolidated policy procedure designed ensure compliance information verified explanation rule ethic professional standard provided accordance third paragraph applicable legal text regulation article r 225 105 french commercial code responsibility statutory auditor 1 order may 13 2013 determining methodology according independent third party entity conduct assignment based work responsibility 2 isae 3000 assurance engagement audit attest required csr information review historical information presented management report event 3 article a225 2 4 omission explained pursuant third art r225 105 2 ii 46 management report statutory auditor report review environmental social societal information verified csr information covered representative sample entities7 consolidated scope ie company selected according activity subsidiary within meaning article l 233 1 contribution consolidated indicator french commercial code company location risk analysis held interview control within meaning article l 233 3 verify correct application procedure french commercial code subject limit implemented substantive test sampling basis set forth methodological memo paragraph consisting verifying calculation performed presented management report reconciling data supporting evidence selected sample represented average 51 based work considering aforementioned quantitative information limit attest completeness required csr information management report regarding consolidated csr information assessed consistency relation knowledge group 2 reasoned opinion fairness csr information finally assessed relevance explanation relating necessary total nature scope procedure partial omission certain information held seven interview person responsible believe sampling method size preparing csr information sample used exercising professional department charge csr information judgment enable u express limited assurance collection process appropriate higher level assurance would required responsible internal control risk indepth verification due use sampling management procedure order technique limit inherent operation information internal control assess appropriateness reporting criterion system risk material anomaly identified respect relevance5 completeness5 csr information cannot totally eliminated reliability5 neutrality5 clarity5 taking 5 consideration relevant sector best practice section 20 nep 9090 6 art a225 3i 7 sartorius stedim fmt sa sartorius stedim biotech gmbh verify setup process collect compile process check csr information regard completeness consistency familiarize conclusion internal control risk management procedure relating compilation based work identify material csr information6 anomaly likely call question fact csr information presented fairly determined nature scope test material aspect accordance reporting control according nature significance criterion csr information regard company characteristic social environmental observation challenge activity sustainable development strategy sector best practice without qualifying conclusion draw attention following matter concerning csr information consider calculation waste indicator specified significant reporting criterion recovery recyclable material paragraph due consolidating entity consulted insufficient level internal control reliability documentary source held interview level reporting waste lower corroborate qualitative information indicator organization policy action implemented analytical procedure quantitative marseille february 24 2014 information verified using sampling technique calculation well data consolidation deloitte associés verified consistency christophe perrau information shown management report management report net worth financial position 47 net worth financial position cash flow cash flow statement summary sartorius stedim biotech group substantially million 2013 2012 increased net cash flow operating activity net cash flow 901 million reporting period compared operating activity 901 489 yearearlier figure 489 million essentially net cash flow investing gain driven higher earnings moreover net activity acquisition 734 329 operating cash flow fiscal 2012 impacted net cash flow financing activity 80 343 nonperiodic tax payment cash cash equivalent 356 278 gross debt owed bank 1656 1415 net cash flow operating activity net debt owed bank 1300 1137 million 919 728 606 489 901 100 consolidated balance sheet 75 balance sheet total sartorius stedim biotech group increased 774 million 50 8712 million december 31 2012 reporting date december 31 2013 mainly 25 due acquisition tap biosystems group expansion production capacity 0 buildup working capital predominantly induced 2009 2010 2011 2012 2013 sale growth asset side noncurrent asset rose 5680 million 2012 6127 million 2013 planned net cash flow investing activity primarily due previously mentioned acquisition taking account cash flow investment made production capacity acquisition disposal subsidiary 283 million last year figure current asset grew 2258 million 384 million however included several large 2585 million due buildup capacity expansion project investment mainly 225 million working capital partly related several small mediumsize project related acquisition tap biosystems production including cash outflow related acquisition cell culture medium business tap biosystems group respectively net cash flow investing activity amounted 734 million compared 329 million 2012 thus group mainly financed investment acquisition operating cash flow 48 management report net worth financial position key working capital figures1 balance sheet structure day 2013 2012 asset equity liability 716 703 548 553 rate turnover 284 297 162 270 inventory 290 177 inventory x 360 54 56 100 sale revenue rate turnover receivables trade receivables 50 x 360 63 61 sale revenue rate turnover net working capital 0 net working capital 2 x 360 80 80 2012 2013 2012 2013 sale revenue noncurrent asset equity 1 better comparability pro forma sale revenue current asset noncurrent liability tap biosystems completely included 2013 current 2 sum inventory trade receivables less trade payable liability equity 4350 million 2012 4818 million 2013 sartorius stedim biotech ratio longterm capital fixed asset increased group equity ratio rose slightly 553 december 31 1009 1189 gearing ratio cal 2012 548 thus remained comfortable culated ratio net debt equity remained level strong level 027 december 31 2012 026 noncurrent liability markedly 2350 million december 31 2013 compared gearing ratio 1284 million december 31 2012 current liability year year 022 028 025 026 027 060 2305 million 1544 million mainly related change maturity syndicated loan refinanced reporting year 045 overall gross debt increased 1415 million 030 december 31 2012 1656 million december 31 2013 net debt reporting date stood 015 1300 million compared 1137 million year ago 000 2009 2010 2011 2012 2013 management report net worth financial position 49 financing treasury consequence global sale distribution structure generate payment various foreign sartorius stedim biotech group financed currency essentially payment u dollar longterm welldiversified basis element japanese yen british pound financing syndicated credit facility affected currency fluctuation especially refinanced reporting year result exchange rate euro u dollar using sartorius stedim biotech group entered global manufacturing network production facility new syndicated loan agreement volume outside germany france north america 250 million term september 2018 uk india compensate majority currency fluctuation natural hedging furthermore longterm loan agreement generally hedge twothirds remaining net volume currently 22 million concluded currency exposure 15 year ahead kreditanstalt für wiederaufbau kfw relating suitable currency transaction investment production capacity financing sartorius stedim biotech group another element financing structure factoring comprises instrument fixed variable program maximum volume 350 million interest generally target hedge two moreover diverse bilateral credit line third bank loan taken far approximately 25 million total variable interest rate increase general interest rate level ratio net debt underlying ebitda remained unchanged 10 year ended december 31 key financials 2013 interest coverage ratio ratio underlying 2013 2012 ebitda interest payable stood 259 december 31 netdebttounderlying ebitda ratio 1 2012 279 hence key financials remained net debt excellent level 10 10 underlying ebitda1 ratio net debt underlying ebitda interest coverage underlying ebitda1 259 279 12 12 10 10 10 interest expense 40 gearing 30 net debt 03 03 equity 20 1 information underlying ebitda please refer 10 group business development chapter glossary 0 2009 2010 2011 2012 2013 50 management report risk opportunity report risk opportunity report every entrepreneurial act entail opportunity throughout group opportunity short risk opportunity risk term nature considered annual budget managed skill done go planning medium longerterm opportunity long way determining future prospect tracked systematically course strategic company sartorius aim management planning status opportunity management opportunity risk identify exploit business permanent fixture corporate management opportunity systematically recognize system mean also feature discussion evaluate risk early stage take measure decision process senior management counter possible unrealistic expect body risk management eliminate risk approach consciously accept certain measure risk key area opportunity presented entrepreneurial activity order able make appropriate reference made relevant section use opportunity successfully important group management report order avoid connection keep risk contained within repetition risk presented section acceptable limit control carefully specific risk could equally seen representing opportunity event develop opposite sartorius single unit charged managing direction opportunity accordingly discus opportunity risk prefers instead make section specific risk opportunity function integral element groupwide end part document planning control system described area opportunity managing opportunity pharmaceutical laboratory sector opportunity management center analysis sartorius draw customer combine strong growth target market sector environment appetite advanced technology assessment trend give strong significant opportunity generated various indication future business opportunity market technology trend described detail identification potential development sector condition outlook context one key role relevant sector section page 21 58 manager initially take place local rather central level marketfacing function assessment rank company one strategic marketing product global market leader many subsegments management department individual division product area believe high quality play leading role respect central business product strong brand recognition development section assist department established customer relationship put u market monitoring data analysis good position continue building leading implementation strategic project market position corresponding strategy growth opportunity initiative based member group executive committee discussed section concerning strategy regularly discus short medium longterm begin page 18 opportunity potential various business area manager operational responsibility also access opportunity realize business development department part improvement profitability strict strategy review subsequent step prioritizing management process cost key target area opportunity evaluating business respect include improvement administration perspective deriving strategic measure procurement chain ongoing effort optimize allocating resource proceed accordance production present page 30 standardized decisionmaking process applies management report risk opportunity report 51 opportunity discussed context urgent reporting procedure place presentation specific risk opportunity ensure new emerging significant risk beginning page 50 net worth financial position profitability identified executive board receives necessary detail without delay risk management case opportunity management overall risk classification responsibility maintenance effective risk management system ensuring comprehensive first level risk management relates four consistent management material risk rest main risk category defined sartorius external risk board director responsibility coordinating operating risk financial risk corporate developing system rest internal governance risk control system compliance corporate department audit committee sartorius stedim biotech sa second level consists additional subcategories monitor effectiveness risk management within main category legal risk system production risk receivables risk organizational risk risk management system risk reporting process also includes allocation functional category example supply chain sale heart risk management system sits distribution human resource accordance sartorius group risk management handbook group structural organization applies throughout organization handbook includes definition framework categorize risk according scale structural organization process risk reporting implication also perform specific evaluation monitoring control effectiveness risk assigned value risk management system based maximum impact time risk analysis internationally recognized coso standard say record maximum risk without also number source contain considering probability occurrence stipulation handling risk including effect risk alleviation measure bylaw rule procedure group company internal guideline specific risk opportunity groupwide risk reporting system form cornerstone internal risk communication object make possible address risk structured general macroeconomic risk manner continuous basis document opportunity accordance relevant statutory regulatory requirement nature various business area mean sartorius whole insulated certain extent prescribed reporting process requires head full force wider cyclical effect central department managing director economic development prove positive various group company review risk expected turn stimulate stronger growth situation within area responsibility two division ongoing basis report finding every quarter process involves evaluating specific risk ability foresee mitigate direct probability occurrence scale potential indirect effect risk broader sense impact reporting case central risk example currency crisis natural disaster management function whenever defined threshold associated damage commercially significant breached critical infrastructure limited 52 management report risk opportunity report supply chain risk opportunity production risk opportunity supply chain extends way manufacture large proportion product procurement production sale distribution belong core area technical expertise problem within sequence consequential involve high level vertical integration effect including delay delivery global supply example include bag filter chain management system introduced product reusable fermenters bioreactors throughout production process prevent manufactured collaboration supplier problem largely minimizes associated risk production risk transferred analyzing controlling operation external third party manufacture product involved strongly international alignment also bear associated risk capacity organization open whole series opportunity bottleneck overcapacity production downtime various risk opportunity encountered excessive reject rate high level tiedup within supply chain explained detail working capital contain reduce risk planning production capacity carefully using versatile machine semiautomated individual procurement risk opportunity workstation flextime work schedule continuously monitoring production process purchase wide range raw material moreover global manufacturing network enables component part service supplier u compensate capacity bottleneck consequently exposed risk unexpected shifting production regional plant delivery bottleneck price increase global supply chain management system reduces risk consider opportunity various enabling u monitor supervise procurement production facility able concentrate activity moreover conduct regular supplier specific production technology result review also use early warning system refine production operation greater continued increase number master efficiency international production network also agreement concluded safeguard supply make possible capitalize cost advantage supplier strategically important raw material offered individual site furthermore continuous fiscal 2013 always maintain reserve inventory improvement production simplifying strategic raw material work multiple process increasing level automation supplier possible created risk manager help drive efficiency even higher function purchasing 2013 within material group management system principal task function classify supplier sale distribution risk opportunity material purchased according risk factor derive implement necessary risk containment make use variety channel sell measure basis distribute product around world potential risk entailed unexpected change opportunity arise area procurement demand structure growing price pressure non growth enables u increase order compliance supply agreement concluded quantity thereby strengthen position customer employ targeted market analysis supplier increased globalization supplier identify emerging demand trend individual pool hold prospect purchasing segment early time respond favorable term moreover also appropriately technical innovation focus possibility expanded purchasing activity less pricesensitive sale market product international market leading u identify supplier validated production process special product technical expertise could biopharmaceutical industry reduce exposure eventually enhance competitive edge risk growing price pressure minimized risk exposure area logistics recent year setting using central warehouse optimize distribution logistics management report risk opportunity report 53 opportunity arise area sale rd risk opportunity distribution increasing breadth product range put u position sell new devote considerable share resource product existing customer business research development potential risk area relationship built long may arise development result diverge term global presence present opportunity market need exceeding planned development moreover ongoing project strengthen deadline unintentional transfer knowhow direct sale also promise improve sale competitor advanced project management prospect intensive rd controlling early involvement customer development process substantially limit rd risk patent quality risk opportunity continuous tracking technology competitor relevant u secure technology customer use sartorius product wide range position critical production process including manufacture pharmaceutical research hand rd sphere also offer development laboratory main risk encountered kind potential opportunity firstly intensive area noncompliance agreed quality collaboration partner rank among criterion lead loss customer global market leader field open may made liable compensation opportunity u develop particularly highly claim employ rigorous quality check modern innovative product joint effort area production method process cleanroom membrane technology turn expertise technology ensure product satisfy specialist put u right forefront stringent quality requirement global research development present u manufacturing method process subject opportunity turn technical knowledge constant review continuous improvement potential sale stronger position market process moreover refined appropriately requirement evolve successful completion host annual audit customer customer risk opportunity accreditation iso 9001 iso 13485 together document high level quality achieved sartorius draw key customer sartorius product process irrespective pharmaceutical biotech industry public measure also maintain significant insurance sector research educational institution coverage product liability risk sartorius customer usually relatively large organization established traceability system enables u existence time recall entire production batch immediately strong credit rating business area necessary minimize adverse consequence highly diversified customer base group event defect discovered product whole dependent individual key account significant degree factoring program quality requirement growing introduced 2009 keep risk exposure regard stringent time least result trade receivables customer constant low regulatory pressure actually regard first level work continuously improve foremost risk opportunity receivables management explore new possibility market challenging quality demand represent considerable barrier entry potential new competitor moreover competitive risk opportunity provide stimulus technical innovation happy respond sartorius leading competitive position market competitor larger u share status global operator example include merck millipore pall substantial technological barrier market entry 54 management report risk opportunity report fact serve large number customer specific risk associated group accounting highly regulated sector like pharmaceutical industry lead u assess risk new competitor specific risk concerning group accounting arise emerging low global presence help attenuate example arrangement unconventional implication regional risk significantly complex transaction cannot processed routine mean discretion granted change competitive environment example employee involved preparation consolidation market throw consolidated financial statement respect opportunity risk sector find recognition measurement asset liability ongoing process change sartorius outsourcing transfer task specific remains active participant made relevance accounting external service provider acquisition continuously recent year reinforce actuary management consultant may market position open new potential synergy also entail risk risk associated accounting stem derivative financial instrument explained note consolidated financial employee risk opportunity statement innovative technology group sartorius employ large number highly qualified people possible exchange rate risk opportunity scarcity necessary specialist represents opportunity well risk company prof generate good third consolidated sale particularly good training retaining revenue u dollar currency pegged staff counter threat demographic change u dollar smaller proportion foreign losing employee especially currency exchange rate fluctuation key position offering performancerelated consequently matter concern u especially remuneration model targeted continuing professional converting currency balance sheet development option interesting development income statement item time global opportunity continuous education training production network enables u offset lion rising star within organization range share sale revenue received foreign currency attractive employee benefit success within group cost likewise incurred measure apparent low attrition rate foreign currency example manufacture many recent year fact people tend product north american market locally average stay company long time therefore disadvantaged way employment contract certain case contain competition u rival continuously clause prohibiting move direct competitor monitor exchange rate net currency exposure proportion foreign currency sale revenue remains settled financial risk opportunity cost make use derivative financial instrument notably spot forward swap transaction global nature sartorius group operation basis current anticipated net currency mean business activity inevitably exposure foreign currency level hedge exposed financial risk significant 70 exposure advance following aside specific risk associated group 18 month hedging transaction set one accounting exchange rate risk interest rate risk group staff monitored another separate group liquidity risk described addressed detail note consolidated financial statement course interest rate risk opportunity financial risk notably exchange rate risk interest rate risk balanced opportunity concluded fixed interest agreement approximately equal magnitude portion outstanding loan eliminate risk posed variable interest payment however financial instrument outstanding reporting date subject interest based market rate almost two third line credit currently covered interest hedge interest rate risk opportunity apply remainder monitor interest rate trend interest rate exposure management report risk opportunity report 55 constantly facility arrange additional environmental risk hedging transaction consider necessary economically advisable sartorius established environmental management system encompasses integrated division cover whole series liquidity risk opportunity environmental regulation order minimize environmental risk system certified sartorius stedim biotech group actively manages iso 14001 several larger production liquidity centrally order check minimize facility corresponding organizational unit liquidity risk optimize liquidity management site concerned ensure related law within organization regulation observed additional technical option limiting environmental risk identified group us various financial instrument ensure ongoing basis longterm liquidity supply sartorius stedim biotech group syndicated loan agreement place established factoring program risk opportunity continued total scope around 35 million sartorius stedim biotech group exposed loan agreement sartorius stedim biotech potential risk realm addition group refinanced september 2013 volume risk already described result pronounced new facility end september 2018 dependence effective system whose smooth increased 250 million previous functioning essential operation reduce figure 1615 million refinancing arrangement security risk continuously enhancing configured provide even greater implementing security guideline policy flexibility capital procurement future rule measure based requirement diversify lending base remaining term two iso 27001 standard german federal four half year respectively loan office information security bsi standard agreement mean sound longterm financing base company existing application system checked potential risk regular external employ various measure shortterm liquidity internal audit moreover appropriate measure procurement central management solvency taken minimize risk identified continuous throughout group credit line alignment strategy business strategy accessed repaid short notice agreed tracking new technical development use syndicated loan agreement individual advanced hardware software minimize risk group company also bilateral credit line inherent operation system place smaller scale amounting 15 million environment new erp system commissioned cash pooling agreement selected group sartorius production site goettingen company primary tool used manage gradually rolled group site around liquidity within group agreement world 2014 paid particular attention gradually expanded throughout delivery project mastering accompanying risk least maintaining precautionary backup system intend continue regulatory risk vein implementation new system brings whole series opportunity role supplier biopharmaceutical especially relation efficiency gain industry health care provider mean standardization harmonization business sartorius also affected underlying process worldwide development area possibility regulatory authority fda emea adopting restrictive approach approval new medication remains principal source risk context move would reduce number new pharmaceutical product marketed would consequently downgrade future prospect sartorius medium term 56 management report risk opportunity report process risk made allowance balance sheet pending legal dispute proceeding potential produce substantial negative impact group result insurance taken insurance policy cover wide range risk possible economically advisable insurance policy include coverage liability business interruption transport material pecuniary damage risk provide comprehensive coverage legal cost independent department working conjunction external insurance broker regularly review nature extent insurance protection make adjustment necessary assessment overall risk situation risk outlook expedient feasible adopted counter measure arranged balance sheet measure reporting year cover discernible risk within sartorius stedim biotech group potential damage net worth financial situation profitability judge probability occurrence risk presented low case occurrence could material significance sartorius stedim biotech group whole individual group company thorough analysis entire risk situation according current review discernible risk could jeopardize existence group similarly based current review discernible risk could jeopardize existence group future management report forecast report 57 forecast report future macroeconomic environment forecast two southern country eurozone italy spain indicate return growth pace global economic growth likely two year recession gross domestic product increase noticeably 36 2014 according expected expand 07 italy 2013 18 figure imf 2013 29 02 spain previous year 13 information oecd point increasing growth export stabilization private domestic demand forecasted gdp growth rate 2014 imf forecast emerging country indicate 36 26 12 10 51 growth 51 2014 2013 45 prime 8 driving force grouping asia china india indonesia malaysia philippine thailand 6 vietnam rate growth economic output expected rise 63 previous 4 year 65 2014 chinese economy appears set grow 73 2013 76 2 make strong contribution region progress 0 imf forecast japan suggests rate global u japan euro developing economic growth drop back somewhat 12 zone emerging 2014 2013 20 result main market anticipated gradual winding expansive source international monetary fund fiscal policy effect time coupled weaker private demand following 3 percentage point increase sale tax planned april 2014 estimate industrialized country suggest growth year 20 2013 12 future exchange interest rate trend imf expects rate economic growth leading central bank expected keep interest u pick strongly 16 reporting rate low 2014 indeed ecb made clear year 26 2014 decisive factor behind option reduction base rate forecast include higher government spending well entirely table continued recovery u real estate market forecast eurous dollar exchange rate germany expected see growth 14 2013 course 2014 range 110 euro u 05 forecast based primarily economic recovery dollar 145 euro u dollar within eurozone particular germany important trading partner france source international monetary fund world economic outlook october 2013 scotiabank global forecast update november 2013 rate economic growth france predicted reuters forex poll december 2013 ecb oecd economic outlook improve 02 reporting year 10 volume 2013 issue 2 november 2013 suggestion increased growth france reflects expected upturn business investment activity country 58 management report forecast report pharmaceutical industry positive prospect expiry austerity measure make presence felt effect introduction state health demographic change steadily increasing access insurance usa yet become apparent healthcare emerging country general japanese government example planning rise lifestyle chronic disease look set remain less double use favorably priced primary factor driving expansion generic period 2018 pharmaceutical industry new medication especially targeting condition currently difficult treat also make significant contribution emerging country continue drive growth future growth expiry patent austerity measure cut healthcare spending particular growth pharmerging market contrast industrialized country nevertheless tend remain well average around 10 13 per weigh future growth industry year 2012 2017 period apart demographic trend rapid growth driven market researcher ims health forecasting notably rising level state investment overall growth 3 6 global healthcare system increased private spending pharmaceutical industry period 2012 2017 especially among fastexpanding middle class consequently share global pharmaceutical market accounted pharmerging market moderate growth industrialized nation increase around ten percentage point approximately 30 next five year growth north american european japanese region expected remain moderate average 1 4 2012 2017 period patent pronounced longterm trend drive average growth biopharmaceutical industry 1 source ims global use medicine outlook 2016 2017 evaluate pharma returning growth june 2013 bioplan 10th annual report april 2013 management report forecast report 59 biotech sector outgrow market whole persistently strong research development pipeline given proportion new development based expert forecast suggest biopharma segment biological manufacturing process particularly pharmaceutical market enjoying high around 40 total pharma pipeline particularly strong growth year continue outperform market whole going forward expiry patent expected proportion sale revenue accounted increasingly strong effect growth rate medication vaccine manufactured using biotech biotechnology sector future noting expiry method expected rise currently around whole series patent ims health forecast sale 21 22 approximately 25 period biosimilars biobetters likely swell 2017 less u 1 billion today u 4 billion 2017 continued overproportionate growth driven part biopharmaceuticals already market observer forecast biotechnology gained approval increasing market penetration market whole reach around u 220 billion expanding range indication additional 2017 average rate growth period growth impetus expected segment 2012 2017 expected 6 8 biopharma growing market percentage worldwide rx otc pharmaceutical sale biotech v conventional technology biotech share within top 100 product 17 39 51 2004 2012 20181 479bn 750bn 941bn biotechnology conventional unclassified 1 2018 split biotech n45 avg 31bn conv n55 avg 24bn source evaluate pharma june 2010 60 management report forecast report squeeze publicsector research continue expert expect reduction overall public sector rd spending result widespread consolidation national budget handful emerging country large market china india investment science education likely rise government plan china example provide massive investment pharma ceuticals research pharmaceutical industry source global use medicine outlook 2016 2017 evaluate pharma returning growth june 2013 bioplan 10th annual report april 2013 cefic tough condition lead eu chemical output contraction growth return 2014 june 2013 future business development outlook fiscal 2014 incorporates risk opportunity outlined report supply biopharmaceutical industry business development generally driven stable longterm trend therefore economic fluctuation play less role example decision regulatory agency regarding drug approval use medication assuming trend toward biomanufacturing pharmaceutical increasing utilization single use technology continue forecast sale revenue rise 11 14 constant currency 2014 cell culture medium small scale fermentation business acquired projected contribute around six percentage point growth management expects underlying ebitda margin rise around 235 without currency effect considered please refer definition operating earnings margin page 25 glossary moreover 2014 plan invest 6 8 sale revenue expansion production capacity among project regard financial position forecast end 2014 ratio net debt underlying ebitda edge slightly without taking potential portfolio change account management report financial statement parent company sartorius stedim biotech sa december 31 2013 61 financial statement parent company sartorius stedim biotech sa december 31 2013 financial statement parent company therefore considering company hold treasury share net dividend 120 paid sartorius stedim biotech sa parent company every share par value 061 group accordance decision extraordinary shareholder meeting held annual shareholder meeting acknowledges 16 april 2013 sartorius stedim biotech sa informed new tax regulation transformed mixt holding company retroactively dividend according 2013 finance law 1 january 2013 company therefore abolished right choose withholding tax managing investment group real 21 submitting dividend estate french company distribution progressive scale tax income application 40 allowance 2013 sale revenue generated sartorius stedim retained without modification accordance biotech sa 1501 k relative 81942 k 2012 article 158 3 2 4 french general code important reduction connection wtih contribution partial asset sartorius stedim biotech dividend paid april 15 2014 sa sartorius stedim fmt sa operating profit 2133 versus 3575 k 2012 net financing income amount distributed january 1 2011 totaled 22717 versus 22443 k 2012 eligible tax rebate follows net profit 2013 20875 k compared 26198 k 2012 income eligible tax rebate income appropriation net profit fiscal year ended dividend distributed dec 31 2012 16876856 0 annual general shareholder meeting agm dec 31 2011 15327238 0 suggest appropriate net profit 2087498653 dec 31 2010 13783264 0 reporting year 2013 director receive director meeting attendance fee whose amount allocation established board director consideration limit set agm sartorius stedim biotech sa share capital follows share capital december 31 2013 legal reserve 6100 total capital amount ten million three hundred balance resulting deduction legal reserve ninetyfive thousand eight hundred six euro 2087492553 sixtysix cent 1039580666 divided 17042306 share worth sixtyone cent 061 following amount added balance fully subscribed paid heading article 6 yearearlier profit carried forward 2896855180 bylaw would yield distributable profit 4984347733 total amount dividend disbursed shareholder 1841231520 balance resulting disbursement 3143116213 remaining amount 3143116213 carried next year 62 management report financial statement parent company sartorius stedim biotech sa december 31 2013 movement sartorius stedim biotech sa share capital increase share capital 2013 exclusively attributable exercise stock option number number share share capital share par share capital share new date nature transaction value increase premium share transaction transaction exercise share 1st half 2008 subscription option 061 32220 301863 5200 16903188 103109450 exercise share 2nd half 2008 subscription option 061 117730 1191580 19300 16922488 103227177 exercise share 1st half 2009 subscription option 061 194590 2691260 31900 16954388 103421770 exercise share 2nd half 2009 subscription option 061 111831 1901606 18333 16972721 103533601 exercise share 1st half 2010 subscription option 061 162669 4869394 26667 16999388 103696270 exercise share 2nd half 2010 subscription option 061 85766 2285999 14060 17013448 103782036 exercise share 1nd half 2011 subscription option 061 61000 1344000 10000 17023448 103843036 exercise share 2nd half 2011 subscription option 061 15250 722500 25000 17025948 103858286 exercise share 1st half 2012 subscription option 061 50980 1734460 83580 17034306 103909266 exercise share 2st half 2012 subscription option 061 42700 2023000 70000 17041306 103951966 exercise share year 2013 subscription option 061 6100 86200 10000 17042306 103958066 sartorius stedim biotech sa shareholding december 31 2013 situation sartorius stedim biotech sa shareholding shareholder share voting right 50 sartorius ag sartorius ag 10 less 50 none none 5 less 10 none none management report financial statement parent company sartorius stedim biotech sa december 31 2013 63 past three year ownership sartorius stedim biotech share capital distributed follows december 312011 december 31 2012 december 31 2013 number share voting number share voting number share voting shareholder share capital right share capital right share capital right sartorius ag 9770178 573 719 9770178 573 725 9771178 573 725 single voting right double voting right 9770178 573 719 9770178 573 725 9771178 573 725 vl finance 1642095 96 121 1642095 96 122 1642095 96 122 single voting right double voting right 1642095 96 121 1642095 96 122 1642095 96 122 total sartorius group 11412273 670 840 11412273 670 846 11413273 670 847 treasury share 1698710 100 00 1698710 100 00 1698710 100 00 personnel shareholder general public 3914965 230 160 3930323 231 154 3930323 231 154 single voting right 3495225 205 129 3719587 138 3719587 138 double voting right 419740 25 31 210736 16 210736 16 total share 17025948 999 1000 17041306 1000 1000 17042306 1000 1000 belonging sartorius ag reverse merger sartorius stedim legal disclosure threshold crossed treasury share held sartorius stedim biotech sa 2013 legal disclosure threshold crossed registered company according resolution passed annual general shareholder meeting agm april 19 2010 share buyback program implemented control company december 31 2013 sartorius stedim biotech sa 2010 sartorius ag hold directly indirectly 67 information following movement done share capital 85 outstanding voting right 2010 movement registered since treasury share without voting right time number share bought 1698710 staff shareholding average purchase price 3610 amount negotiation cost 2243 exception stock subscription plan stock number share held end year 1698710 option plan company run employee value purchase price 61327190 profitsharing scheme nominal value 061 corresponding fraction share capital 997 64 management report financial statement parent company sartorius stedim biotech sa december 31 2013 treasury share held company affected security representative theshare capital following goal none 5 return share exchange payment within scope potential external project authority delegated annual general 5 deliver share case exercise shareholder meeting board director right attached security giving access mean immediately certain future date annual general shareholder meeting capital company delegate authority board director increase capital board director decided propose resolution 8 april 2014 ordinary annual shareholder meeting order modify security giving access share capital allocation treasury share knowing maximum purchase price paid company share shall exceed fortyfive euro 45 per stock option share specified informative purpose 16994388 share constitute share capital company maximum sum allocated share subscription plan share buyback plan amount seventysix million four hundred seventyfour thousand seven hundred stock option plan detailed table ten euro 76474710 authority delegated board director setting new plan recently expired board director longer delegated unpaid capital authority set new plan none authorized unissued capital none management report financial statement parent company sartorius stedim biotech sa december 31 2013 65 number share total number subscribed number number date total option senior number option target number agm number granted executive initial subscrip jan 1 granted performance beneficiary authorized option senior bene bene tion dec 31 based valid plan board meeting granted executive ficiaries ficiaries price 2013 exercisable option option june 23 2000 aug 2 2000 139105 0 0 5 859 0 0 0 0 june 23 2000 sept 28 2001 142855 0 0 7 1194 0 0 0 0 june 23 2000 oct 14 2002 12100 0 0 1 678 0 0 0 0 june 23 2000 sept 10 2003 22000 0 0 1 79 0 0 0 0 june 23 2000 feb 11 2004 66000 0 0 1 642 0 0 0 0 june 23 2000 july 23 2004 140000 0 0 19 923 1000 15642 0 2 june 10 2005 sept 15 2005 127500 0 0 15 1887 0 5000 0 1 june 10 2005 nov 10 2005 35000 0 0 2 2951 0 3000 0 1 total 684560 0 0 51 1000 23642 0 4 23642 agm annual general shareholder meeting change number stock option january 1 2011 december 31 2013 2013 2012 2011 outstanding share january 1 24642 40000 52500 allocated period 0 0 cancelled period 0 0 exercised period 1000 15358 12500 lapsed period 0 0 outstanding december 31 23642 24642 40000 share capital dilution share subscription option granted ten top nonsenior executive beneficiary option december 31 2013 total number share exercised 2013 fiscal year capable issued basis performance based share subscription option potential none 23642 share 014 fully diluted share capital option exercised fiscal year share subscription option granted senior reported year 1000 option exercised executive company option exercised ten significant accounted total fiscal 2013 option exercised 2013 none 66 management report financial statement parent company sartorius stedim biotech sa december 31 2013 share subscription warrant dividend distribution policy sartorius stedim biotech sa issued share company dividend distribution policy based subscription warrant net profit generated group level relevant fiscal year well group foreseeable growth profitability pledging share april 16 2013 annual general shareholder sartorius stedim biotech sa share pledged meeting voted payment net dividend 110 per share dividend available payment april 19 2013 pledging asset dividend interim dividend unclaimed five none year following payment date must paid state ie france article 2277 french civil code 2012 2011 2010 2009 2008 dividend per share fiscal year 110 100 090 060 030 number share 15342596 15327238 15314738 16972721 16922488 dividend corrected per share 1 110 100 090 066 033 1 compared number share december 31 2012 senior executive membership committee director receives lumpsum amount 4000 per information sartorius stedim biotech sa senior full year membership addition executive list position hold attendance fee 1200 insofar hold held past five year included chair instead receive lumpsum corporate governance report amount 8000 per full year hold chairperson addition attendance fee remuneration activity committee director meeting attendance fee due together remuneration term previous subsection hereof director meeting attendance fee calculated annual basis method calculating fee valueadded tax reimbursed changed 2013 fiscal year corporation insofar member board entitled invoice corporation separately director receive director meeting attendance valueadded tax exercise right fee whose amount allocation established board director consideration limit resolution applied set agm director got executive top management activity group level context director receives fixed remuneration executive corporate officer receive 25000 per year paid annual remuneration membership financial statement adopted annual shareholder meeting fall due total 197600 paid director meeting payment annual shareholder meeting attendance fee 2013 chairman board receives twice amount furthermore member board receive attendance fee 1200 per meeting reimbursement expense addition annual remuneration management report financial statement parent company sartorius stedim biotech sa december 31 2013 67 compensation executive management team director meeting base fixed annual long term stock departure attendance salary incentive incentive other2 option indemnity fee k k k k k k k total 2012 15550 9600 8600 5080 00 00 00 total 2013 16370 9540 6480 1180 00 00 00 joachim kreuzburg1 2012 6030 2720 5990 3660 00 00 00 joachim kreuzburg1 2013 6540 2680 4470 740 00 00 00 reinhard vogt3 2012 3740 1660 2610 1420 00 00 00 reinhard vogt3 2013 4040 1640 2010 440 00 00 00 volker niebel4 2012 2900 2610 00 00 00 00 00 volker niebel4 2013 2910 2610 00 00 00 00 00 5 oscarwerner reif 2012 2880 2610 00 00 00 00 00 oscarwerner reif5 2013 2880 2610 00 00 00 00 00 1 dr joachim kreuzburg receives salary sartorius ag duty entire sartorius group remuneration determined annually supervisory board sartorius ag 2 phantom stock plan used variable longterm incentive component incorporates risk remuneration component depends development sartorius ag share price period least four formerly three year payable price exceeds least 75 formerly 10 per year relative time phantom stock assigned share price outperformed tecdax comparative index amount paid capped maximum 25 time share price time phantom stock assigned based case actual annual tranche concerned use component designed longterm incentive effect incorporates risk corresponds suggestion french german corporate governance code date payment made joachim kreuzburg reinhard vogt according phantom stock plan 3 reinhard vogt receives salary sartorius ag duty entire sartorius group remuneration determined annually supervisory board sartorius ag 4 volker niebel receives salary subsidiary sartorius stedim biotech gmbh work entire sartorius stedim biotech group remuneration determined annually shareholder sartorius stedim biotech gmbh 5 oscarwerner reif receives salary subsidiary sartorius stedim biotech gmbh work entire sartorius stedim biotech group remuneration determined annually shareholder sartorius stedim biotech gmbh independent auditor current regulated agreement independent auditor sartorius stedim shareholder sartorius stedim biotech biotech sa group requested approve agreement covered article l225 38 french ernst young represented xavier senent commercial code duly authorized board alternate auditor auditex director form submitted deloitte associés represented christophe perrau alternate auditor beas payment term trade payable december 31 2013 balance trade payable totaled 1701683 trade payable comprised following 8183 invoice paid 30 day regarding invoice issue date 68 management report financial statement parent company sartorius stedim biotech sa december 31 2013 18 invoice paid 60 day regarding december 31 2012 balance trade payable invoice issue date totaled 707031700 trade payable comprised following date cumulative overdue trade payable amounted 017 8850 invoice paid 30 day regarding invoice issue date 042 invoice paid 60 day regarding invoice issue date date cumulative overdue trade payable amounted 1108 fiveyear financial result parent company sartorius stedim biotech sa k 2009 2010 2011 2012 2013 share capital end period share capital capital stock 10353 10378 10386 10395 10396 number share outstanding 16972721 17013448 17025948 17041306 17042306 transaction financial performance sale revenue excl vat 64626 65026 71855 81942 1501 profit tax employee profit sharing plan amortization depreciation provision expense reversal 16067 25884 23617 26218 21180 income tax 1813 1185 1069 678 292 contribution employee profitsharing plan 0 0 0 0 0 net profit 14160 21066 23860 26198 20875 dividend paid proposal dividend 10184 13783 15327 16877 16878 earnings per share eps tax employee profitsharing amortization depreciation provision expense 105 159 145 158 126 eps tax employee profitsharing amortization depreciation provision expense 084 124 140 154 122 dividend per share 060 090 100 110 110 personnel workforce size 299 293 336 388 0 personnel cost 11381 11177 11843 14171 0 social security cost 5758 6007 6574 6574 0 corporate governance 70 corporate governance board director committee board director committee board director joachim kreuzburg board director composed eight member chairman chief executive officer two independent director date birth april 22 1965 appointed threeyear period nationality german composition board director appointed april 19 2010 december 31 2013 first appointment 29 june 2007 mandate renewed 16 april 2013 appointed date annual general shareholder meeting 2016 approve financial statement fiscal year ending 31 december 2015 number sartorius stedim biotech share held 1 current directorship position within group chairman executive board vorstand sartorius ag vice chairman supervisory board sartorius stedim biotech gmbh managing director sartorius lab holding gmbh member board director sartorius stedim north america inc member board director sartorius stedim filter inc member board director sartorius stedim japan kk member board director sartorius stedim lab ltd président vl finance sa member board director sartorius japan kk member board director denver instrument beijing co ltd member board director sartorius scientific instrument beijing co ltd member board director sartorius hong kong ltd member board director sartorius biohit liquid handling oy member board director sartorius north america inc président member comité exécutif sartorius stedim fmt sa member board director sartorius stedim biotech sarl member board director sartorius stedim integrated service sarl member board director sartorius stedim bioprocess sarl corporate governance board director committee 71 past directorship held past five year volker niebel within group vice chairman supervisory board executive member sartorius weighing technology gmbh executive vice president operation managing director geschäftsführer date birth august 14 1956 sartorius corporate administration gmbh nationality german member board director sartorius stedim sus inc first appointment 29 june 2007 member board director mandate renewed 16 april 2013 sartorius stedim industry sarl appointed date annual general member board director shareholder meeting 2016 approve sartorius stedim sus sarl financial statement fiscal year ending 31 december 2015 current directorship position number sartorius stedim biotech share held 1 outside group current directorship position member advisory board regionalbeirat within group commerzbank ag germany managing director geschäftsführer member advisory board beirat sartorius stedim biotech gmbh hameln group gmbh germany member board director member advisory board beirat sartorius stedim north america inc otto bock holding gmbh co kg germany member board director member economic advisory board wirtschafts sartorius north america inc beirat norddeutsche landesbank germany member board sartorius stedim filter inc member board director educational professional background sartorius stedim india pvt ltd diplommaschinenbauingenieur dr rer pol member board director university degree mechanical engineering sartorius stedim lab ltd doctorate economics member board director sartorius stedim aseptics sa managing director member board 19921995 research associate institute director sartorius stedim biotech sarl solar energy research hamelin managing director member board germany director sartorius stedim integrated service sarl 19951999 research associate faculty managing director member board economics management director sartorius stedim bioprocess sarl university hanover germany directeur général member comité executif since sartorius ag goettingen germany sartorius stedim fmt sa may 1 1999 recent position promotion executive board past directorship held past five year vice president finance within group investor relation member board director since member executive board sartorius stedim sus inc nov 11 2002 sartorius ag goettingen germany managing director member board may 1 2003 spokesman sprecher executive director sartorius stedim sus sarl nov 10 2005 board sartorius ag goettingen managing director sartorius stedim dd sarl germany managing director member board since ceo executive board chairman director sartorius stedim industry sarl nov 11 2005 sartorius ag goettingen germany member board director currently responsible operation sartorius stedim system inc human resource legal affair compliance corporate communication 72 corporate governance board director committee educational professional background 2007 2009 sartorius stedim biotech gmbh diplombetriebswirt university degree business recent position vice president administration economics rd technology since 2009 managing director sartorius 19831985 schmidt clemens lindlar stedim biotech gmbh goettingen germany sale manager petro germany chemical industry usa 19851998 gambro ab lund sweden 19982001 skanska ab malmö sweden reinhard vogt member executive management team poggenpohl executive member gmbh herford germany executive vice president marketing sale service 20012007 sartorius ag goettingen germany date birth august 4 1955 recent position senior vice nationality german president operation biotechnology division first appointment 29 june 2007 since 2007 managing director sartorius stedim mandate renewed 16 april 2013 biotech gmbh goettingen germany appointed date annual general shareholder meeting 2016 approve financial statement fiscal year ending 31 december 2015 oscarwerner reif number sartorius stedim biotech share held 1 executive member executive vice president research development current directorship position within group date birth november 11 1964 member executive board sartorius ag nationality german managing director sartorius stedim biotech gmbh first appointment 29 april 2009 managing director ofsartorius weighing technology gmbh appointed 17 april2012 managing director appointed date annual general sartorius lab holding gmbh shareholder meeting 2015 approve financial member board director statement fiscal year ending december 31 2014 sartorius stedim north america inc member board director number sartorius stedim biotech share held 1 sartorius north america inc member board director current directorship position within group sartorius stedim india pvt ltd managing director sartorius stedim biotech gmbh member board director member board director sartorius stedim malaysia sdn bhd sartorius stedim switzerland ag switzerland member board director sartorius stedim australia pty ltd past directorship held past five year member board director none sartorius australia pty ltd member board director educational professional background denver instrument beijing co ltd diplomchemiker dr rer nat university degree member board director chemistry molecular biology msc doctorate sartorius scientific instrument beijing co ltd chemical engineering member board director sartorius hong kong ltd 19911995 research associate institute member board director chemical engineering sartorius stedim switzerland ag university hanover germany member board director 19952009 sartorius ag goettingen germany sartorius japan kk recent position vice president member board director rd technology sartorius stedim japan kk member board director sartorius korea ltd corporate governance board director committee 73 past directorship held past five year research later university within group california berkeley california usa member board director sartorius stedim sus inc 19771981 psa automobile citroën member board director head department charge sartorius stedim india pvt ltd overall manufacturing planning member board director programming sartorius stedim biotech beijing co ltd 19811986 renault automation robotics managing director geschäftsführer vice president strategic planning sartorius technology service gmbh 19861989 ceo chairman board managing director geschäftsführer hightech startup company specializing sartorius food beverage gmbh artificial intelligence cognitech managing director sartorius stedim poland sp zoo 19892005 consultant human resource managing director sartorius stedim hungária kft management company executive especially multicultural educational professional background industriekauf environment mann vocational diploma industrial business administration 20052007 ceo stedim biosystems 20072008 executive vice president 19791983 sarstedt ag nuembrecht germany sartorius stedim biotech general manager sarstedt ab sweden since managing director l2 l conseil 19832007 sartorius ag goettingen germany may 2008 sarl management consulting service recent position management human resource senior vice president sale marketing biotechnology division since 2007 managing director sartorius stedim bernard lemaître biotech gmbh goettingen germany since 2009 member executive board nonexecutive member sartorius ag goettingen germany date birth december 16 1938 currently responsible marketing nationality french sale service first appointment 29 june 2007 mandate renewed 16 april 2013 liliane de lassus appointed date annual general shareholder meeting 2016 approve nonexecutive member financial statement fiscal year ending date birth december 29 1943 31 december 2015 nationality french number sartorius stedim biotech share held first appointment 29 june 2007 202744 mandate renewed 16 april 2013 appointed date annual general shareholder current directorship position outside meeting 2016 approve financial statement group fiscal year ending 31 december 2015 président financière de la seigneurie sa member board director senova system inc number sartorius stedim biotech share held 1 member board director sycovest asset management paris current directorship position outside group member supervisory board managing director l2 l conseil sarl management azulis capital sa paris consulting service human resource management solon venture ltd london qualium investment sa paris educational professional background phd organic chemistry 1972 mba 1966 past directorship held past five year master degree sanskrit 1969 outside group member supervisory board intrasense sa 19691977 scientific employee charge research french cnrs educational professional background national center scientific 19792007 founder ceo chairman stedim sa 74 corporate governance board director committee arnold picot 19841987 university professor faculty business administration technical nonexecutive member university munich director date birth december 28 1944 institute general industrial nationality german business administration since 1988 university professor faculty first appointment 29 june 2007 business administration university mandate renewed 16 april 2013 munich director institute appointed date annual general information organization shareholder meeting 2016 approve management financial statement fiscal year ending 20042005 konrad adenauer visiting professor 31 december 2015 georgetown university washington dc usa number sartorius stedim biotech share held 1 current directorship position within henri riey group chairman supervisory board nonexecutive member sartorius ag independent member chairman supervisory board date birth november 5 1961 sartorius stedim biotech gmbh nationality monegasque past directorship held past five year first appointment 29 june 2007 within group mandate renewed16 april 2013 chairman supervisory board appointed date annual general sartorius weighing technology gmbh shareholder meeting 2016 approve financial statement fiscal year ending current directorship position outside 31 december 31 2015 group member supervisory board takkt ag number sartorius stedim biotech share held 100 member supervisory board wissenschaftliches institut für infrastruktur und current directorship position outside kommunikationsdienste gmbh und wikconsult group gmbh president aidea president groupe hr sa past directorship held past five year director princess grace monaco foundation outside group vice chairman supervisory board past directorship held past five year etelon esolutions ag outside group none educational professional background educational professional background diplôme institut supérieur de gestion france bankkaufmann diplomkaufmann banker university degree earned french higher institute degree business administration dr rer pol post business management institut supérieur de gestion doctoral lecture qualification venia legendi betriebs wirtschaftslehre authorization teach business 19851988 fund manager paribas bank managerial economics university 19881996 fund manager responsible european equity fund management 19701975 research assistant assistant team barclays bank france professor university munich 19961999 head research barclays asset 19761984 university professor faculty management europe business administration university 19992004 executive vice president barclays hanover germany director asset management charge institute management fund management business organization 2004 2013 cfo hendyplan sa 19801981 visiting scholar stanford university california usa corporate governance board director committee 75 registered address information regard social mandate member accordance bylaw sartorius stedim board director general manage biotech sa company diretor owns personally ment domiciled company headquarters least one share company director fulfill mentioned threshold independent director regard number mandate listed company pursuant principle good corporate governance independent member may executive director maximum two principal shareholder employee former group mandate company belonging group employee supplier banker group major customer may link likely non executive director maximum four impair judgment mandated company belonging group sartorius stedim biotech sa board director company knowledge within last five year includes two independent director mr liliane de member board director lassus mr henri riey convicted fraud last five criterion needed qualify independent year subject official public director following investigation sanction statutory regulatory authority may employee senior executive employee director parent company associated capacity manager one consolidated company may bankruptcy receivership liquidation five previous year past five year may senior executive company disqualified court acting company directly indirectly hold capacity member administrative director position employee management supervisory body issuer senior executive company either acting capacity management currently less five year executive conducting business issuer hold director position past five year may significant client supplier business company knowledge family relationship exist banker investment banker company among member company board director group company group represents significant part business furthermore company knowledge conflict interest duty member may close family tie one board director private interest senior executive duty director must inform board soon aware conflict interest may auditor company even possibility potential conflict must five past year refrain participation discussion relevant subject matter voting may director company associated resolution twelve year company knowledge settlement agreement reached shareholder client supplier others appoint member board director company knowledge service contract linking board member sartorius stedim biotech group granting benefit 76 corporate governance board director committee audit committee audit committee currently composed four member mr henri riey chairman committee since december 5 2007 mr arnold picot mr liliane de lassus mr bernard lemaître chairman audit committee mr de lassus independent chairman board director also ceo group permanent guest audit committee voting right audit committee met five time fiscal 2013 remuneration committee remuneration committee currently composed four member mr arnold picot chairman committee since june 29 2007 mr liliane de lassus mr henri riey mr bernard lemaître two four member remuneration committee independent remuneration committee met fiscal 2013 company decided move forward taking account best practice corporate governance code mr joachim kreuzburg executive board member replaced committee mr liliane de lassus information organization function activity committee fiscal 2013 please refer chairman report pursuant article l 225 37 french commercial code included publication following page corporate governance executive committee 77 executive committee executive committee manages operational business company decides strategic important topic relating company provided decision interfere responsibility board director executive committee also implement decision resolution board director daily business composed following person joachim kreuzburg volker niebel reinhard vogt oscarwerner reif joerg pfirrmann dominique baly executive committee met twelve time fiscal 2013 78 corporate governance chairman report pursuant article l 225 37 french commercial code chairman report pursuant article l 225 37 french commercial code pursuant article l 225 37 french decided go joint chairman ceo commercial code chairman board board director two separated function director us report cover fiscal year corporate governance structure implemented ended december 31 2013 present composition mist french listed company board board director application director allow u simplify daily business principle balanced representation men increase efficiency addition approach take woman condition preparation account company owned majority organization work board director shareholder following implementation internal controlling control procedure corporate governance best practice due historical implemented company within group reason related shareholding company composition board director pursuant last paragraph article l 225 235 committee give majority shareholder french commercial code company possibility get fair balance representation independent auditor prepare report director representing shareholder independent concerning report chairman board member executive director reason director internal control risk management contrary afepmedef recommendation gradual procedure relative preparation processing renewal director membership accounting financial information implemented top company closely related german regulation regard corporate governance code code cancelled gradual corporate governance code renewal recommendation recently addition board director composed 125 woman since fiscal 2008 sartorius stedim biotech sa compliance afepmedef code board director therefore decided adopt requiring 20 however company working afepmedef recommendation reference code getting conform corporate governance best corporate governance see wwwmedeffr practice follow topic coming year indeed possible change structure afepmedef corporate governance code board considered fiscal 2014 code defines set regulation good regard structure general regard responsible corporate governance follows independent member participation woman comply explain principle implemented board eg board discus change country european union listed current onetier structure two tier structure company comply recommendation executive supervisory board andor code must explain corporate add another independent woman board governance report threshold 66 independent member audit committee reached company level sartorius stedim biotech sa essentially complies practical majority shareholder code though sartorius stedim biotech sa need however two four independent member explain certain divergence code last chairman remuneration committee independent member company decided board sartorius stedim biotech sa composed apply afepmedef recommendation currently 25 independent member accordance order get chairman remuneration afepmedef independency criterion committee group level consistent according code board director sartorius stedim biotech sartorius ag company comprised least 33 independent director board director corporate governance chairman report pursuant article l 225 37 french commercial code 79 condition preparation organization mission mentioned summarize internal work board director bylaw board director internal rule regulation activity report board director fiscal 2013 procedure governing organization functioning board director defined board director met sept time fiscal internal rule regulation board year average attendance 96 board director deal matter board reviewed approved corporate concerning proper operation company consolidated account 2012 take decision subject concern board director considered debated following meeting mission 1 strategic direction major group project main mission board director 2 annual halfyear quarterly financial follows statement 3 budget presented executive management board director shall define company 4 information financial structure cash strategic goal assess overall flow item perspective least year proposed 5 significant offbalance sheet commitment ceo ensure goal implemented 6 risk indicator group shall also appoint corporate officer responsible 7 internal organization project managing company pursuit strategy 8 stock market performance review delegation authority 9 selfassessment board member 10 implementation syndicated loan sartorius board director shall review management stedim biotech group group monitor quality information 11 legal reorganization split sartorius stedim provided shareholder market biotech sa activity pure holding company financial statement material event manufacturing company occur especially company shareholding 12 renewal mandate chairmanchief executive officer two executive vice president board director responsible approving 13 election member audit committee strategic investment project transaction remuneration committee particular acquisition disposal likely 14 strategy partnershipacquisitions materially affect company result structure lonzatap biosystems plc balance sheet risk profile board member carried formal assessment board director shall deliberate prior work board director questionnaire making change management structure sent board member summary company shall informed principal result show positive overall assessment organizational change board performance selfassessment show director consider well informed board director shall examine corporate executive management company belief consolidated account approve manage ceo moderating properly discussion ment report section annual report board director dealing corporate governance setting company policy respect committee chairman submitted committee remuneration stock option work report board discussion board director shall convene general independent auditor invited two board shareholder meeting propose change meeting article association 80 corporate governance chairman report pursuant article l 225 37 french commercial code information provided director audit committee duty field accounting policy internal controlling consist board meeting director receive report mainly agenda item require prior consideration due time following notification examining annual corporate consolidated account reviewing halfyearly annual corpus preliminary figure annual interim tion consolidated account including note statement generally sent director least financial statement management one week meeting audit committee port presented board director always held day day annual general shareholder meeting convened board meeting approve statement fiscal 2013 present ing observation recommendation addition board meeting chairman regularly board director informs director event development ensuring suitability consistent application may material impact group operation accounting method procedure chosen information previously communicated company guaranteeing correct appli board cation examining accounting treatment signifi member board director receive copy cant transaction carried company press release published company director may time request audit committee duty area external information chairman board controlling consist shall assess relevance request submitting recommendation board direc tor concerning statutory auditor ap board committee pointment reappointment annual general shareholder meeting audit committee remuneration analyzing issuing opinion definition committee responsible studying making scope timetable assignment fee preparation board main deliberation analyzing independence legal auditor order improve board efficiency audit committee duty field risk board meeting preceded meeting analysis prevention consist least one two committee depending item agenda committee report defining internal audit plan group com board work observation submit panies obtaining report audit carried opinion proposal recommendation defining necessary action plan imple menting new procedure respective compa procedure committee also defined ny internal rule regulation examining company exposure significant risk risk mapping duty audit committee verifying appropriate application internal control accounting financial reporting procedure audit committee assist board director company accounting policy reporting audit committee duty area financial treasury hedging instrument internal communication consists reviewing company external controlling financial communication risk proposed financial communication respect management publication halfyearly annual corporate account quarterly result corporate governance chairman report pursuant article l 225 37 french commercial code 81 committee may also perform activity remuneration committee deliberated main deemed necessary appropriate committee following topic board director reviewing remuneration corporate officer activity report audit committee fiscal 2013 reviewing payment director fee reviewing nomination renewal mem audit committee met five time fiscal bers board director year average attendance 95 validation respect balanced representation men woman board director audit committee dealt following major topic within scope remuneration committee consulted board director proposal 1 examining corporate consolidated annual concerning account reviewing financial statement quar terly halfyearly annual corporate consol total budget allotted director fee idated account including implementation term allocation thereof taking account specific action related ifrs standard actual presence director board meeting 2 working hedging instrument possibly committee meeting 3 review internal audit work fixed remuneration corporate officer 4 review quarterly risk management report term variable remuneration 5 approval auditor fee general policy granting share subscrip 6 implementation syndicated loan sartorius tion option share purchase option free allot stedim biotech sa ment company share 7 asset contribution project policy director nomination renewal 8 30 june 31 december 2013 audit ac count auditor presented essential 2013 mandate joachim kreuzburg result audit option decided reinhard vogt volker niebel arnold picot bernard lemaître liliane de lassus henri riey board duty remuneration committee director member renewed purpose remuneration committee help company board director establish limitation power chairman remuneration policy corporate officer chief executive officer particular incentive mechanism granting share subscription option share purchase option june 29 2007 board director voted free allotment share company may combine function chairman chief introduce executive officer without limitation power included internal regulation remuneration committee also board director mainly strategic responsibility give recommendation regard investment project transaction especially new potential director committee member acquisition disposal may lead material profit loss impact procedure concern activity report remuneration committee operation one million euro 2013 remuneration committee met fiscal year average attendance 100 82 corporate governance chairman report pursuant article l 225 37 french commercial code remuneration senior executive remuneration oscarwerner reif volker senior nonexecutive board member niebel discussed within remuneration committee mandataires sociaux subsequently voted annual general shareholder meeting sartorius stedim biotech gmbh total remuneration including benefit paid oscarwerner reif volker niebel year senior executive chairman employment contract remuneration consists board director chief executive officer fixed variable component line director including sharebased payment disclosed respective degree responsibility corporate governance report sartorius stedim biotech group see page 77 84 internal control procedure remuneration committee set review remuneration board director executive member furthermore remuneration committee introduction also responsible checking annual director fee paid director objective defined chairman internal control system sartorius stedim biotech dr joachim kreuzburgs reinhard vogts follows remuneration determined annually sartorius ag supervisory board remuneration prevent risk would endanger quality consists fixed variable component asset sartorius stedim biotech even exist line respective area responsibility ence variable portion contains short mid longterm ensure executive management activity component shortterm component paid transaction completed conduct employ every year mid term component paid every ee comply guideline defined executive three year based average achieved management applicable law regulation target threeyear term long term fundamental value standard internal rule component comprised phantom stock plan business ethical code convention subject risk remuneration component healthcare industry depends development sartorius ag share ensure accounting financial information price period least four formerly three management data provided executive year year payable price exceeds management company accurately reflect least 75 formerly 10 per year relative time operation sartorius stedim biotech phantom stock assigned share price prevent risk arising operation error fraud outperformed tecdax comparative index especially accounting financial area amount paid capped maximum 25 time share price time phantom stock assigned based case actual scope internal control annual tranche concerned use component designed longterm incentive effect internal control system described cover entail risk recommendation adopted parent company affiliate german french corporate governance code date payment made dr kreuzburg reinhard vogt according phantom stock plan component internal control part remuneration cross charged annually environment internal control sartorius stedim biotech group core business people individual attribute including integrity ethical value expertise environment operate engine drive organization foundation support company corporate governance chairman report pursuant article l 225 37 french commercial code 83 risk assessment process risk mapping audit committee company must aware deal audit committee responsible carrying risk face must set objective integrate necessary review evaluation internal sale production marketing financial controlling procedure including relating activity organization operates financial information also assist concert must also establish mechanism preparation group consolidated financial identify analyze manage related risk statement information audit committee see page 80 81 control activity risk management control activity undertaken every level group ensure internal control sartorius stedim biotech group inevitably efficient checking accuracy completeness exposed wide variety risk nature authorization validation recording transaction operation around world accordingly internal ensuring different people discharge different risk management system set help duty reduce risk error fraud identify assess manage risk efficiently within risk management system ad hoc information communication committee comprised representative different department regularly study current issue risk availability accurate reliable complete management enables committee provide information essential achieve business executive management overview risk objective enable proper reporting party company exposed enabling take concerned compliance applicable law appropriate action required regulation internal auditing department monitoring control management internal auditing department charge responsibility authority must defined monitoring effectiveness suitability risk understood level company internal management internal control system control function effectively duty must sartorius stedim biotech group company well assigned way person work always compliance activity process internal checked approved different person external rule standard provides size local unit concerned permit independent auditing consulting service responsibility initiating authorizing recording focus primarily compliance relevant legal processing transaction must always assigned provision improvement business process different individual company ensure independence internal auditor audit committee receives unit management responsible maintaining least year report internal auditing internal check internal control time department work done according audit plan established committee finding regard group affiliate internal controlling role finance controlling department executive management finance controlling department track chairman chief executive officer monitor operation project optimize responsible internal control system group profitability cash flow providing management level also responsible internal external stakeholder reliable development operation monitoring management information internal control controlling system providing necessary assurance step two department define group accounting implemented rule method principle financial process fiveyear business plan budget etc well reporting tool order monitor daytoday business 84 corporate governance chairman report pursuant article l 225 37 french commercial code procedure preparing group financial financial information reporting statement accounting financial information group rule procedure relation financial reporting accounting set accounting account subsidiary prepared reporting manual application compliance accordance group accounting policy principle rule procedure data adjusted necessary produce direct responsibility finance director company account comply applicable subsidiary must ensure information provided local legal tax provision integrated consolidation via management information system complies fully software used management reporting applicable disclosure requirement purpose produce group financial statement executive management review effectiveness internal controlling financial reporting regularly group decided implement hard close particular verifies transaction process 30 november 2013 order anticipate recorded consistently accordance ifrs improve annual audit international accounting standard applied group set accounting reporting accounting standard manual order ensure pertinence transaction asset recognized within time set consolidated financial statement prepared accordance ifrs accounting standard currently adopted european union internal control 2013 consolidated financial statement comply accounting rule method detailed note internal control perspective group consolidated financial statement focused following year role group finance controlling department training code conduct anticorruption code finance controlling department check quality reporting package submitted collaborator consult sartorius code subsidiary focusing primarily following conduct sartorius anticorruption code element checking corporate data consolidated initial training process closed transfered adjustment entered locally intercompany controlled operation elimination accounting treatment non recurring transaction reporting period verifying principal movement opening midterm prospect closing balance sheet prepare cash flow statement group continue work internal control issue strengthening approach risk mapping finance department also verifies result risk management process based procedure including currency translation element amf internal control reference intercompany elimination etc framework hereto 2013 group risk management handbook revised expected key point review include preparation enter force within short addition process validation statement change defining mandatory minimum standard internal shareholder equity cash flow statement control applying group company initiated pursued 2014 aubagne february 20 2014 chairman joachim kreuzburg corporate governance remuneration executive nonexecutive member board 85 remuneration executive nonexecutive member board table summarizing remuneration well option share granted corporate officer joachim kreuzburg oscarwerner reif chairman board chief executive officer executive vice president research development k year 2013 year 2012 k year 2013 year 2012 due remuneration 1369 1474 due remuneration 549 549 option valuation granted option valuation granted reporting period 0 0 reporting period 0 0 valuation performance valuation performance share granted previous year 74 366 share granted previous year 0 0 total 1443 1840 total 549 549 volker niebel summary remuneration executive vice president operation corporate officer k year 2013 year 2012 joachim kreuzburg1 chairman board chief executive officer due remuneration 552 551 option valuation granted reporting period 0 0 year 2013 year 2012 valuation performance due paid due paid share granted previous year 0 0 k amount amount amount amount total 552 551 fixed remuneration 635 585 variable remuneration2 268 272 reinhard vogt longterm incentive3 521 965 executive vice president marketing sale service exceptional remuneration k year 2013 year 2012 director fee due remuneration 769 801 benefit kind4 19 18 option valuation granted total 789 654 1237 603 reporting period 0 0 valuation performance 1 joachim kreuzburg receives salary sartorius ag share granted previous year 44 142 duty performed entire sartorius group total 813 943 remuneration determined annually supervisory board sartorius ag 2 variable remuneration contains component based economic success group particular sale revenue profit ratio net debt ebitda 3 addition pension plan addition phantom stock plan one longterm component including valuation component granted prior year 4 company car 86 corporate governance remuneration executive nonexecutive member board volker niebel 1 oscarwerner reif 1 executive vice president operation executive vice president research development year 2013 year 2012 year 2013 year 2012 due paid due paid due paid due paid k amount amount amount amount k amount amount amount amount fixed fixed remuneration 280 280 remuneration 280 280 variable variable remuneration2 261 261 remuneration2 261 261 exceptional exceptional remuneration remuneration director fee director fee benefit benefit kind3 11 10 kind3 8 8 total 261 291 261 290 total 261 288 261 288 1 1 volker niebel receives salary sartorius stedim oscarwerner reif receives salary sartorius stedim biotech gmbh duty performed sartorius biotech gmbh duty performed sartorius stedim biotech group stedim biotech group 2 2 variable remuneration contains component variable remuneration contains component based economic success group particular based economic success group particular sale revenue profit ratio net debt sale revenue profit ratio net debt ebitda ebitda 3 3 company car company car reinhard vogt1 executive vice president marketing sale service table director meeting attendance fee remuneration received year 2013 year 2012 nonexecutive corporate officer due paid due paid k amount amount amount amount k year 2013 year 2012 fixed bernard lemaître remuneration 388 358 director fee 450 410 variable remuneration2 164 166 remuneration longterm arnold picot incentive3 245 403 director fee 526 470 exceptional remuneration remuneration liliane de lassus director fee director fee 474 310 benefit kind4 16 16 remuneration total 409 404 569 374 henri riey director fee 526 440 1 reinhard vogt receives salary sartorius ag remuneration duty performed entire sartorius group remuneration determined annually supervisory total 1976 1630 board sartorius ag 2 variable remuneration contains component based economic success group particular sale revenue profit ratio net debt ebitda 3 addition pension plan addition phantom stock plan one longterm component including valuation component granted prior year 4 company car corporate governance remuneration executive nonexecutive member board 87 stock option granted reporting period executive corporate officer issuer company group valuation number option option regard granted price name executive corporate date nature calculation reporting exercised officer plan option method period option window period joachim kreuzburg volker niebel none reinhard vogt oscarwerner reif total stock option exercised performance share available reporting period corporate officer corporate officer number number exercised share name executive date stock price available corporate officer plan option exercise performance share available date reporting acquisition joachim kreuzburg corporate officer1 plan period condition volker niebel none joachim kreuzburg none reinhard vogt oscarwerner reif volker niebel applicable total reinhard vogt none oscarwerner reif applicable liliane de lassus applicable bernard lemaître applicable henri riey applicable total 1 performance share bonus share allocated corporate officer within framework l2251971 article following commercial law subjected additional requirement laid recommendation afepmedef october 2008 88 corporate governance remuneration executive nonexecutive member board performance share granted corporate officer valuation performance share granted share asm reporting according period corporate officer number consolidated issuer date share granted account date date performance company group plan year methodology acquisition availability conditions1 joachim kreuzburg 2289 175 jan 01 2013 jan 01 2017 volker niebel 0 reinhard vogt 1397 107 jan 01 2013 jan 01 2017 oscarwerner reif 0 liliane de lassus bernard lemaître henri riey total 3686 282 1 performance share comprised phantom stock plan phantom stock plan used variable incentive component includes risk portion remuneration component depends development sartorius ag share price period least four formerly three year payable price exceeds least 75 formerly 10 per year relative time phantom stock assigned share price outperformed tecdax comparative index amount paid capped maximum 25 time share price time phantom stock assigned based case actual annual tranche concerned use component designed longterm incentive effect entail risk recommended french german corporate governance code corporate governance remuneration executive nonexecutive member board 89 stock option granted historical information plan n2 plan n3 plan n4 plan n5 plan n6 plan n7 plan n8 plan n9 annual shareholder meeting board director meeting total number stock subscribed bought thereof following people joachim kreuzburg ceo chairman board reinhard vogt volker niebel none arnold picot oscarwerner reif bernard lemaître liliane de lassus henri riey starting point stock option expiration date price exercised modality number stock option suscribed dec 2013 number erased stock option stock option yet exercised stock option granted top ten noncorporate officer exercised total number stock option granted top 10 granted average employee non corporate officer stock price plan plan plan plan plan plan plan plan exercised option n2 n3 n4 n5 n6 n7 n8 n9 option granted reporting period issuer company group top 10 employee issuer company group lead maximum number 0 0 0 0 0 0 0 0 0 0 option owned issuer company group exercised reporting period top 10 employee lead maximum number 1000 862 0 0 0 0 0 1000 0 0 90 corporate governance remuneration executive nonexecutive member board additional information executive board member indemnity due compensation regard employment additional termination contract non compete corporate officer contract pension plan position clause indemnity yes yes yes yes joachim kreuzburg ceo chairman 1 4 5 6 reinhard vogt 2 none 1 5 6 oscarwerner reif 3 none 1 5 7 volker niebel 3 none 1 none 7 1 joachim kreuzburg service contract without social security component sartorius ag duty performed ceo entire sartorius group including sartorius lab product service standard practice germany 2 reinhard vogt service contract without social security component sartorius ag duty performed member executive board entire sartorius group including sartorius lab product service standard practice germany 3 oscarwerner reif volker niebel employment contract sartorius stedim biotech gmbh duty performed managing director company standard practice germany 4 common pension plan place sartorius ag level joachim kreuzburg level entitlement benefit paid company pension plan depends respective tenure 5 severance cap member executive committee remuneration two year based actual remuneration time termination employment contract case employment contract last less two year severance payment capped amount remaining remuneration employment contract 6 joachim kreuzburg reinhard vogt mandatory noncompete clause time appointed member executive board sartorius ag time period two year end appointment member executive board sartorius ag got additional noncompete clause grant indemnity half received gross salary per year noncompete period noncompete period two year 7 twoyear period end employment contract sartorius stedim biotech gmbh volker niebel oscarwerner reif bound noncompetition clause grant compensation equal half annual gross salary noncompetition period noncompete period two year additional information remuneration executive board member general fixed remuneration total value remuneration executive company similar company remuneration member reflects scope responsibility comprised fixed variable component executive member concerned executive member reviewed annually ensure remains personal performance company economic appropriate variable remuneration component situation sustainable progress addition paid addition fixed base salary represent extent amount remuneration typical approximately half total remuneration excluding considered taking account peer company pension commitment fringe benefit case remuneration structure place area 100 target achievement corporate governance remuneration executive nonexecutive member board 91 variable remuneration issue shadow share called phantom stock executive member treated variable portion remuneration contains owner certain number share sartorius ag component paid annually without however entitled receive dividend component determined multiyear assessment development value phantom stock category component making one linked development sartorius share half target achievement possible increase decrease share price taken account later phantom stock annually paid variable remuneration valuated based share price time equivalent paid provided associated portion variable remuneration paid condition met phantom stock cannot traded annually consists following weighted entail share subscription right component sale revenue order intake ebita ratio net debt ebitda minimum target according sartorius phantom stock plan achievement required component executive member credited beginning amount paid depends degree every year phantom stock unit valued target achieved cap provided agreed monetary sum value phantom stock variable component paid paid entire annual tranche payment requested earliest element mentioned fine compared period four year later eight year budget approved annualy board director order pay concerned amount executive member entitled receive payment phantom stock unit share price b variable remuneration consolidated net profit time payment request appreciated least 75 per year relative time phantom stock component determined multiyear assessment assigned share price outperformed depend degree target achieved tecdax comparative index phantom stock consolidated net profit considered plan rule subsequent change parameter context used comparative stock valuation amount paid capped maximum 25 time share consolidated net profit price time phantom stock assigned based case actual annual tranche subordinate target basis assessment concerned consolidated net profit minority interest excluding amortization impairment value assignment phantom stock payment intangible asset due business combination monetary equivalent depend mean value pursuant ifrs 3 target achievement assessing calculated average price class annual variable remuneration based average sartorius ag share closing auction xetra taken period three fiscal year beginning trading frankfurt stock exchange last 2011 smooth amount paid partial 20 day trading previous year 20 day payment amounting 50 target achievement trading prior submission payment request fiscal year effected overpayment serf compensate shortterm result partial payment offset fluctuation share price following year remuneration component fixed variable cap component payment phantom stock blocked four provided well week preceding scheduled publication date quarterly preliminary yearend result c variable remuneration phantom stock plan 20 day trading stock exchange following actual publication quarterly preliminary phantom stock plan yearend result blackout period intended prevent executive board member profiting joachim kreuzburg reinhard vogt access insider knowledge phantom stock plan responsibility sartorius ag level 92 corporate governance remuneration executive nonexecutive member board pension commitment severance cap executive board member receive pension commit service contract concluded connection ments reappointed first time new appointment reappointments include level entitlement benefit paid severance pay cap maximum two annual company pension scheme calculated based salary cover case membership salary german federal civil servant executive board terminated prematurely salary class b ministry official according federal civil service remuneration act bundes fringe benefit besoldungsgesetz depended term respective appointment benefit company member executive board entitled pension scheme still granted form use company car reclaim expense incurred retirement pension old age invalidity business travel covered accident form survivor benefit surviving spouse insurance insurance fringe benefit child decedent member addition receiving remuneration component turned 65 shall considered regular age mentioned insurance provides limit member shall automatically retire application deductible excess amount required law executive board member reappointed second time benefit company pension scheme used extended externally financed defined contribution plan commitment besides securing basic retirement amount commitment used provide thirdterm executive board member make contribution variable earnings company match contribution bonus amount practice modified resolution adopted supervisory board august 24 2011 upon reappointed first time executive board member receive externally financed defined contribution plan commitment addition securing basic retirement amount provides secondterm executive board member make contribution variable earnings company match contribution bonus amount remuneration component reporting year remuneration policy amended include rule authorize supervisory board grant special remuneration according equitable discretion executive board member latter extraordinary performance corporate governance statutory auditor report prepared accordance article l 225 235 93 statutory auditor report prepared accordance article l 225 235 statutory auditor report prepared accordance article l 225 235 french commercial code code de commerce report prepared chairman board director sartorius stedim biotech free translation english report issued french information internal control risk provided solely convenience english speaking user management procedure relating report read conjunction construed french preparation processing accounting law professional standard applicable france financial information year ended december 31 2013 professional standard require perform necessary procedure assess fairness shareholder information provided chairman report respect internal control risk management capacity statutory auditor sartorius stedim procedure relating preparation processing biotech accordance article l 225 235 accounting financial information french commercial code code de commerce procedure consist mainly hereby report report prepared chairman company accordance article l 225 37 obtaining understanding internal control french commercial code code de commerce risk management procedure relating year ended december 31 2013 preparation processing accounting financial information information pre chairman responsibility prepare submit sented chairman report based board director ou supervisory board approval existing documentation report internal control risk management procedure obtaining understanding work involved implemented company provide preparation information exist information required article l 225 37 french ing documentation commercial code code de commerce relating matter determining material weakness internal corporate governance control procedure relating preparation processing accounting financial infor role mation would noted course work properly disclosed chairman report report matter information contained chairman report respect basis work matter report internal control risk management procedure information relating company internal relating preparation processing control risk management procedure relating accounting financial information preparation processing accounting financial confirm report also includes information contained report prepared information required article l 225 37 chairman board director article l 225 37 french commercial code code de commerce french commercial code code de commerce noted role verify fairness information information confirm report prepared chairman conducted work accordance board director also contains professional standard applicable france information required article l 225 37 french commercial code code de commerce marseille 24 february 2014 ernst young audit deloitte associés xavier senent christophe perrau 94 corporate governance independent auditor fee independent auditor fee principal independent auditor ernst young audit deloitte et associés 08 avenue du prado bp 116 13267 marseille 10 place de la joliette le dock atrium 104 cedex 08 france bp 64529 13567 marseille cedex 02 france represented xavier senent represented christophe perrau first commissioned combined general first commissioned annual general share shareholder meeting june 28 1985 date holder meeting may 19 2006 date commission commission expires 2015 annual general shareholder expires 2018 annual general shareholder meeting meeting approve 2014 financial statement approve 2017 financial statement member compagnie régionale de versailles member compagnie régionale de versailles independent auditor fee ernst young deloitte k 2013 2012 2013 2012 audit independent audit certification parent company consolidated financial statement parent company 80 349 129 949 110 232 129 209 subsidiary 50 218 5 37 340 716 391 635 service directly related audit service parent company subsidiary subtotal 130 568 134 985 450 947 520 844 service legal tax corporate 0 17 36 18 29 information technology 99 432 2 15 8 17 78 127 subtotal 99 432 2 15 25 53 96 156 total 229 100 136 100 475 100 616 100 corporate governance independent auditor fee 95 substitute independent auditor auditex beas tour ernst young faubourg de larche 79 villa houssay 92200 neuilly sur seine france 92037 parisla défense first commissioned annual general share represented alain pons holder meeting april 21 2009 date commission commissioned annual general shareholder expires 2015 annual general shareholder meeting meeting may 19 2006 date commission expires approve 2014 financial statement 2018 annual general shareholder meeting approve 2017 financial statement member compagnie régionale de versailles member compagnie régionale de versailles total 2013 2012 2013 2012 190 188 258 229 277 899 273 724 667 659 669 593 277 899 273 724 857 847 927 821 25 81 58 154 42 42 76 67 6 19 46 122 113 112 126 112 31 101 104 276 155 153 202 179 308 100 377 100 1012 100 1129 100 96 corporate governance independent auditor fee consolidated financial statement note 98 consolidated financial statement note statement profit loss comprehensive income statement profit loss comprehensive income note 2013 2012 12 month 12 month k k 1 sale revenue 10 588378 543964 cost sale 295253 272078 gross profit sale 293125 271886 selling distribution cost 128674 119405 research development cost 35998 31776 general administrative expense 30022 29637 operating income expense 12 2915 5460 earnings interest tax ebit 101346 85609 financial income 13 949 2929 financial expense 13 7850 6671 financial result 6901 3742 profit tax 94445 81867 income tax 14 26970 23981 net profit period 67474 57886 attributable equity holder sartorius stedim biotech 66276 56756 noncontrolling interest 1198 1130 earnings per share 16 432 370 diluted earnings per share 16 431 370 1 presentation statement profit loss adjusted compared previous year detail see chapter 2 statement comprehensive income 2013 2012 12 month 12 month k k 1 net profit period 67474 57886 cash flow hedge 2141 1783 income tax cash flow hedge 642 535 net investment foreign operation 1832 304 income tax net investment foreign operation 549 91 currency translation difference 6986 1723 item probably reclassified profit loss net tax 4204 262 actuarial gain loss defined benefit obligation 1048 4833 income tax actuarial gain loss 314 1337 item reclassified profit loss net tax 734 3496 total comprehensive income 64005 54128 attributable equity holder sartorius stedim biotech 62893 52967 noncontrolling interest 1112 1161 1 presentation comprehensive income includes retroactive application ia 19r note consolidated financial statement integral part statement consolidated financial statement note statement financial position 99 statement financial position note dec 31 2013 dec 31 2012 k k1 noncurrent asset goodwill 17 303041 288055 intangible asset 17 122590 108734 property plant equipment 18 175858 160291 investment nonconsolidated subsidiary 1300 1236 receivables asset 571 1056 deferred tax asset 19 9359 8655 612719 568027 current asset inventory 20 92178 85079 trade receivables 21 107555 92202 current tax asset 8073 6501 asset 22 15097 14251 cash cash equivalent 35605 27807 258507 225839 total asset 871226 793866 equity issued capital 23 10396 10395 capital reserve 278791 278782 retained earnings including net profit 189152 143122 noncontrolling interest 3499 2727 481838 435026 noncurrent liability pension provision 24 22601 22883 deferred tax liability 19 34855 29523 provision 25 3003 3648 loan borrowing 26 137207 35636 liability 26 37338 36690 235005 128380 current liability provision 27 4998 4433 trade payable 28 62843 56952 loan borrowing 26 28352 105859 current tax liability 4476 3777 liability 28 53714 59440 154383 230461 total equity liability 871226 793866 1 figure adjusted final purchase price allocation cell culture medium business lonza retroactive application ia 19r 100 consolidated financial statement note statement cash flow statement cash flow 2013 2012 12 month 12 month k k profit tax 94445 81867 financial result 6901 3742 earnings interest tax ebit 101346 85609 depreciation amortization fixed asset 30558 25868 increase decrease provision 440 1355 gain disposal fixed asset 0 3522 income tax paid 28247 38448 gross cash flow operating activity 104096 68152 increase decrease receivables 7260 294 increase decrease inventory 5016 18981 increase decrease liability 1714 51 net cash flow operating activity 90106 48927 capital expenditure 29276 38783 proceeds disposal fixed asset 1058 510 payment 99 121 net cash flow investing activity 28318 38394 payment acquisition consolidated subsidiary business operation net cash acquired 45090 0 proceeds disposal consolidated subsidiary business operation 0 5454 net cash flow investing activity acquisition 73408 32940 change capital 10 385 interest received 267 929 interest paid financial charge 5604 3432 dividend paid shareholder sartorius stedim biotech sa 16875 15325 noncontrolling interest 342 104 gross cash flow financing activity 22544 17547 loan borrowing raised 103590 0 loan borrowing repaid 89055 16751 net cash flow financing activity 8010 34297 net increase decrease cash cash equivalent 8689 18310 cash cash equivalent beginning period 27807 46825 net effect currency translation cash cash equivalent 891 708 cash cash equivalent end period 35605 27807 consolidated financial statement note statement change equity 101 statement change equity foreign cash flow currency non issued capital hedging pension retained translation group controlling total k capital reserve reserve reserve earnings reserve equity interest equity balance jan 1 2012 10386 278406 2525 1816 106692 3141 394283 1667 395950 net profit period 0 0 0 0 56756 0 56756 1130 57886 cash flow hedge 0 0 1783 0 0 0 1783 0 1783 actuarial gain loss defined benefit obligation 0 0 0 4694 0 0 4694 139 4833 currency translation difference 0 0 0 0 0 1863 1863 140 1723 net investment foreign operation 0 0 0 0 304 0 304 0 304 related deferred tax 0 0 535 1307 91 0 681 30 711 comprehensive income period 0 0 1248 3387 213 1863 3789 31 3758 total comprehensive income 0 0 1248 3387 56969 1863 52967 1161 54128 stock option 9 376 0 0 0 0 385 0 385 dividend 0 0 0 0 15325 0 15325 104 15429 change 0 0 0 0 11 0 11 3 8 balance dec 31 2012 jan 1 2013 10395 278782 1277 5203 148324 1278 432299 2727 435026 net profit period 0 0 0 0 66276 0 66276 1198 67474 comprehensive income period 0 0 1499 775 1283 6940 3383 86 3470 total comprehensive income 0 0 1499 775 67559 6940 62893 1112 64005 stock option 1 9 0 0 0 0 10 0 10 dividend 0 0 0 0 16875 0 16875 341 17216 change 0 0 0 0 12 0 12 2 14 balance december 31 2013 10396 278791 222 4428 199021 5662 478340 3499 481838 102 consolidated financial statement note note financial statement note financial statement 1 general information consolidated financial statement prepared euro unless otherwise specified amount sartorius stedim biotech leading provider disclosed thousand euro abbreviated k cuttingedge equipment service case sum figure given development quality assurance production report may precisely equal stated total process biopharmaceutical industry percentage may exact due rounding integrated solution covering fermentation filtration purification fluid management cell culture medium consolidated financial statement approved supporting biopharmaceutical industry around board director february 20 2014 world develop produce drug safely timely submitted approval shareholder economically nextgeneration process meeting april 8 2014 sartorius stedim biotech focus singleuse technology addedvalue service meet rapidly changing technology requirement 2 change presentation statement industry serf strongly rooted scientific profit loss statement community closely allied customer technology partner company dedicated fiscal 2013 sartorius stedim biotech group philosophy turning science solution slightly changed reporting format statement profit loss order follow headquartered aubagne france sartorius stedim established international reporting practice thus biotech sa listed euronext paris isin code provide financial data best comparable fr 0000053266 manner relevant change relate amortization well tax shown compliance european regulation functional expense change cost allocation 16062002 july 19 2002 requiring listed company impact net profit use international accounting standard con sartorius stedim biotech group solidated financial statement sartorius stedim biotech group year ended december 31 2013 following table translates business figure compliant standard interpretation financial year 2012 new format ifrs ifric iasb adopted european union available following site httpeceuropaeuinternal_marketaccountingiasind ex_enhtm consolidated financial statement note note financial statement 103 2012 restatement 2012 k restatement amortization tax restatement sale revenue 543964 0 0 543964 cost sale 269455 1663 960 272078 gross profit sale 274510 1663 960 271886 selling distribution cost 113586 5592 227 119405 research development cost 30972 749 54 31776 general administrative expense 29286 0 351 29637 operating income expense 5460 0 0 5460 earnings interest tax amortization ebita 95206 8005 1592 85609 amortization 8005 8005 0 0 earnings interest tax ebit 87201 0 1592 85609 financial income 2929 0 0 2929 financial expense 6671 0 0 6671 financial result 3742 0 0 3742 profit tax 83459 0 1592 81867 income tax 23981 0 0 23981 tax 1592 0 1592 0 net profit period 57886 0 0 57886 furthermore slight change applied ia 19 employee benefit revised 2011 referred presentation statement change equity following ia 19r contains revised statement cash flow especially accounting rule defined benefit pension plan subtotal gross cash flow operating activity severance agreement contrary previous implemented operating cash flow rule ia 19r requires past service cost change working capital recognized immediately profit loss addition net interest cost calculated net pension liability applying discount rate 3 effect new financial reporting highquality corporate bond recognized standard profit loss measurement effect resulting actuarial gain loss effect asset compared yearearlier consolidated financial ceiling recognized outside profit loss statement following new amended standard statement comprehensive income net interest obligatorily applied first time expense continues recognized financial result described change lead ifrs 13 fair value measurement provides uniform significant change statement financial definition fair value measured fair position statement profit loss value defined price would group already recognize actuarial gain received sell asset paid transfer liability loss comprehensive income ifrs 13 also requires specific note previous period consolidated financial statement asset liability measured fair value ia 19r specifies severance payment earned future period must recognized pursuant amendment ia 1 presentation profit loss respective period service financial statement published june 2011 revision led change accounting item comprehensive income payment employee preretirement part first time reported separately according whether time working agreement partial retirement may subsequently become reclassifiable provision germany past provision profit loss established time offer respective working agreement made agreement concluded even service remained provided employee future 104 consolidated financial statement note note financial statement sartorius stedim biotech applying ia 19r amendment ia 12 deferred tax recovery retrospectively data statement underlying asset financial position january 1 2012 statement profit loss statement annual improvement ifrss 20092011 issued comprehensive income restated including may 2012 relating tax impact ifric 20 stripping cost production phase furthermore following standard surface mine interpretation applied initially amendment mentioned necessarily amendment ifrs 1 severe hyperinflation applicable group firsttime application removal fixed date firsttime adopter result material impact group financial statement sartorius stedim biotech amendment ifrs 1 government loan following standard interpretation revision amendment ifrs 7 offsetting financial asset amendment yet applied financial liability consolidated financial statement reporting year yet adopted eu application obligatory 2013 applicable endorsement financial standard interpretation title year 1 eu commission standard ifrs 10 consolidated financial statement january 1 2014 yes ifrs 11 joint arrangement january 1 2014 yes ifrs 12 disclosure interest entity january 1 2014 yes amendment ifrs 10 ifrs11 ifrs 12 transition guidance january 1 2014 yes amendment ifrs 10 ifrs12 ia 27 investment entity january 1 2014 yes revised ia 27 separate financial statement january 1 2014 yes revised ia 28 investment associate joint venture january 1 2014 yes amendment ia 32 offsetting financial asset financial liability january 1 2014 yes recoverable amount disclosure nonfinancial amendment ia 36 asset january 1 2014 yes novation derivative continuation hedge amendements ia 39 accounting january 1 2014 yes amendment ia 19 employee contribution july 1 2014 various annual improvement ifrss 2010 2012 cycle july 1 2014 various annual improvement ifrss 2011 2013 cycle july 1 2014 ifrs 9 financial instrument published interpretation ifric 21 levy january 1 2014 1 required applied endorsed eu commission standard may provide earlier mandatory application process measuring potential impact change consolidated financial statement standard interpretation consolidated special purpose entity financial statement sartorius stedim biotech associate joint operation presently firsttime group progress group anticipate application planned reporting period stage analysis significant impact standard interpretation amendment consolidated account likewise firsttime enter force application ifrs 10 11 12 lead consolidated financial statement note note financial statement 105 4 significant accounting policy significant acquisition purchase price allocation carried assistance independent thirdparty valuation specialist basis preparation valuation based information available acquisition date consolidated financial statement group based principle historical cost expense directly related business combination acquisition construction production reported profit loss period exception item reflected fair value financial asset held trading available sale derivative foreign currency translation consolidated financial statement sartorius consolidation stedim biotech group prepared thousand euro annual financial statement consolidated financial statement sartorius individual company foreign currency transaction stedim biotech group include annual financial translated exchange rate applicable statement company controlled time transaction monetary asset debt directly indirectly sartorius stedim biotech sa whose value given foreign currency term ia 27 consolidated financial statement translated exchange rate balance sheet accounting investment subsidiary date rate gain loss recognized controlling interest exists sartorius stedim profit loss period biotech sa subsidiary power govern financial operating policy enterprise subsidiary annual financial statement prepared obtain economic benefit activity foreign currency translated pursuant enterprise included consolidated financial ia 21 effect change foreign exchange statement time sartorius stedim rate accordance concept functional biotech sa subsidiary acquired control currency foreign subsidiary regarded longer included time control independent subdivision sartorius stedim transferred entity outside group biotech group balance sheet item translated exchange rate balance sheet subsidiary included basis date income expense item converted annual financial statement reporting average rate translation difference period parent company using uniform group resulting use different exchange rate recognition measurement method balance sheet item statement profit loss recognized comprehensive intragroup asset liability equity income income shareholder equity expense cash flow relating transaction tween member group eliminated full certain defined loan granted longterm basis consolidation group applies principle net investment foreign operation foreign currency translation difference resulting loan recognized business combination comprehensive income according ia 2132 business combination measured according acquisition method identifiable acquired asset assumed liability potential liability recorded fair value date combination 106 consolidated financial statement note note financial statement exchange rate major currency item general administrative expense includes euro considered follows mainly employee benefit expense cost material general administrative area yearend exchange rate average exchange rate 1 2013 2012 2013 2012 profit loss item cannot allocated one mentioned functional area recognized usd 137910 131940 132806 128519 income expense includes essentially gbp 083370 081610 084938 081107 effect currency translation sale fixed asset jpy 14472000 11361000 12958904 10255169 allowance trade receivables reorganization inr 8536600 7256000 7793433 6857962 extraordinary expense income grant cny 834910 822070 816496 811078 related income recognized income reasonable assurance condition attached grant complied sale revenue grant received recognized period necessary match systematic basis revenue derived selling product cost intended compensated rendering service recognized sale revenue operational revenue recognized operating income sale recognized borrowing cost statement profit loss significant risk reward ownership good borrowing cost expensed incurred unless transferred customer company retains directly attributable acquisition neither continuing managerial effective control construction production qualifying asset good sold amount revenue cost therefore part cost asset incurred incurred measured reliably qualifying asset defined asset take sufficiently probable economic period least twelve month get ready benefit associated transaction flow intended use company income tax functional cost current income tax determined based general operating expense type assigned respective local taxable income period local function following functional area tax rule addition current income tax include corresponding profit cost center expense adjustment uncertain tax payment tax refund relating crossfunctional initiative project period yet assessed change deferred tax assigned respective functional cost based asset liability included income tax ex appropriate allocation principle cept change recognized comprehensive income directly equity item cost sale report cost product sold acquisition cost merchandise sold deferred tax asset liability determined based besides directly imputable expense raw temporary difference carrying material supply employee benefit expense amount tax basis asset liability energy expense cost sale also includes including difference consolidation loss carry overhead allocated manu forward tax credit measurement based facturing area corresponding depreciation tax rate expected effective period ich amortization asset realized liability settled selling distribution cost pertain particular purpose tax rate tax rule used cost sale marketing organization enacted substantively enacted distribution advertising market research reporting date deferred tax asset recognized extent probable taxable profit research development cost comprise cost level relevant tax authority available research product process development unless utilization deductible temporary recognized asset amortization capitalized difference loss carried forward development cost also indicated item consolidated financial statement note note financial statement 107 goodwill capitalized development cost essentially cover cost allocated staff involved rd goodwill represents future economic benefit raw material supply outside service arising asset acquired business directly attributable overhead intangible asset combination individually identified generated internally amortized straight line separately recognized basis useful life generally exceed four year according ia 36 goodwill acquired business combination may amortized rather must internally generated intangible asset may tested annually impairment soon recognized development cost included indication asset impairment period incurred cost research activity reported expense period purpose impairment testing goodwill must incurred allocated acquirer cashgenerating unit cgus expected benefit amortization intangible asset based synergy combination cashgenerating following period useful life unit cgu represents lowest level within entity goodwill monitored internal software 2 5 year management purpose may larger customer relation technology 5 15 year segment brand name na intangible asset property plant equipment intangible asset acquired stated cost less property plant equipment item reported accumulated regular amortization calculated cost subject depreciation depreciated according straightline method useful life scheduled straightline method applied intangible asset period depreciation reported consolidated financial asset expected contribute directly indirectly statement cash flow entity depreciation fixed asset based following cost incurred within scope development period useful life new product method capitalized internally generated intangible asset following building 15 50 year criterion met machinery 5 15 year factory office equipment 3 13 year technical feasibility completing intangible asset available use sale intention complete intangible asset impairment intangible tangible asset use sell book value carrying amount property plant ability use sell intangible asset equipment intangible asset examined whether indication asset might demonstration intangible asset impaired pursuant ia 36 impairment asset generate probable future economic benefit asset impaired recoverable amount asset estimated recoverable amount asset availability adequate technical financial cashgenerating unit higher fair value resource complete development less cost sell asset cgu value use sell intangible asset use event individual asset recoverable amount cannot estimated recoverable amount ability measure reliably expenditure asset cashgenerating unit cgu estimated attributable intangible asset development 108 consolidated financial statement note note financial statement estimated recoverable amount asset inventory cgu go book value carrying amount carrying amount reduced recoverable amount raw material supply including merchandise reported inventory average cost cause asset impairment removed principle finished good work progress book value asset cgu credited reported cost conversion cost includes newly estimated recoverable amount however direct cost allocated material book value increase limited value appropriate portion production asset cgu would asset impairment material handling overhead general administrative loss would assessed previous financial expense fixed asset normal depreciation year amortization rate provided expense caused production lease inventory must evaluated lower amount cost net realizable value net realizable lease considered agreement whereby lessor value represents estimated selling price conveys lessee return payment series ordinary course business less estimated cost payment right use asset agreed completion estimated cost necessary period time according ia 17 lease classified marketing sale distribution inventory either operating finance lease finance risk exist risk reduced shelf life lease lease transfer substantially risk result storage period limited usability reward incidental ownership asset inventory marked accordingly lease designated operating lease group lessee finance lease amount trade receivables equal fair value leased property lower present value minimum lease trade receivables reported payment recognized asset balance discernible risk covered book value trade sheet simultaneously recognized financial receivables receivables representative liability minimum lease payment essentially fair value considering maturity date consist finance charge reduction credit risk determining recoverability trade outstanding liability measured according receivables group considers change effective interest method leased asset credit quality date credit originally depreciated straightline basis period granted expected useful life shorter lease term group lessor finance lease sale revenue construction contract equal net investment lease recognized well lease receivable leasing construction contract contract specifically rate receives also apportioned negotiated construction asset finance charge reduction liability according combination asset closely interrelated effective interest method interdependent term design technology function ultimate purpose use operating lease lease rate paid outcome construction contract lessee recognized expense lease estimated reliably revenue constructiontype rate received lessor recognized income project generally recognized respectively leased asset continues percentageofcompletion method based recognized lessor balance sheet property percentage cost date compared total plant equipment estimated contract cost expected loss construction contract recognized expense immediately consolidated financial statement note note financial statement 109 contract disclosed receivables liability agreement supplier dealer including percentage completion cumulative work leasing contract restructuring provision contract cost contract result exceeds recognized group detailed formal plan advance payment received construction contract either commenced implementation recognized receivables amount due announced customer balance deduction advance payment received negative obligation construction contract recognized liability financial instrument amount due customer financial instrument contract give rise financial asset one entity financial pension obligation liability equity instrument another entity financial asset mainly include cash cash pension provision similar obligation equivalent availableforsale financial asset trade recognized consolidated financial statement loan receivables derivative financial sartorius stedim biotech group accordance instrument positive fair value actuarial principle ia 19 employee benefit stipulates projected unit credit method financial liability group mainly comprise loan method measurement addition known bank trade payable finance lease payable pension life expectancy expected cash derivative financial instrument negative fair value method take account future salary value pension increase initially financial instrument recognized actuarial gain loss recognized fair value transaction cost directly attributable comprehensive income directly equity pension acquisition issue financial instrument reserve according standard ia 19r recognized determining carrying amount financial instrument measured fair value profit loss subsequently financial provision asset liability measured according category cash cash equivalent availablefor provision recognized liability third sale financial asset loan receivables financial party incurred outflow resource liability measured amortized cost financial probable amount obligation asset liability classified held trading reasonably estimated amount recognized assigned provision represents best estimate obligation balance sheet date provision original maturity one year cash cash equivalent discounted present value expenditure expected settle obligation end group considers highly liquid investment reporting period less three month maturity date acquisition cash equivalent mainly includes provision regularly reviewed adjusted check cash hand deposit bank cash information becomes available cash equivalent measured cost circumstance change provision warranty cost based historical experience restructuring provision set connection program materially change scope business performed segment business unit manner business conducted case restructuring expense include termination benefit compensation payment due termination 110 consolidated financial statement note note financial statement investment statement cash flow investment nonconsolidated subsidiary statement cash flow cash flow present associate security measured cost ed according allocation operating activity active market exists share security investing activity financing activity fair value asset cannot reliably measured instance cash flow operating activity determined using indirect method ie expense without effect payment added loan receivables profit tax income without effect payment subtracted cash flow financial asset classified loan receivables financing activity composed primarily change measured amortized cost using effective equity addition repayment loan interest method less impairment loss impairment loss trade receivables recognized using separate allowance account 5 critical accounting judgment key source estimation uncertainty financial liability preparation consolidated financial statement management us estimate financial liability measured except derivative assumption based best knowledge financial instrument amortized cost using current future situation period however effective interest method actual result may differ estimate estimate assumption revised regular basis impact change immediately derivative financial instrument recognized income expense period derivative financial instrument foreign addition group management exercise judgment currency exchange contract interest rate swap defining accounting treatment specific trans contract measured fair value derivative action existing standard financial instrument classified held trading interpretation specifically treat accounting unless designated hedging instrument problem concerned hedge accounting applied change fair value derivative financial instrument assumption estimate primarily concern recognized either net income case following topic hedge comprehensive income business combination cash flow hedge accounting business combination requires effective portion change fair value asset acquired liability assumed derivative instrument designated cash flow hedge recorded respective fair value date recognized comprehensive income group obtains control application ineffective portion recognized immediately net acquisition method requires certain estimate income financial result amount accumulated assumption made especially concerning fair equity reclassified net income value acquired intangible asset property period hedged item affect net income plant equipment liability assumed acquisition date useful life acquired intangible asset property plant equipment measurement based large extent anticipated cash flow actual cash flow vary used calculating fair value may materially affect group future result operation consolidated financial statement note note financial statement 111 impairment asset due changing market economic condition underlying key assumption may differ actual impairment test conducted certain event lead development may lead significant change assumption asset might impaired pension postemployment benefit obligation case carrying amount asset compared recoverable amount difference recognized full directly higher net realizable value value use equity period occur without calculation value use generally based affecting profit loss sensitivity analysis see discounted cash flow method using cash note0 pension employee benefit provision flow projection five year projection take account past experience represent management best estimate future sale provision contingent liability revenue cost development cash flow contingent asset planning period extrapolated using individual growth rate key assumption management provision recognized legal constructive based determination value use include obligation exist balance sheet date estimated growth rate weighted average cost determine amount obligation certain esti capital tax rate estimate mate assumption applied including material impact respective value evaluation probability amount ultimately amount impairment cost incurred typically significant estimate carrying amount exceeds recoverable amount involved determination provision related impairment loss recorded onerous contract warranty cost asset retirement obligation legal proceeding intangible asset income tax capitalization selfconstructed intangible asset also includes certain level estimation group operates various tax jurisdiction assumption eg evaluation feasibility therefore determine tax position development project expected market prospect respective local tax law tax authority view determination useful life complex subject different interpretation taxpayer local tax authority trade receivables deferred tax asset recognized deductible temporary difference unused tax allowance doubtful account involves loss extent probable future significant management judgment review taxable profit available individual receivables based individual customer deductible temporary difference unused tax creditworthiness current economic trend well loss utilized future development analysis historical bad debt portfolio uncertain partly beyond management control basis assumption necessary estimate future taxable profit well period deferred tax asset recover employee benefit pension provision estimate revised period obligation pension postemployment sufficient evidence revise assumption benefit determined accordance actuarial management considers probable portion valuation valuation rely key assumption deferred tax asset cannot realized including discount rate expected salary increase corresponding valuation allowance taken account mortality rate discount rate assumption determined reference yield highquality corporate bond appropriate duration currency end reporting period 112 consolidated financial statement note note financial statement 6 operating segment extraordinary item expense income exceptional onetime nature accordingly according ifrs 8 operating segment distort sustainable profitability segment identification reportable operating segment material impact net worth financial based management approach ie position earnings group example segment defined analogously internal item restructuring expense large group project control reporting structure entity therefore well proceeds loss disposal sale area activity considered operating transfer financial asset property plant segment business activity may result equipment provided recur revenue expense operating result rent nature regularly reviewed entity chief operating decision maker executive committee previously sartorius stedim biotech group board director discrete financial information also used underlying ebita key performance available internal reporting internal control indicator figure referred earnings reporting within sartorius stedim biotech based interest tax amortization amortization approach operating total solution resulting recognition intangible asset provider customer accordingly arising business combination chapter 2 identification sartorius stedim biotech reportable contains reconciliation table former format operating segment biopharm statement profit loss including item amortization key performance indicator operating segment sartorius stedim biotech group segment asset segment liability socalled underlying ebitda ebitda corresponds reported regular basis chief operating earnings interest tax depreciation decision maker therefore part amortization underlying ebitda mean ebitda segment report adjusted extraordinary item connection biopharm group k 2013 2012 change 2013 2012 change sale revenue 588378 543964 8 588378 543964 8 underlying ebitda 135586 117049 16 135586 117049 16 sale revenue 230 215 230 215 ebit 101346 85609 18 101346 85609 18 sale revenue 172 157 172 157 employee december 31 3484 2986 17 3484 2986 17 consolidated financial statement note note financial statement 113 reconciliation segment profit loss country allocated asia pacific region market segment primarily consists k 2013 2012 latin america africa underlying ebitda segment 135586 117049 key figure geographical area refer depreciation company location except sale revenue amortization 30558 25545 reported according customer location extraordinary effect 3682 5896 ebit 101346 85609 noncurrent asset correspond property plant financial result 6901 3742 equipment well intangible asset profit tax 94445 81867 group affiliate allocated various region european region following country account material noncurrent asset supplementary information region germany 1974 million 1925 million 2012 france 3102 million 3123 million 2012 provide additional information required ifrs 8 goodwill resulting reverse acquisition stedim table present supplementary 2007 associated intangible asset information geographical region european presented noncurrent asset europe region includes market western eastern europe north american region comprised amount sale revenue single customer u marketplace canadian market japan exceed 10 consolidated sale revenue china australia south korea india well 2013 2012 europe north america k 2013 2012 change 2013 2012 change sale revenue 287145 261830 10 150807 149216 1 total 488 481 256 274 noncurrent asset 565259 519799 9 19599 20175 3 employee december 31 2291 1962 17 523 414 26 asia pacific market group k 2013 2012 change 2013 2012 change 2013 2012 change sale revenue 125769 112375 12 24657 20544 20 588378 543964 8 total 214 207 42 38 1000 1000 noncurrent asset 15537 15729 1 1094 1377 21 601489 557080 8 employee december 31 472 453 4 198 157 26 3484 2986 17 7 scope consolidation 2013 financial statement following subsidiary included scope consolidation cause figure minor importance sartorius stedim hungary sessing financial position group sartorius stedim poland sartorius icr russia sale revenue total asset non tap biosystems phc ltd uk consolidated company 1 group tap biosystems ltd uk figure sartorius stedim financiére sa france sartorius stedim integrated service sarl tunisia financial statement following company sartorius stedim biotech sarl tunisia included group financial statement 114 consolidated financial statement note note financial statement ownership europe sartorius stedim biotech sa aubagne france parent company sartorius stedim belgium nv vilvoorde belgium 100 sartorius stedim nordic taastrup denmark 100 sartorius stedim biotech gmbh goettingen germany 100 sartorius stedim plastic gmbh goettingen germany 100 sartorius stedim system gmbh guxhagen germany 100 sartorius stedim uk ltd epsom uk 100 sartorius stedim lab ltd louth uk 100 tap biosystems group ltd royston uk 100 tap esop management ltd royston uk 100 automation partnership cambridge ltd royston uk 100 sartorius stedim fmt sa aubagne france 100 sartorius stedim france sa aubagne france 100 sartorius stedim aseptics sa lourdes france 100 sartorius stedim ireland ltd dublin ireland 100 sartorius stedim italy spa florence italy 100 sartorius stedim netherlands bv rotterdam netherlands 100 sartorius stedim austria gmbh vienna austria 100 sartorius stedim switzerland ag tagelswangen switzerland 100 sartorius stedim spain sa madrid spain 100 north america sartorius stedim filter inc yauco puerto rico 100 sartorius stedim north america inc bohemia new york usa 100 automation partnership inc greenville usa 100 asia pacific sartorius stedim australia pty ltd dandenong south victoria australia 100 sartorius stedim biotech beijing co ltd beijing china 100 sartorius stedim india pvt ltd bangalore india 100 sartorius stedim japan kk tokyo japan 100 sartorius korea biotech co ltd seoul south korea 1 49 sartorius stedim malaysia sdn bhd kuala lumpur malaysia 100 sartorius stedim singapore pte ltd singapore 100 market sartorius stedim bioprocess sarl mhamdia tunisia 100 associate joint venture included scope consolidation company consolidated full ownership rate equal share voting right 1 company sartorius korea biotech included scope consolidation due contractual agreement call option consolidated financial statement note note financial statement 115 8 statement cash flow following table show preliminary final purchase price allocation statement cash flow show impact cash inflow outflow cash cash equivalent preliminary fair group cash flow classified value fair value acquisition date operating investing financing activity according date acquisition ia 7 statement cash flow k k trademark right use 0 4625 context cash equivalent asset customer relationship 24519 11355 converted cash within short maturity generally net asset acquired 24519 15980 less three month amount considered statement cash flow includes mainly cash hand purchase price 49140 49140 bank balance similar item equal goodwill 24621 33160 amount statement financial position following noncash transaction concluded reflected statement cash flow intangible asset identified purchase price allocation right use trademark lonza acquisition cell culture medium business customer relationship connection december 2012 lead cash outflow cell culture medium business assumed useful 2012 2013 payment 149 million made life acquired asset 15 year trademark recognized cash flow investing 12 year customer relation respectively activity acquisition recognized goodwill represents asset capital expenditure finance lease amounted separately identified recognized 22 million 2013 112 million 2012 also generate economic benefit group especially expansion group portfolio strengthened position relevant 9 business combination biopharm market well synergy resulting combination named acquisition cell culture medium business deferred tax recognized upon initial lonza consolidation due structure transaction future period deferred tax liability december 2012 sartorius stedim biotech recognized arising taxable temporary difference acquired exclusive sale marketing right full amount goodwill deductible cell culture medium business swisslocated local tax purpose life science company lonza taken respective employee acquisition treated according ifrs 3 business combination acquisition tap biosystems group plc purchase price determined present value future cash payment 1st tranche december 2013 sartorius stedim biotech 2013 two tranche 5 10 year acquired 100 share british tap biosystems group plc company primarily specializes design development small scale multi parallel fermentation system particularly biopharmaceutical application addition company array product cover automated cell culture system bioprocessing bench top equipment biotech application 116 consolidated financial statement note note financial statement acquisition sartorius stedim biotech extends current portfolio fermentation business multiparallel small scale bioreactors range 15 milliliter 250 milliliter tap portfolio stand gain substantial market penetration based sartorius stedim biotech greater sale strength global reach well benefit synergy related product fluid management cell culture medium business purchase price allocation made provisional basis timeframe acquisition balance sheet date sufficient gather relevant information fair value acquiree preliminary fair value acquisition date k intangible asset 22075 property plant equipment 6960 inventory 3681 trade receivables 7610 asset 810 cash cash equivalent 2846 deferred tax net 3475 provision 208 loan borrowing 7413 liability 14966 net asset acquired 17920 purchase price 33050 goodwill 15130 purchase price paid cash acquisition related cost amounting 376 k recognized expense statement profit loss acquisition closed right balance sheet date inclusion tap group minor impact consolidated sale revenue earnings acquisition made january 1 2013 sale would approx 618 million net result approx 69 million excluding synergy hypothetical financing cost consolidated financial statement note note statement profit loss 117 note statement profit loss 10 sale revenue employee benefit expense sale revenue broken geographical item broken follows area consists following 2013 2012 2013 2012 12 month 12 month 12 month 12 month k k k k wage salary 140487 134662 france 43247 40115 social security 28895 28543 germany 79186 70603 expense retirement country 465945 433247 benefit pension 2768 2493 total 588378 543964 total 172149 165698 amount 11198 k earned 12 operating income expense subsidiary sartorius group 2013 11260 k 2012 2013 2012 12 month 12 month k k sum approximately 234 million earned providing service 2012 approx 209 million currency translation gain 9654 10201 income decrease allowance bad debt 1636 724 income release use 11 functional cost provision liability 937 575 income grant 2186 2070 statement profit loss built according income 4409 1959 cost sale format ie expense operating income 18823 15530 allocated relevant function production sale marketing research development general currency translation loss 10062 10987 administration extraordinary expense 3682 5896 allowance bad debt 789 1404 operating expense nature reconciled expense 1375 2703 profit loss statement nature note 15 operating expense 15908 20990 total operating material expense employee benefit expense income expense 2915 5460 follows item reported income grant discloses raw material supply grant expense essentially related research development project recognized item consists following income soon sufficiently reliable indication necessary prerequisite met 2013 2012 12 month 12 month k k income fiscal 2013 includes income acquired cell culture medium business purchase consumed 143964 126379 cost purchased service 13847 11488 extraordinary item amounted 37 million total 157811 137867 previous year 59 million essentially cover onetime expense strategic group project integration acquisition related item 118 consolidated financial statement note note statement profit loss 13 financial result considering french german average tax rate impact tax legislation expected 2013 2012 tax rate sartorius stedim biotech group 12 month 12 month roughly 29 30 2012 following table k k describes difference tax expense interest similar income 168 909 expected income tax expense reported affiliated particular financial year company 137 844 income derivative financial instrument 0 1901 2013 2012 12 month 12 month financial income 781 119 k k financial income 949 2929 expected tax expense 30 interest similar expense 4050 4766 2012 29 2013 27389 24560 affiliated difference group company 96 100 average income tax rate 1050 1419 expense derivative financial permanent difference 895 1236 instrument 0 450 taxfree income interest expense pension 778 855 tax exemption 884 1334 financial expense 3022 601 620 572 financial expense 7850 6671 total 26970 23981 total 6901 3742 effective tax rate 286 293 14 income tax 15 profit loss statement nature 2013 2012 12 month 12 month 2013 2012 k k 12 month 12 month k k current income tax 27374 19999 sale revenue 588378 543964 deferred tax 404 3982 purchase consumed 143964 126379 total 26970 23981 cost purchased service 13847 11488 personnel cost 172149 165698 amortization matter principle income tax france depreciation 30558 25868 calculated 3333 estimated taxable profit operating cost 126514 128922 year germany rate 30 applied subtotal 487031 458356 taxable income income generated outside operating profit ebit 101346 85609 france germany taxed particular rate financial income expense 6901 3742 valid corresponding country income tax 26970 23981 noncontrolling interest 1198 1130 group net profit 66276 56756 consolidated financial statement note note statement profit loss 119 16 earnings per share according ia 33 earnings per share earnings per share class share must determined separately basic earnings per share basic eps calculated basis weighted average number ordinary share period diluted earnings per share measured taking account share subscription option outstanding end period certain group employee acquired entitlement subscribe total 23642 share 24642 december 31 2012 therefore diluted net earnings per share calculated basis 2013 financial year item including number existing potential future share including optional share treasury share included calculation earnings per share 2013 2012 net profit tax k 67474 57886 group net profit tax k 66276 56756 earnings per share 432 370 diluted earnings per share 431 370 number share statutory level 17042306 17041306 treasury share share buyback program average amount 1698710 1698710 dilution stock option exercized 63 9509 number share used earnings per share calculation 15343533 15333087 future option 23642 24642 potential option 0 0 number share used diluted earnings per share calculation 15367175 15357729 120 consolidated financial statement note note individual balance sheet item note individual balance sheet item 17 goodwill intangible asset cgu represents lowest level within entity goodwill monitored internal management purpose may larger segment goodwill combination former sartorius biotechnology division former stedim group newly goodwill founded sartorius stedim biotech group follows k strategy total solution provider customer gross book value jan 1 2012 254608 various interdependency within currency translation 286 business lowest level goodwill change scope consolidation monitored biopharm segment therefore acquisition 33161 acquired goodwill allocated cgu gross book value dec 31 2012 288055 amortization impairment loss 2012 impairment test conducted 2013 jan 1 2012 0 measure recoverable amount basis currency translation 0 value use particular cashgenerating unit amortization impairment loss 0 biopharm segment cash flow forecast consider amortization impairment loss previous experience generally based group dec 31 2012 0 management forecast period three five net book value dec 31 2012 288055 year calculation based terminal year growth rate 25 year 2017 rate goodwill derived market expectation forecast k significant growth rate targeted biopharma gross book value jan 1 2013 288055 ceutical market major growth driver currency translation 144 sartorius stedim biotech group aging change scope consolidation people increase population improved acquisition 15130 access drug emerging market well gross book value dec 31 2013 303041 ongoing paradigm shift reusable product amortization impairment loss jan 1 2013 0 singleuse product utilized biomanufacturing currency translation 0 biopharmaceutical industry amortization impairment loss 0 amortization impairment loss discount rate applied correspond weighted dec 31 2013 0 capital cost rate recognized follows net book value dec 31 2013 303041 2013 2012 item reported goodwill amount tax tax tax tax 303041 k capitalized difference asset biopharm resulting business combination according segment 84 68 78 60 ia 36 goodwill acquired business combination may amortized rather must tested annually impairment soon 2013 impairment test result indication asset impairment recognition impairment loss context various sensitivity analysis based realistic variation increase recorded 2012 concern acquisition assumption disclosed result cell culture medium business swiss impairment either following variation would entity lonza 2013 acquisition refers tap theoretically represent breakeven point biosystems see note 9 2013 2012 purpose impairment testing goodwill must discount rate wacc tax 144 155 allocated acquirer cashgenerating terminal growth rate 132 215 unit cgus expected benefit cash flow 66 75 synergy combination cashgenerating unit consolidated financial statement note note individual balance sheet item 121 intangible asset patent capitalized licence customer development payment similar right brand name relationship cost account total k k k k k k gross book value jan 1 2012 28269 10779 83014 29016 54 151132 currency translation 40 0 77 19 0 137 change scope consolidation acquisition 4625 0 11354 0 0 15979 capital expenditure 279 0 0 4621 0 4900 disposal 445 0 0 0 0 445 transfer 6014 0 6532 0 0 518 gross book value dec 31 2012 26754 10779 100977 33656 54 172221 amortization impairment loss jan 1 2012 13867 0 24624 13908 0 52399 currency translation 3 0 2 4 0 2 amortization impairment loss 1568 0 6516 2942 0 11025 disposal 443 0 0 0 0 443 transfer 4446 0 4949 0 0 503 amortization impairment loss dec 31 2012 10543 0 36090 16854 0 63487 net book value dec 31 2012 16212 10779 64887 16802 54 108734 patent capitalized licence customer development payment similar right brand name relationship cost account total k k k k k k gross book value jan 1 2013 26754 10779 100977 33656 54 172221 currency translation 297 0 78 40 0 415 change scope consolidation acquisition 5528 888 9103 6586 0 22105 capital expenditure 890 0 0 5139 0 6029 disposal 595 0 0 0 0 595 transfer 82 0 0 0 0 82 gross book value dec 31 2013 32363 11667 110002 45342 54 199427 amortization impairment loss jan 1 2013 10543 0 36090 16854 0 63487 currency translation 155 0 20 18 0 193 amortization impairment loss 2000 0 7362 4775 0 14137 disposal 593 0 0 0 0 593 transfer 0 0 0 0 0 0 amortization impairment loss dec 31 2013 11794 0 43432 21612 0 76837 net book value dec 31 2013 20569 11667 66570 23730 54 122590 122 consolidated financial statement note note individual balance sheet item stedim brand name acquired 2007 considered relationship amounted 459 million 2012 indefinite useful life therefore 513 million year ended december 31 2013 amortized foreseeable limit period remaining period useful life nine year brand name expected generate net cash inflow group brand name 2013 development cost 5139 k tested annually impairment soon recognized asset 4621 k 2012 indication asset impairment capitalized development cost essentially covered cost allocated staff involved rd integration stedim brand raw material supply outside service sartorius stedim biotech brand separate directly attributable overhead internally generated measurement relevant cash flow longer intangible asset amortized according possible therefore separate impairment test straightline method useful life carried 2013 recoverability brand usually exceed four year name considered level biopharm segment cashgenerating unit cgu amortization intangible asset allocated corresponding function statement profit customer relationship obtained part loss capitalized development cost amortization reverse acquisition stedim constitute material disclosed research development cost intangible asset book value customer 18 property plant equipment factory office payment land building technical equipment account machinery construction improvement equipment equipment progress total k k k k k gross book value jan 1 2012 100266 66946 56077 24140 247429 currency translation 732 330 135 51 1145 change scope consolidation acquisition 0 0 0 0 0 capital expenditure 20523 11118 7700 5756 45097 disposal 2038 1397 6135 32 9601 transfer 12896 5962 901 20426 667 gross book value dec 31 2012 130914 82300 58409 9489 281112 depreciation jan 1 2012 31776 46356 37728 0 115860 currency translation 90 190 104 0 385 depreciation 4011 4849 5983 0 14843 disposal 2018 1253 5549 0 8820 transfer 106 724 153 0 676 depreciation dec 31 2012 33572 49038 38211 0 120821 net book value dec 31 2012 97343 33262 20198 9489 160292 consolidated financial statement note note individual balance sheet item 123 factory office payment land building technical equipment account machinery construction improvement equipment equipment progress total k k k k k gross book value jan 1 2013 130914 82300 58409 9489 281112 currency translation 1539 962 741 28 3269 change scope consolidation acquisition 5555 1212 225 0 6992 capital expenditure 3398 7823 7625 9342 28188 disposal 212 896 3156 78 4342 transfer 646 2673 1266 4319 266 gross book value dec 31 2013 138764 92150 63627 14406 308948 depreciation jan 1 2013 33572 49038 38211 0 120821 currency translation 261 540 440 0 1240 depreciation 4458 5470 6487 6 16421 disposal 58 468 2734 0 3260 transfer 0 27 375 0 348 depreciation dec 31 2012 37711 53473 41900 6 133090 net book value dec 31 2013 101053 38678 21727 14400 175858 depreciation included income statement capitalized property plant equipment include according use asset cost sale asset held finance lease amounting selling distribution cost research 17760k 2012 10996 k cost acquisition development cost general administrative expense asset total 18352 2012 11214 k operating expense 2013 rental payment amounting 44 million 2013 fiscal 2012 significant 2012 41 million made asset leased impairment loss recognize intangible asset operating lease property plant equipment 19 deferred tax deferred tax asset deferred tax liability dec 31 2013 dec 31 2012 dec 31 2013 dec 31 2012 k k k k intangible asset 272 361 28664 25507 tangible asset 0 0 3673 3906 inventory 2857 2917 2281 181 receivables current asset 664 622 959 1873 provision 3541 3911 0 116 liability 628 300 726 1428 gross amount 7962 8111 36303 33012 carry forward taxable loss 1535 544 0 0 offset 138 0 1448 3489 net amount 9359 8655 34855 29523 change 704 5332 thereof recognized profit loss 87 491 124 consolidated financial statement note note individual balance sheet item deferred tax asset k 2013 2012 cash flow hedge 642 535 balance sheet date group unused tax actuarial gain loss loss amount carried forward 81 million defined benefit obligation 314 1337 deducted future taxable profit 28 million net investment foreign 2012 deferred tax amount reported approx operation 549 91 69 million loss 17 million 2012 total 1505 711 concerning remaining loss carried forward deferred tax amount recognized lack visibility future taxable profit 20 inventory like 2012 deferred tax asset dec 31 2013 dec 31 2012 k k relation company reported loss year review earlier reporting year raw material supply 27472 21745 work progress 22624 20793 finished good merchandise 40396 37704 deferred tax liability payment account 1686 4837 total 92178 85079 deferred tax liability connection intangible asset refer asset acquired business combination consequently mainly linked customer relationship dec 31 2013 dec 31 2012 k k addition group recorded deferred tax liability gross amount inventory 100905 94305 tax amount 13 million approx 88 million writedowns 8727 9225 cumulative undistributed earnings subsidiary net amount inventory 92178 85079 05 million 2012 effect group considers cumulative undistributed earnings intended systematically reinvested 21 current trade receivables subsidiary rather might used pay dividend france germany dec 31 2013 dec 31 2012 k k group recognize deferred tax liability trade receivables third party 94921 80437 remaining retained earnings subsidiary amount due earnings intended reinvested customer contract work 7705 7739 operation dividend paid receivables subsidiary amount 5 dividend taxed sartorius ag group 4929 4026 french german taxation rule applicable trade receivables 107555 92202 withholding tax furthermore additional income tax consequence could arise case intermediate holding company therefore receivables subsidiary sartorius ag possible estimate amount taxable temporary group item refers company sartorius difference undistributed earnings group fiscal 2013 previous year tax effect 2013 group transferred 216 million hedging instrument deferred tax asset trade receivables item unrelated entity recognition actuarial gain loss 257 million 2012 factoring program pension reserve recognized directly group provided transferee credit consolidated equity likewise amount current guarantee part expected loss income tax incurred net investment foreign receivables transfer qualify operation recognized comprehensive derecognition ia 39 accordingly group income deferred current income tax continues recognize full carrying amount recognized comprehensive income receivables recognized cash received disclosed follows table transfer secured borrowing consolidated financial statement note note individual balance sheet item 125 group business area group aging trade receivables past due carry longterm construction contract impaired customerspecific contract recognized application ia 11 construction contract based dec 31 2013 dec 31 2012 percentage completion method k k 130 day 14059 12556 item amount due customer contract 3190 day 8757 9048 work represents net amount cost incurred plus 91180 day 3502 2449 recognized profit less recognized loss progress 181360 day 298 1121 billing connection construction contract 360 day 302 161 aggregate amount cost incurred recognized total 26917 25334 profit loss project progress reporting date 29921 k 2012 11248 k project advance payment 22215 k 2012 13514 k recorded year contract revenue trade receivables 26917 k 2012 25334 k project progress 21901 k 2012 6513 k past due reporting date valuation allowance made material trade receivables reported change creditworthiness debtor discernible risk covered book value trade could expected would pay amount receivables receivables representative outstanding trade receivables yet due fair value considering maturity date financial asset written credit risk determining recoverability trade indication impairment receivables group considers change credit quality date credit originally granted significant concentration 22 asset credit risk due large base unrelated customer accordingly necessary make dec 31 2013 dec 31 2012 k k provision cover risk beyond allowance already considered derivative financial instrument 2890 1173 financial asset 6695 7099 asset incl prepaid development trade allowance expense 5512 5979 total 15097 14251 dec 31 2013 dec 31 2012 k k valuation allowance beginning year 4278 3886 23 issued capital increase year 789 1404 derecognition december 31 2013 group share capital totaled consumption 449 256 10396 k equity structure reflects issued recovery amount previously impaired 1636 724 share legal parent company sartorius stedim foreign currency translation biotech sa comprise 17042306 share difference 86 32 par value 061 share fully paid valuation allowance end year 2897 4278 december 31 2012 december 31 2013 dilutive instrument share subscription option plan share registered name owner least four year benefit double voting right 126 consolidated financial statement note note individual balance sheet item agm held april 19 2010 authorized sartorius 24 pension employee benefit provision stedim biotech sa introduce share buyback program maximum period eighteen 18 month october 19 2011 defined contribution plan end december 2010 sartorius stedim sartorius stedim biotech group company biotech sa bought back 1698710 treasury share make payment defined contribution plan amount 613 million share primarily relating governmentrun pension plan repurchased related party see note 32 country percentage company pay movement recorded year 2011 social security contribution national insurance 2013 contribution oldage retirement benefit cannot reliably determined 2013 total expense recognized remaining company amounted dividend 11108 k 2012 10685 k board director submit proposal annual general shareholder meeting payment defined benefit plan dividend year ended december 31 2013 follows payment net dividend 120 per share pension provision similar obligation 2012 110 ie total disbursement recognized consolidated financial statement 184123152 201216876856 sartorius stedim biotech group accordance actuarial principle actuarial gain loss dec 31 2013 dec 31 2012 shown directly comprehensive income number share according standard ia 19r actuarial gain beginning period 17041306 17025948 transferred pension reserve stock option exercised 1000 15358 essentially resulted change discount rate increase capital 0 0 totaled 1048 k actuarial loss 4833 k number share 2012 end period 17042306 17041306 nominal value per share 061 061 amount 17837 k relates particular issued capital amount k 10396 10395 pension provision retirement pension plan germany provision totaled 18276 k 2012 primarily relate direct commitment defined benefit pension plan commitment employee earn benefit year service rendered company benefit earned depend salary level age respective employee pension benefit generally funded asset assumed discount factor reflect interest rate paid reporting date prime corporate industrial bond matching maturity denominated relevant currency corporate bond available matching long term maturity insufficiently available matching interest rate determined extrapolation consolidated financial statement note note individual balance sheet item 127 measurement postemployment benefit statement profit loss current service obligation based following actuarial cost disclosed according assignment assumption employee respective function amount included consolidated statement germany financial position arising group obligation respect defined benefit plan follows dec 31 2013 dec 31 2012 discount rate 350 330 dec 31 2013 dec 31 2012 jan 1 2012 k k k future salary increase 300 300 present value future pension increase 200 200 obligation 27017 26831 21542 fair value plan asset 4416 3948 3901 net liability 22601 22883 17640 france dec 31 2013 dec 31 2012 present value defined benefit obligation discount rate 350 280 developed follows future salary increase 300 300 future pension increase 200 250 2013 2012 k k present value amount reported statement profit obligation jan 1 26831 21339 loss comprehensive income consist current service cost 1089 980 following past service cost 0 0 interest cost 778 855 2013 2012 actuarial gain loss 1030 4876 k k currency translation current service cost 1089 980 difference 159 53 past service cost 0 0 retirement benefit paid reporting year 1115 1651 net interest expense 690 765 employee contribution 153 178 component defined benefit cost recognized contribution plan profit loss 1779 1746 participant 391 143 return plan asset excl change scope interest 35 0 consolidation 0 0 actuarial gain loss 1025 4851 change 79 58 component defined present value benefit cost recognized obligation dec 31 27017 26831 comprehensive income 1060 4851 total 719 6597 128 consolidated financial statement note note individual balance sheet item actuarial gain loss defined benefit sensitivity analysis obligation allocated follows increase decrease actuarial assumption 2013 2012 would following impact defined k k benefit obligation experience adjustment 492 184 change demographic k assumption 55 0 change financial demographic assumption assumption 588 4667 life expectancy 1 year 1 year total 1025 4851 effect 421 402 financial assumption plan asset discount rate 100 bps 100 bps effect 3226 4098 2013 2012 future salary increase 50 bps 50 bps k k effect 475 449 plan asset jan 1 3948 3901 future pension increase 25 bps 25 bps interest income 88 90 effect 599 571 return plan asset excl interest 35 0 actuarial gain loss 5 26 sensitivity analysis presented may group contribution representative actual change defined payment 572 563 benefit obligation unlikely change currency translation difference 74 60 assumption would occur isolation one another employee contribution 153 178 furthermore present value defined benefit employer contribution 451 227 obligation calculated using method contribution plan applied calculating defined benefit participant 391 143 obligation liability recognized statement change scope financial position projected unit credit method consolidation 0 0 change 0 114 plan asset dec 31 4416 3948 maturity analysis undiscounted cash flow defined benefit composition plan asset obligation allocated maturity follows plan asset primarily refer insurance dec 31 2013 contract germany switzerland k major equity debt investment included 1 year 865 subsidiary south korea deposited amount 15 year 4046 08 million local bank cash cash 610 year 6922 equivalent 10 year 46260 total 58093 weighted average duration defined benefit obligation 151 year consolidated financial statement note note individual balance sheet item 129 25 noncurrent provision payment employee early retirement plan total k k k balance jan 1 2012 2963 526 3489 currency translation 0 11 11 consumption 363 12 375 reversal 0 0 0 addition 456 89 545 reclassification 0 0 0 balance dec 31 2012 3056 592 3648 payment employee early retirement plan total k k k balance jan 1 2013 3056 592 3648 currency translation 0 17 17 consumption 1170 35 1205 reversal 33 0 33 addition 527 84 611 reclassification 0 0 0 balance dec 31 2013 2380 623 3003 noncurrent provision comprise mainly provision noncurrent provision reported present partial retirement employee anniversary value reporting date discount rate bonus included item employee early retirement plan obligation arise mainly german group company provision accrued company anniversary 08 partial retirement plan allow employee work 2012 07 parttime 3 5 year actual retirement provision employee beneficiary early according ia 19r treatment severance retirement plan partial retirement maximum payment earned future period must period five year actuarial gain loss well recognized profit loss respective period past service cost obligation service explained section 3 revision led recognized income expense change accounting payment employee preretirement parttime working agreement partial retirement provision germany past provision established time offer respective working agreement made agreement concluded even service remained provided employee future retroactive application ia 19r resulted adjustment statement financial position january 1 2012 244 k 130 consolidated financial statement note note individual balance sheet item 26 noncurrent liability loan borrowing balance current balance current dec 31 2013 dec 31 2013 dec 31 2012 dec 31 2012 k k k k liability bank 146989 27078 130410 104871 finance lease liability 18570 1274 11085 988 total loan borrowing 165559 28352 141495 105859 september 2013 sartorius stedim biotech took noncurrent liability longterm syndicated credit line 250 million next five year agreement signed dec 31 2013 dec 31 2012 international bank syndicate led commerzbank ag k k nordlb addition syndicate participant derivative financial bnp paribas deutsche bank dz bank hsbc lbbw instrument 2573 2460 société générale liability 34765 34230 total 37338 36690 transaction group putting financing broadbased international footing long term credit line based variable derivative financial instrument represent fair interest rate value interest rate swap agreement noncurrent liability include liability remaining purchase price cell culture medium business company lonza see chapter 8 27 current provision financial 2012 2013 current provision developed follows warranty total k k k balance jan 1 2012 1742 3627 5370 currency translation 12 43 55 consumption 925 1395 2320 release 55 940 995 addition 579 1854 2434 change 0 0 0 balance dec 31 2012 1331 3103 4433 consolidated financial statement note note individual balance sheet item 131 warranty total k k k balance jan 1 2013 1331 3103 4433 currency translation 23 105 128 change scope consolidation 208 0 208 consumption 425 890 1315 release 246 3980 4226 addition 1165 4861 6026 change 0 0 0 balance dec 31 2013 2009 2989 4998 measuring provision recognizable liability obligation based past business transaction past event probably resulting cash dec 31 2013 dec 31 2012 payment resource representative k k economic benefit whose amount derivative financial reliably estimated reported provision instrument 106 1126 tax social security 10610 7413 provision considered result personnelrelated liability 14631 16372 legal constructive obligation respect third liability 28367 34529 party total 53714 59440 provision entail mainly onerous contract uncertain employee benefit 29 financial obligation contingent asset liability 28 current liability like previous year significant contingent liability contingent asset trade payable reported group major financial obligation refer operate lease follows dec 31 2013 dec 31 2012 k k dec 31 2013 dec 31 2012 payment received k k account order 14731 16810 operate lease trade payable third due within one year 4333 3815 party 39787 30529 due within 2 5 year 7645 6653 payable participation 352 275 due thereafter 2249 696 payable subsidiary sartorius ag group 7973 9338 total 62843 56952 30 financial instrument financial risk payable subsidiary sartorius ag group refer company sartorius general information group section give overview impact financial instrument financial statement sartorius stedim biotech group provides additional information balance sheet item contain financial instrument 132 consolidated financial statement note note individual balance sheet item derivative measured fair value determined b class financial instrument according marktomarket method recognized mathematical method used fair following table compare carrying amount value based market data available fair value category financial time value derivative calculated instrument reconcile balance reflect estimate market condition sheet item end year carrying carrying amount fair value amount fair value category acc dec 31 2013 dec 31 2013 dec 31 2012 dec 31 2012 ia 39 k k k k investment nonconsolidated subsidiary available sale 1300 1300 1236 1236 loan trade receivables receivables 107555 107555 92202 92202 loan receivables asset receivables 7266 7266 7379 7379 derivative financial instrument held trading 0 0 318 318 hedging derivative financial instrument instrument 2890 2890 1631 1631 asset ifrs 7 5512 5512 5979 5979 receivables asset 15668 15668 15307 15307 loan cash cash equivalent receivables 35605 35605 27807 27807 financial liability loan borrowing cost 146989 147659 130410 130633 finance lease liability ifrs 7 18570 18253 11085 11770 loan borrowing 165559 165912 141495 142403 financial liability trade payable cost 48112 48112 40142 40142 trade payable ifrs 7 14731 14731 16810 16810 trade payable 62843 62843 56952 56952 derivative financial instrument held trading 0 0 0 0 hedging derivative financial instrument instrument 2679 2679 3586 3586 financial liability liability cost 61464 67424 67456 67456 liability ifrs 7 26909 26909 25088 25088 liability 91052 97012 96130 96130 carrying amount financial instrument category shown following table dec 31 2013 dec 31 2012 k k available sale asset 1300 1236 loan receivables 150425 127387 held trading asset 0 318 asset held hedging instrument 2890 1631 financial liability cost 256565 238008 held trading liability 0 0 liability held hedging instrument 2679 3586 fair value financial instrument level 1 financial instrument calculated determined basis market information basis price quoted active market identical available balance sheet date asset liability level 2 financial instrument allocated one three level fair value calculated basis input factor hierarchy accordance ifrs 7 derivable observable market data basis consolidated financial statement note note individual balance sheet item 133 market price similar instrument level 3 net result financial asset liability held financial instrument calculated basis trading predominantly comprises change input factor derivable observable fair value derivative financial instrument well market data interest income interest expense financial instrument equity investment measured acquisition cost mainly investment nonconsolidated net result liability measured amortized cost subsidiary possible determine fair value mainly comprises effect foreign currency translation reliably due absence active market applies mainly share nonconsolidated total interest income expense financial asset subsidiary assumed carrying amount liability measured fair value without correspond fair value balance sheet recognition profit loss follows date 2013 2012 financial instrument carried fair value 12 month 12 month k k balance sheet date derivative form forward contract interest rate swap agreement interest income 362 1028 valuation done based quoted foreign interest expense 4492 4551 exchange rate available interest rate curve taking consideration counterparty risk level 2 c capital risk management calculation fair value financial liability amortized cost especially loan bank sartorius stedim biotech group capital finance lease liability done level 3 managed order maximize earnings calculation based market interest rate curve participating company optimizing ratio following zerocoupon method consideration equity liability furthermore ensure expected indicative credit spread group company operate premise goingconcern principle fair value remaining financial asset liability approximate carrying amount financial liability detailed regarded account predominantly shortterm maturity managed capital furthermore cash cash equivalent well equity capital net gain loss financial instrument goal financial risk management net gain loss various category financial instrument presented following table treasury department sartorius stedim biotech group centrally focused sartorius corporate 2013 2012 administration gmbh subsidiary sartorius ag 12 month 12 month centralized treasury department performs service k k company sartorius group including sartorius available sale asset 0 4339 stedim biotech group coordinate access national loan receivables 3414 1859 international financial market addition financial asset treasury department monitor control financial risk liability held trading 742 437 internal risk reporting analyzes risk according financial liability cost 1246 393 degree scope essentially risk entail currency interest rate liquidity risk net result financial asset available sale sartorius stedim biotech group strives mini mainly comprises gain loss equity investment mize impact currency interest rate risk dividend gain disposal share using derivative financial instrument hedging transaction controlling carried net result loan receivables mainly different staff member moreover group includes effect currency translation internal auditing department regularly monitor change allowance use financial instrument trading derivative financial instrument done hedging purpose 134 consolidated financial statement note note individual balance sheet item e management exchange rate risk group exposed currency risk one swap agreed amount foreign currency third sale revenue generated u dollar corresponding euro amount fixed exchange currency linked u dollar lesser rate several target date long profit extent foreign currency therefore derivative resulting exchange transaction financial instrument used hedge net exceed contractually defined limit currency exposure resulting currency translation sale revenue currency hedging foreign group strategy provides hedging one currency option forward contract used half year also hedging measure limited extent structured hedge transaction reviewed regular interval order adapt currency fluctuation forward contract secure right simultaneously create obligation sell established foreign balance sheet date forward contract currency amount exercise date specific carried amount 46 million 2012 exchange rate euro independently 57 million hedge risk fluctuation exchange rate actually valid date profit eur usd exchange rate amount cover loss resulting difference current roughly two third expected net exposure previously established exchange rate u dollar within period 15 year furthermore generally measured income expense japanese yen amount jpy 650 million statement profit loss jpy 800 million hedged addition target profit forward following table show forward transaction concluded optimize hedging transaction well target profit forward contract transaction secure right create obligation balance sheet date fair value dec 31 2012 currency volume maturity k forward contract usd 5500000 q1 2013 171 usd 13000000 q2 2013 13 usd 9000000 q3 2013 102 usd 10500000 q4 2013 118 usd 8000000 q1 2014 512 usd 46000000 548 forward contract jpy 150000000 q1 2013 127 jpy 150000000 q2 2013 158 jpy 100000000 q3 2013 174 jpy 250000000 q4 2013 356 jpy 150000000 q1 2014 268 jpy 800000000 1083 target profit forward usd 12000000 q4 2013 318 usd 12000000 318 consolidated financial statement note note individual balance sheet item 135 fair value dec 31 2013 currency volume maturity k forward contract usd 11500000 q1 2014 749 usd 18500000 q2 2014 687 usd 19500000 q3 2014 552 usd 7500000 q4 2014 11 usd 57000000 1999 forward contract jpy 150000000 q1 2014 551 jpy 100000000 q2 2014 68 jpy 200000000 q3 2014 136 jpy 200000000 q4 2014 136 jpy 650000000 891 derivative financial instrument measured f interest risk management time acquisition cost fair value subsequent balance sheet date change value financing sartorius stedim biotech group derivative financial instrument recognized usually done german subsidiary sartorius statement profit loss balance sheet stedim biotech gmbh french parent company date derivative financial instrument serve sartorius stedim biotech sa ensure financing hedge cash flow risk qualified hedging group company using internal group loan relationship exists based criterion ia 39 treasury hedging valuation adjustment loan taken variable interest recognized directly equity amount recognized rate group exposed interest rate risk equity included profit loss period control interest risk appropriate ratio hedged transaction affect result fixed variable loan maintained furthermore group concluded interest rate hedge form 2013 positive amount 2141 k 2012 interest swap cover majority positive impact 1783 k recognized loan outstanding variable interest rate result comprehensive income cash flow hedging reserve group receives particular variable interest effective hedging relationship rate valid market pay fixed interest rate ineffective portion 2012 293 k amount following table provides overview interest 851 k transferred profit loss hedging contract available reporting date period 2012 1459 k u dollar would depreciated 5 euro equity would increased 45 million 2012 25 million result would increased 04 million 2012 06 million vice versa u dollar would appreciated 5 euro resulting impact financial result would 04 million 2012 05 million comprehensive income 49 million 2012 33 million 136 consolidated financial statement note note individual balance sheet item hedging volume hedging volume fair value fair value dec 31 2013 dec 31 2012 hedged interest dec 31 2013 dec 31 2012 instrument k k end term rate k k swap 60000 80000 sep 2015 237277 2378 1020 forward swap 40000 60000 aug 2018 168178 195 2460 total 2573 3480 group hedging strategy secure one variable interest rate amount 100 million third 50 risk exposure period hedged volume 40 million 60 million five year dec 31 2013 raised loan next five year g liquidity risk management maturity financial liability excluding derivative financial instrument show following pattern carrying amount cash flow dec 31 2012 dec 31 2012 1 year 1 5 year 5 year k k k k k loan borrowing 130410 135272 106626 15385 13261 finance lease 11085 29247 1029 4782 23436 trade payable 40142 40142 40142 0 0 liability excluding derivative 67456 78787 33226 16567 28994 financial liability 249092 283447 181022 36734 65691 carrying amount cash flow dec 31 2013 dec 31 2013 1 year 1 5 year 5 year k k k k k loan borrowing 146989 157325 27135 123547 6643 finance lease 18570 41681 5956 7495 28230 trade payable 48112 48112 48112 0 0 liability excluding derivative 61464 71502 26699 16292 28511 financial liability 275135 318620 107902 147333 63384 loan borrowing include liability arising following table illustrate liquidity analysis sale trade receivables factoring derivative financial instrument based program initiated 2009 undiscounted cash flow liability include liability acquisition cell culture medium business company lonza carrying amount cash flow dec 31 2012 dec 31 2012 1 year 1 5 year 5 year k k k k k interest rate swap 3586 3679 1321 2358 0 derivative 3586 3679 1321 2358 0 consolidated financial statement note note individual balance sheet item 137 carrying amount cash flow dec 31 2013 dec 31 2013 1 year 1 5 year 5 year k k k k k interest rate swap 2679 3900 1266 2634 0 derivative 2679 3900 1266 2634 0 group control liquidity risk maintaining credit line additional facility bank continuously tracking forecasted actual cash flow managing maturity profile financial asset liability table provides overview credit line available reporting date credit line credit line credit line 1 year 1 5 year 5 year interest rate used unused dec 31 2012 k k k dec 31 2012 dec 31 2012 syndicated credit line 168000 168000 0 0 variable 78000 90000 bilateral credit variable line 47919 26044 12500 9375 fixed 35818 12101 total 215919 194044 12500 9375 113818 102101 credit line credit line credit line 1 year 1 5 year 5 year interest rate used unused dec 31 2013 k k k dec 31 2013 dec 31 2013 syndicated credit line 250000 0 250000 0 variable 100000 150000 bilateral credit variable line 46500 27750 12500 6250 fixed 38200 8300 total 296500 27750 262500 6250 138200 158300 market interest rate 10 percentage agreement sartorius stedim biotech point higher interest expense statement required comply standard financial key ratio profit loss would 10 million 2012 covenant context ratio net debt 04 million higher 20 million 22 million underlying ebitda see glossary may greater would shown comprehensive 30 interest coverage ratio underlying income part effective hedging transaction ebitda see glossary interest payable may lower 60 essentially unchanged compared regard decrease interest rate previous financing december 31 2012 2013 considered base interest rate 0 resulting sartorius stedim biotech achieved following ratio impact financial result would 03 million 01 million equity dec 31 2013 dec 31 2012 20 million 10 million k k k ratio net debt explained note 26 september 2013 group ebitda 10 10 put place syndicated loan agreement interest coverage credit line 250 million term five year 259 279 138 consolidated financial statement note note individual balance sheet item underlying ebitda corresponds ebitda 31 sharebased payment earnings interest tax depreciation amortization adjusted extraordinary item net sharebased payment relate stock option plan debt defined outstanding bank loan less cash allocated group personnel cash equivalent held interest payable amount refers interest expense loan dec 31 2013 dec 31 2012 number number option option risk associated financial outstanding beginning period 24642 40000 instrument allocated period 0 0 cancelled period 0 0 reporting date sartorius stedim biotech exercised period 1000 15358 group exposed risk volatility lapsed period 0 0 share price outstanding end period 23642 24642 exercisable end period 23642 24642 various stock option plan outstanding december 31 2012 december 31 2013 summarized follows number number number share number option option total date initial sub number share granted subject number general date number scribed director number subscribed target per bene meeting board share director initial subscrip exercisable formance ficiaries authorizing granted executive bene tion fiscal year dec 31 dec 31 valid plan approval subscribed executive concerned ficiaries price 2012 2012 2012 option june 23 2000 july 23 2004 140000 0 0 19 923 3358 16642 0 2 june 10 2005 sept 15 2005 127500 0 0 15 1887 0 5000 0 1 june 10 2005 nov 10 2006 35000 0 0 2 2951 12000 3000 0 1 total 302500 0 36 15358 24642 0 4 24642 number number number share number option option total date initial sub number share granted subject number general date number scribed director number subscribed target per bene meeting board share director initial subscrip exercisable formance ficiaries authorizing granted executive bene tion fiscal year dec 31 dec 31 valid plan approval subscribed executive concerned ficiaries price 2013 2013 2013 option june 23 2000 july 23 2004 140000 0 0 19 923 1000 15642 0 2 june 10 2005 sept 15 2005 127500 0 0 15 1887 0 5000 0 1 june 10 2005 nov 10 2006 35000 0 0 2 2951 0 3000 0 1 total 302500 0 36 1000 23642 0 4 23642 cost fiscal 2013 0 k new additional service performed consideration allocation stock option granted 2013 option measured reference fair value option date allocation sartorius stedim biotech share purchase option order perform estimate group us allocated group senior binomialtype mathematic model managerial employee director fair value consolidated financial statement note note individual balance sheet item 139 total fair value plan thus measured certain number phantom stock year recognized expense spread full vesting represent agreed amount money exercise period plan expense recognized stock possible four year personnel cost offset increase reserve depending certain requirement regarding cash received group upon exercise performance sartorius ag share option recognized cash cash equivalent stock paid amount based share corresponding item issued capital price exercise date payment capped reserve amount 25 time share price time virtual option granted detail please level sartorius stedim biotech majority refer remuneration report shareholder sartorius ag sharebased payment exist form socalled phantom stock unit fair value phantom stock unit disclosed plan respective board member granted follows fair value granted number jan 1 fair value phantom stock subscription particular yearend unit price year dec 31 2013 paid exercisable k k k tranche phantom stock unit 13469 1578 213 531 0 2010 tranche phantom stock unit 8358 2662 223 539 0 2011 tranche phantom stock unit 7115 3312 235 554 0 2012 tranche phantom stock unit 3686 6936 256 282 0 2013 total 32628 927 1906 0 140 consolidated financial statement note disclosure disclosure consolidated financial statement prepared several service sublease agreement place going concern basis sartorius group company sartorius stedim biotech group company contract include mainly sublease office space material event reporting date central administrative function accounting controlling human resource management material event occurred reporting date respect relevant company charge rent salary social security cost expense service well prorated profit margin number employee service provide average workforce employed year 2013 important contract place one 3226 2994 2012 sartorius stedim biotech gmbh germany sartorius corporate administration gmbh germany 100 affiliate sartorius ag 32 related party company provides central service administrative function sartorius stedim biotech gmbh well majority shareholder sartorius stedim sartorius ag arm length term 2013 biotech sa sartorius ag hold either service approx 189 million provided directly indirectly 100 subsidiary vl sartorius stedim biotech gmbh 152 million 2012 finance sa controlling stake company 67 equity capital taking account treasury furthermore comparable service agreement share 744 excluding treasury share group company rendered administrative 846 voting right service worth 13 million related party part group spent 242 million 2013 transaction sartorius stedim biotech sa service received 11 million 183 million subsidiary presented note 7 2012 respectively amount includes charge related party company eliminated sartorius stedim biotech sa board member consolidation disclosed note 07 million administrative service 07 million detail transaction group related party primarily company 2013 group continued following belonging sartorius group disclosed contractual relationship related party sartorius group entity entity nonconsolidated sale revenue purchase receivables payable 2013 2013 dec 31 2013 dec 31 2013 k k k k related party sartorius group 11198 5722 4929 7973 sale revenue purchase receivables payable 2012 2012 dec 31 2012 dec 31 2012 k k k k related party sartorius group 11260 5499 4026 9338 consolidated financial statement note disclosure 141 compensation key management personnel 2012 2013 executive board management received following remuneration post long shortterm employment term termination sharebased benefit benefit benefit benefit payments2 k k k k k 20131 2473 118 348 0 418 1 2012 2350 172 388 0 781 1 amount include dr joachim kreuzburgs reinhard vogts salary receive sartorius ag work performed entire sartorius group remuneration determined annually supervisory board sartorius ag 2 amount remuneration component phantom stock plan depends development sartorius ag share price period least four year formerly three payable price exceeds established minimum share price appreciation outperforms comparative index use component designed longterm incentive effect subject risk suggested french german corporate governance code 142 consolidated financial statement note statutory auditor report consolidated financial statement statutory auditor report consolidated financial statement free translation english statutory opinion consolidated financial statement give auditor report consolidated financial statement true fair view asset liability issued french language provided solely financial position group 31 december 2012 convenience english speaking user result operation year ended accordance international financial reporting statutory auditor report includes information standard adopted european union specifically required french law report whether modified information presented without qualifying opinion draw attention opinion consolidated financial note 2 note consolidated financial statement includes explanatory paragraph discus statement describes change made sing auditor assessment certain significant presentation statement profit loss accounting auditing matter assessment statement made purpose issuing audit opinion consolidated financial statement taken whole ii justification assessment provide separate assurance individual account caption information taken outside accordance requirement article l 823 9 consolidated financial statement french commercial code code de commerce relating justification assessment bring report also includes information relating attention following matter specific verification information given management report note 3 accounting policy assumption estimate consolidated financial statement refers report read conjunction significant judgment estimate made management construed accordance french law particularly concerning capitalization research professional auditing standard applicable france development expenditure impairment test goodwill asset indefinite useful life year ended december 31 2013 periodend company systematically shareholder performs impairment test goodwill asset indefinite useful life also assesses whether compliance assignment entrusted u indication loss value longterm asset annual general meeting hereby report according term condition defined note 15 year ended 31 december 2013 goodwill intangible asset consolidated financial statement audit accompanying consolidated financial statement sartorius stedim biotech work consisted assessing data assumption judgment estimate based reviewing justification assessment test basis calculation performed company comparing accounting estimate previous period specific verification required law corresponding achievement examining procedure implemented management approve consolidated financial statement approved estimate verifying note consolidated board director role express opinion financial statement provide appropriate disclosure consolidated financial statement based audit assumption option adopted company opinion consolidated financial statement assessment made part audit consolidated financial statement taken whole conducted audit accordance professional therefore contributed opinion formed standard applicable france standard require expressed first part report plan perform audit obtain reasonable assurance whether consolidated financial iii specific verification statement free material misstatement audit involves performing procedure using sampling required law also verified accordance technique method selection obtain audit professional standard applicable france information evidence amount disclosure presented group management report consolidated financial statement audit also includes matter report fair presentation evaluating appropriateness accounting policy used consistency consolidated financial statement reasonableness accounting estimate made well overall presentation consolidated marseille 24 february 2014 financial statement believe audit evidence obtained sufficient appropriate provide ernst young audit deloitte associés basis audit opinion xavier senent christophe perrau annual financial statement sartorius stedim biotech sa note 144 finacial statement note annual financial statement annual financial statement parent company balance sheet asset thousand depreciation amortization material event gross provision net net fiscal year page 146 dec 31 2013 dec 31 2013 dec 31 2013 dec 31 2012 intangible asset 552 4 548 463 property plant equipment 15273 8387 6885 11545 financial investment 189465 0 189465 146302 total noncurrent asset 205290 8391 196899 158310 inventory work progress 0 0 0 8306 receivables trade receivables third party 0 0 0 12291 receivables 9426 0 9426 40759 marketable security 0 0 0 0 deposit cash equivalent 559 559 158 total current asset 9985 0 9985 61514 prepaid expense 45 45 57 currency translation adjustment 0 0 2162 total asset 215320 8391 206929 222043 parent company balance sheet equity liability thousand material event fiscal year page 146 dec 31 2013 dec 31 2012 share capital 10396 10395 share premium 59884 59876 reserve 1630 1629 retained earnings carried forward 28969 19647 profit period 20875 26198 regulated provision 4088 4088 total equity 125841 121833 provision liability charge 0 2789 total provision liability charge 0 2789 loan borrowing 0 0 trade payable 1702 7455 tax social charge payable 337 5538 liability noncurrent asset 0 220 liability 79049 84185 total liability 81088 97398 currency translation adjustment 23 total equity liability 206929 222043 finacial statement note annual financial statement 145 parent company income statement thousand material event fiscal year page 146 dec 31 2013 dec 31 2012 sale revenue 1501 81942 inventory movement 0 17 capitalized production cost 0 0 depreciation amortization reversal 0 1322 operating income expense reallocation 0 428 purchase consumed 0 41930 external charge service 2021 10654 tax duty 793 1870 personnel cost 0 22140 addition amortization depreciation provision 598 3041 operating expense 223 465 operating profit ebit 2133 3575 net financing income expense 22716 22443 profit loss ordinary activity 20583 26018 exceptional income expense 0 498 income tax 292 678 net profit loss 20875 26198 146 finacial statement note annual financial statement 1 materiel event fiscal year 2 accounting principle method 16th april 2013 shareholder parent company financial statement year company sartorius stedim biotech sa approved ended december 31 2013 prepared 13th resolution extraordinary shareholder presented accordance french accounting rule meeting proposed draft partial asset compliance principle prudence contribution company sartorius stedim reporting distinct financial year pre biotech sa made contribution sartorius stedim fmt sumption going concern annual financial sa complete autonomous branch statement prepared accordance activity management fluid provision french commercial code accounting decree november 29 1983 crc regulation asset transferred valued 68632974 99 03 april 29 1999 revision french liability assumed 25692854 therefore net chart account asset contributed 42940120 sartorius stedim biotech sa listed compartment transaction completed october 1 2013 euronext paris stock exchange isin fr code retroactive effect 1 january 2013 0000053266 also prepares consolidated financial statement accordance ifrs standard largely explains significant change adopted european union december 31 2013 recorded balance sheet find detail following chapter 21 noncurrent asset sartorius stedim biotech sa includes activity holding sartorius stedim biotech noncurrent intangible tangible asset valued group ownership share subsidiary also acquisition cost excluding cost incurred cover real estate related activity holding acquisition manufacturing activity site aubagne therefore sartorius stedim biotech sa present intangible asset property plant equip income statement including ment company applied french regulation crc 2002 10 recodified article 2 4 regulation income expense rental business crc 2004 06 relative amortization depreciation impairment asset according income expense arising holding component approach activity mainly dividend 5th july sartorius stedim biotech sa acquired 211 intangible asset leasing contract building warehousestorage located aubagne following thus valuated heading incorporation cost patent software entire property amount 3251 k including land building asset amortized straightline basis using following indicative useful life incorporation cost one five year software one three year patent twenty year part implementation integrated software direct labor cost concerned included amount capitalized cost function time elapsed intangible asset valued acquisition cost less amortization impairment reported ongoing basis finacial statement note annual financial statement 147 212 property plant equipment 22 inventory work progress property plant equipment ppe recognized value merchandise supply determined acquisition value including installation cost using fifo method storage acquisition cost asset included depreciation calculated standard work progress finished product valuated economic life asset using straightline production cost using full industrial cost method method writedown provision made appropriate noncurrent asset depreciated realizable value prospect use straightline basis using following indicative sale inventory lower period use gross carrying value building twenty forty year improvement fixture fitting ten fifteen year 23 receivables payable plant equipment four ten year office equipment three five year receivables payable recorded nominal motor vehicle four five year value property plant equipment valued receivables whose collection doubtful subject acquisition cost less depreciation impairment provision doubtful debt reported ongoing basis 24 currency translation adjustment 213 financial investment foreign currencydenominated receivables investment relate mainly shareholding liability converted recognized based subsidiary treasury share held within december 31 exchange rate difference observed scope share buyback program recorded historical cost posted currency acquisition cost including fee linked translation adjustment item acquisition unrealized loss resulting currency translation writedown provision may established take recognized currency translation loss account particular either stock exchange value receivable liability price underlying asset subsidiary hedged forward transaction financial position prospect shareholding subsidiary subject impair ment test 148 finacial statement note annual financial statement 3 noncurrent asset thousand 31 intangible asset contribution gross value dec 31 2012 increase 2013 decrease 2013 asset transfer dec 31 2013 incorporation cost 4 0 0 0 4 patent 325 0 0 325 0 software license 2398 0 0 2398 0 business goodwill 2 548 0 2 548 intangible asset progress 243 0 0 243 0 total 2972 548 0 2968 552 amortization depreciation 2509 0 0 2505 4 net amount 463 548 0 463 548 32 property plant equipment contribution gross value dec 31 2012 increase 2013 decrease 2013 asset transfer dec 31 2013 land 396 100 0 496 building 13674 678 0 14352 plant equipment 8263 0 0 8263 0 5110 250 0 5110 250 property plant equipment 2605 progress 2605 175 0 175 total 30048 1202 0 15978 15272 contribution amortization depreciation dec 31 2012 addition release asset transfer dec 31 2013 building 7789 574 0 0 8363 plant equipment 6720 0 0 6720 0 3994 25 0 3994 25 total 18503 598 0 10714 8387 property plant equipment net 11545 604 0 5264 6885 net variation tangible asset 14776 k primarily due transfer manufacturing activity sartorius stedim biotech sa sartorius stedim fmt sa amount 15978 k element corresponding leasing contract leaseback new building amount 1202 k finacial statement note annual financial statement 149 33 financial investment contribution investment dec 31 2012 increase 2013 decrease 2013 asset transfer dec 31 2013 shareholding 84937 0 0 42940 127877 writedown shareholding 0 0 0 0 0 deposit guarantee 38 260 0 38 260 treasury share 61327 0 0 0 61327 writedown treasury share 0 0 0 0 0 total 146302 260 0 42902 189465 following included financial investment treasury share item corresponds share buyback program implemented following approval 9999 share capital sartorius stedim seventh eighth resolution annual bioprocess sarl tunisian company general shareholder meeting april 19 2010 end 2011 2012 number share rose 100 share capital sartorius stedim 1698710 repurchased average price biotech gmbh company governed german law 3610 total amount 61327190 following merger sartorius stedim group june 2007 100 share capital sartorius stedim aseptics sa french company acquired 2004 100 share capital sartorius stedim fmt sa french company created connection contribution asset transfer investment 01 k 4 inventory trade receivables thousand 41 inventory yearend contribution asset inventory dec 31 2012 transfer dec 31 2013 raw material 5059 5059 consumables 163 163 work progress finished good 3619 3619 merchandise 616 616 gross value 9457 9457 0 depreciation writedown raw material consumables 173 173 depreciation writedown work progress finished good 473 473 depreciation writedown merchandise 505 505 depreciation writedown inventory 1151 1151 0 net 8306 8306 0 diminution recorded 2013 correponds inventory transfer entity sartorius stedim fmt sa frame contribution asset transfer 150 finacial statement note annual financial statement 42 maturity receivables yearend thousand type receivable net amount less 1 year 1 year deposit guarantee 260 0 260 noncurrent asset 260 0 260 advance payment account 0 0 0 trade receivables 0 0 0 personnel 0 0 0 social security 0 0 0 tax duty 1932 1932 0 group 7449 7449 0 receivables 0 0 0 current asset 9381 9381 0 prepaid expense 45 45 0 total receivables 9686 9426 260 group item receivables group subsidiary 7449 k relates current account cash advance provided sartorius stedim biotech gmbh sartorius stedim fmt sa sartorius stedim france tax duty 1932 k item primarily entail net tax receivable including french tax relief system 1735 k vat receivables 5 maturity liability yearend thousand less 1 1 5 type liability net amount year 5 year year loan borrowing credit institution originally less 2 year 0 0 0 0 originally 2 year 0 0 0 0 current bank overdraft accrued interest 0 0 0 0 trade payable 326 326 0 0 including bill exchange 0 0 0 0 advance payment account order 0 0 0 0 tax social security payable 337 337 0 0 liability noncurrent asset 0 0 0 0 group associate 80216 80216 0 0 210 210 0 0 total liability 81088 81088 0 0 finacial statement note annual financial statement 151 accrued expense included account represented 366 k concerned following item type expense dec 31 2013 accrued banking charge 0 supplier invoice received 323 paid vacation including social charge 0 bonus including social charge profit sharing 0 social security payable 40 tax payable 2 employee profit sharing 0 total charge payable 366 6 parent company statement change equity thousand 61 equity december 31 2013 share capital 10396 k annual general shareholder meeting april 16 comprising 17042306 share 061 par value 2013 approved appropriation net profit change equity 2012 result year 26198 k follows following event allocation retained earnings exercise stock option resulting issue carried forward 9321 k 1000 share par value 061 total 1 k paid legal reserve 1 k 9 k share premium associated share dividend total 16877 k net dividend per capital increase share 110 paid treasury share excluded equity appropriation appropriation profit profit 2012 2013 change increase decrease number share 17041306 17041306 1000 17042306 share capital 10395 10395 1 10396 share premium 43736 43736 8 43744 merger premium 16140 16140 16140 legal reserve 1039 1 1040 1040 reserve 590 590 590 balance carried forward 19647 9321 28968 28968 dividend paid 0 16877 16877 16877 0 net profit appropriated 26198 26198 0 0 profit reporting year 0 20875 20875 regulated provision 4088 4088 4088 total 121833 0 121834 20884 16877 125841 62 stock option number share subscription option vested exercised date 23642 part policy motivating group senior executive sartorius stedim biotech sa granted potential stock option issued stock option number employee depending achievement future target 152 finacial statement note annual financial statement 7 risk provision thousand 71 provision provision addition release contribution provision type provision dec 31 2012 2013 2013 asset transfer dec 31 2013 regulated provision accelerated amortization depreciation 4088 0 0 0 4088 subtotal 1 4088 0 0 0 4088 provision liability charge exchange risk 2162 2162 0 cost 627 627 0 taxation 0 0 0 0 0 subtotal 2 2789 0 0 2789 0 grand total 6877 0 0 2789 4088 72 market risk exposure operating cash flow risk december 31 2013 net amount foreign currency current asset liability finacial statement note annual financial statement 153 current future tax position thousand january 1 2008 company chose adopt future income tax position result french tax integration regime within framework tax group lead company tax paid advance expense recognized group sartorius stedim biotech sa fiscal year deductible subsequent member company tax integration group fiscal year tax relief sartorius stedim aseptics sa sartorius stedim france sa sartorius stedim fmt sa tax paid advance unrecognized unrealized sartorius stedim financière sa gain member company report income tax deferred tax recognized integration tax regime parent balance sheet corporation benefit tax relief related consolidating gain loss temporary difference taxable income member company expense follows 2013 net impact according consolidation rule french tax integration regime tax relief income 799 k amount income tax fiscal 2013 settled sartorius stedim biotech sa 2014 tax integration regime 3237 k contribution future tax position asset transfer dec 31 increase 2013 solidarity contribution 2 net movement 2013 currency translation difference 2013 employee profit sharing depreciation customer inventory total increase 2 decrease 2012 solidarity contribution 131 net movement 2012 currency translation difference 23 2012 employee profit sharing 0 depreciation customer inventory 63 total decrease 0 2013 future tax position 217 2 increase 2012 solidarity contribution 131 net movement 2012 currency translation difference 23 2012 employee profit sharing 0 depreciation customer inventory 63 total increase 217 decrease 2011 solidarity contribution 115 net movement 2011 currency translation difference 10 2011 employee profit sharing 0 depreciation customer inventory 0 total decrease 125 2012 future tax position 92 154 finacial statement note annual financial statement 8 operating income thousand 81 sale revenue operating segment operating segment non comparable regarding contribution asset 2013 2012 biopharm 1501 100 81942 100 total 1501 100 81942 100 82 sale revenue geographical region geographical region non comparable regarding contribution asset 2013 2012 france 1501 100 12066 15 export 0 69876 85 eu country 0 60251 8623 north american continent 0 9625 1377 total 1501 100 81942 100 sale revenue corresponds reblling rent th entity sartorius stedim fmt sa following contribution asset transfer 9 exceptional income expense thousand dec 31 dec 31 2013 2012 exceptional income operation 0 0 capital transaction 0 112 release provision transfer charge 0 0 total exceptional income 0 112 exceptional expense operation 0 26 capital transaction 0 160 addition amortization depreciation provision 1 0 424 total exceptional expense 0 610 exceptional income expense 0 498 1 amortization depreciation charge comprised 2007 4104860 recognized non accelerated depreciation amortization current asset amortized prorated capitalized cost associated acquisition basis 5 year stedim sartorius june 2007 expense charged share premium treated deduction calculation company tax liability finacial statement note annual financial statement 155 10 breakdown income tax thousand dec 31 2013 dec 31 2012 profit income tax profit profit income tax tax charge tax tax charge profit tax gross taxable income 20583 507 20076 26018 38 25980 exceptional income expense 0 0 0 498 0 498 employee profitsharing contribution 0 0 0 0 0 0 rd tax credit 0 0 0 0 1436 1436 french tax integration relief 0 799 799 0 720 720 net taxable income 20583 292 20875 25520 678 26198 11 workforce analysis workforce december 31 2013 2012 men woman total men woman total executive 0 56 53 109 employee 0 112 167 279 total 0 0 0 168 220 388 following contribution asset transfer sartorius stedim biotech sa sartorius stedim fmt sa complete autonomous branch activity sartorius stedim biotech sa salaried people 2013 12 information director remuneration 13 offbalance sheet commitment thousand remuneration paid member board director director meeting attendance fee dec 31 dec 31 amounted 163 k fee related 2012 type commitment comment 2013 2012 fiscal year paid 2013 commitment given retirement commitment 1 0 1756 meeting attendance fee paid sartorius guarantee bilateral stedim biotech sa general management credit line 2 3 37375 14500 company fiscal 2013 guarantee currency hedging contract 2 3 20000 31500 commitment part executive board remuneration renting leasing 0 362 recharged sartorius stedim biotech sa commitment received contractual loan capacity credit institution 3000 3000 1 frame contribution asset transfer totality salaried people transferred entity sartorius stedim fmt sa 1st october 2013 therefore pension commitment transferred entity 2 reporting year sartorius stedim biotech sa concluded new 5 year syndicated loan agreement total amount 250 million loan booked sartorius stedim biotech gmbh 156 finacial statement note annual financial statement financial statement agreement sartorius 3 commitment given concern company stedim biotech required comply key sartorius stedim biotech gmbh financial ratio covenant detail please refer note 29 section g consolidated commitment connection lease statement page 138 summarized following table 1 year 1 5 year 5 year leasing k k k total buyback value tangible asset building improvments 363 1450 256 2069 0 total 363 1450 256 2069 payment cumulatives depreciation cumulative leasing historical value year payment year depreciation tangible asset building improvments 2391 91 91 0 0 total 2391 91 91 0 0 14 information related party share buyback program thousand agm held april 19 2010 authorized affiliate company owned sartorius stedim company sartorius stedim biotech sa introduce biotech sa sartorius stedim fmt sa share buyback program maximum duration sartorius stedim bioprocess sarl sartorius stedim eighteen 18 month october 19 2011 aseptics sa sartorius stedim biotech gmbh company sartorius stedim biotech sa consolidated financial statement sartorius ag weender landstrasse 94 108 37075 goettingen germany following find table main amount related party item dec 31 2013 dec 31 2012 investment 127877 84937 trade receivables 1770 12233 receivables 5672 39402 trade payable 1376 3040 liability 78840 83996 income investment 24282 23000 financial income 25 56 finance expense 1437 2016 finacial statement note annual financial statement 157 following find table subsidiary shareholding reserve share premium retained loan change sale earnings outstand exvat ing deposit share appro owner book value advance financial dividend dec 31 2013 capital priation ship share held granted pledge year net profit received gross net sartorius stedim biotech gmbh 10000 euro 6000 84232 79949 79949 44611 0 283912 31320 22000 sartorius stedim fmt sa 10000 euro 42940 0 42940 42940 44611 0 84325 2870 0 sartorius stedim bioprocess sarl 9999 dinar 5950 2743 29959 3012 608 euro 3132 3132 2243 0 13880 1395 282 sartorius icr 10000 ruble 10 0 0 677 0 euro 0 0 0 0 0 0 16 0 sartorius stedim aseptics sa 448 3277 10000 euro 1848 1848 4350 0 7448 2061 2000 reserve share premium retained loan sale earnings outstand change exvat ing deposit share appro owner book value advance financial dividend dec 31 2012 capital priation ship share held granted pledge year net profit received gross net sartorius stedim biotech gmbh 10000 euro 6000 67629 79949 79949 37274 0 264059 38464 22000 sartorius stedim bioprocess sarl 9999 dinar 5940 1267 20860 2086 0 euro 3132 3132 27 0 10413 1041 0 sartorius icr 10000 ruble 10 0 0 509 0 euro 0 0 0 0 0 0 13 0 sartorius stedim aseptics sa 10000 euro 448 2970 1848 1848 4337 0 8062 2352 1000 158 finacial statement note statutory auditor report financial statement statutory auditor report financial statement free translation english report issued french note 213 33 financial statement set provided solely convenience englishspeaking rule accounting method relative user report read conjunction valuation investment treasury share within construed accordance french law professional scope assessment rule auditing standard applicable france accounting principle company verified appropriateness accounting year ended december 31 2013 method specified information provided note financial statement made sure shareholder correct application compliance assignment entrusted u assessment made part audit annual general meeting hereby report financial statement taken whole year ended december 31 2013 therefore contributed opinion formed expressed first part report audit accompanying financial statement sartorius stedim biotech iii specific verification information justification assessment specific verification information required law also performed accordance professional standard applicable france annual financial statement approved specific verification required french law board director role express opinion financial statement based matter report fair audit presentation consistency financial statement information given opinion financial statement management report board director document addressed shareholder conducted audit accordance respect financial position financial professional standard applicable france statement standard require plan perform audit obtain reasonable assurance whether concerning information given accordance financial statement free material misstatement requirement article l 225 102 1 audit involves performing procedure using french commercial code code de commerce relating sampling technique method selection remuneration benefit received obtain audit evidence amount director commitment made disclosure financial statement audit also favor verified consistency includes evaluating appropriateness accounting financial statement underlying policy used reasonableness accounting information used prepare financial statement estimate made well overall presentation applicable information obtained financial statement believe audit company company controlling evidence obtained sufficient company controlled based work appropriate provide basis audit opinion attest accuracy fair presentation information opinion financial statement give true fair view asset liability financial accordance french law verified position company december 31 2011 required information concerning identity result operation year ended principal shareholder holder voting accordance french accounting principle right properly disclosed management report ii justification assessment marseille february 24 2014 accordance requirement article l 823 9 french commercial code code de commerce ernst young audit deloitte associés relating justification assessment xavier senent christophe perrau bring attention following matter supplementary information 160 supplementary information information legal nature information legal nature general information issuer corporate purpose france abroad company purpose corporate name manufacture sell distribute equipment used biopharmaceutical area generally corporate name company carry property financial security sartorius stedim biotech sa transaction relate directly indirectly operation likely assist legal deed document issued com completion pany always preceded followed word société anonyme abbreviation sa trade commercial register ape code statement share capital heading 1 article 1 company bylaw company registered registre du commerce et de sociétés de marseille number rcs b 314 093 352 economic activity code registered office ape 6420z holding company activity registered office aubagne 13400 france zi le paluds avenue de jouques phone number inspection legal document registered 33 04 42 84 56 00 office company office may transferred another location reference document may viewed département french county state registered office company website adjacent county state simple decision website amf validity board director subject ratification next present reference document bylaw annual general shareholder meeting anywhere statutory auditor report financial else france decision taken extraordinary statement last three fiscal year although general shareholder meeting report mail document historical financial information company board director decides transfer subsidiary last three fiscal year evaluation registered office authorized revise bylaw declaration made expert result heading 1 article 2 company document statutory statutory bylaw document found registered office legal form applicable law financial year public limited liability company joint stock company financial year also referred fiscal year société anonyme subject french legislation cover period twelve month beginning particularly french commercial code january 1 ending december 31 year date incorporation duration specific clause company bylaw company incorporated september 28 1978 société anonyme company duration form share 99 year effective upon registration french trade commercial register registre du commerce share may nominative bearer form according et de sociétés unless subject dissolution shareholder choice share entitled extension provided present company bylaw recorded account accordance heading 1 article 3 french law supplementary information information legal nature 161 appropriation profit agenda income statement summarizes income heading 3 point 2 excerpt article 14 bylaw expense reporting year discloses difference deduction amortization depreciation notice letter call shall indicate provision profit said reporting year least 5 indication required law particularly must deducted annual profit reduced agenda company electronic address written appropriate prior loss set legal reserve question shareholder may sent eventually deduction cease obligatory legal mention obligation collect opinion reserve amount one tenth share capital prior approval mass security share obligatory deduction resume whatever reason holder giving access share capital legal reserve fall one tenth distributable profit comprises profit reporting meeting may deliberate matter year less prior loss amount transferred reserve placed agenda may however remove one pursuant french law company bylaw director time increased profit brought forward profit distributed among shareholder proportion one shareholder representing percentage number share one hold annual general share capital required law may shareholder meeting may decide distribute amount condition time limit set forth law require taken reserve available expressly indicating inclusion agenda draft resolution reserve transfer made however dividend disbursed way priority annual accordance article r 225 71 r 225 74 profit reporting year except reduction commercial code request made capital distribution may made shareholder shareholder register draft resolution equity fall would consequently fall agenda written question sent amount capital together headquarters registered letter recorded reserve french law company bylaw delivery beginning publication meeting permit distribute revaluation surplus announcement 25 day general distributable may corporated full part meeting delay 20 day beginning company capital however transferring publication meeting announcement amount reserve pursuant french law one published 45 day general annual general shareholder meeting may transfer meeting date reception request amount considers necessary available reserve company taken account ordinary extraordinary reserve carry forward request new item agenda must motivated request register draft resolution shareholder meeting provided text draft resolution may short explanation reason request convocation subject justification possession representation required share capital accordance regulatory rule annual ordinary general shareholder meeting convened take decision result moreover accordance article l 2323 67 revision bylaw extraordinary general paragraph 2 labor code request draft shareholder meeting called decide resolution made work council added authorize direct indirect revision bylaw special agenda sent next 10 day following meeting bring together holder specific class publication meeting announcement share consider revision right class share decision made general meeting binding heading 3 point 1 excerpt article 14 bylaw shareholder even absent dissenting legally incapable incapacitated heading 3 article 13 meeting unable make valid bylaw general meeting convened decision due lack required quorum board director default independent auditor second meeting appropriate second person thus empowered general meeting held meeting adjourned called least ten day registered office place stated advance form first meeting notice convocation heading 3 excerpt article 14 heading 3 excerpt article 14 bylaw bylaw form timescale notice convocation governed french law 162 supplementary information information legal nature admission meeting power heading 3 point 3 legal document relative legal information excerpt article 14 bylaw shareholder made available registered office company every shareholder right attend general meeting participate discussion provision applicable administration person proxy regardless number share management company held simple proof identity ownership share right participate general meeting board director subject condition share must recorded name shareholder 1 subject legal exemption company shareholder appointed broker either directed board director composed nominative share account held company minimum three member maximum bearer share account held authorized eighteen broker zero hour paris time third working day prior meeting recording registration 2 duration company existence share bearer share account held director shall appointed renewed office authorized broker must confirmed share ordinary general meeting however case certificate provided broker share merger director may appointed extra certificate must attached postal voting form ordinary general meeting deciding transaction proxy form application admission pas issued name shareholder 3 director must entire term office behalf shareholder represented least one share appointed broker certificate must also supplied shareholder wish attend general 4 director term office three year meeting person received admission pas zero hour paris time third director duty shall cease end ordinary working day prior meeting general meeting deciding account financial year elapsed held year term shareholder may represented another office director concerned expires shareholder spouse partner signed civil partnership furthermore director may renewed office may may represented moral removed office time ordinary physical person choice accordance general meeting article l 225 106 106 3 commercial code aim representative must present 5 person may appointed director valid proof proxy reached age 75 appointment would result one third member board legal representative shareholder director exceeding age proportion legally incapable incapacitated individual exceeded oldest director shall automatically representing corporate shareholder take part deemed resigned end ordinary meeting whether shareholder general meeting approving account financial year exceeded shareholder may also postal voting using registration form sent company according 6 director may individual legal entity law regulation acceptable director legal entity required upon registration must received company 3 day appointment appoint permanent date meeting representative subject condition obligation incurs liability case remote voting using electronic vote though personally director without prejudice proxy vote given electronic signature vote several liability legal entity represented made according condition current regulation legal entity director terminates mandate given permanent representative shall promptly notify company registered letter supplementary information information legal nature 163 decision well identity new 3 chairman represents board director permanent representative applies organizes directs work report event death resignation permanent general meeting ensures proper operation representative company decisionmaking body ensures particular director 7 one director seat become vacant position fulfill duty two general meeting due death resignation board director may proceed 4 case absence impediment affecting make appointment interim basis fill chairman board director appoints acting seat board appointment must made chairman meeting within three month vacancy number director fallen minimum 5 board director appoints secretary article association without falling may chosen either among director statutory minimum outside secretary shall replaced simple decision board interim appointment made manner board subject ratification next ordinary meeting decision board general meeting failing ratification decision taken act accomplished shall nonetheless 1 board director meet upon call remain valid chairman often required interest company however director representing least one number director fall third member board director may statutory minimum director remaining office precisely indicating meeting agenda call required immediately call ordinary meeting board met within last two month fill vacant seat board ceo chairing board director may director appointed replacement another shall request chairman call board meeting remain office remaining term office specified agenda predecessor 2 meeting shall take place registered 8 director individual cannot concomitantly office location indicated notice hold five seat board director call call meeting indicating agenda supervisory board sociétés anonymes sent least 7 day beforehand letter registered office metropolitan france subject telegram telex fax call may verbal exception provided law meeting may held immediately director agreement 9 company employee may appointed director unless employment agreement corresponds 3 board director validly deliberate effective employment shall lose benefit least one half director required employment agreement number director present represented bound company employment agreement may exceed one third director office board decision taken majority member present represented organization management board director acting chairman casting vote 1 board director elect chairman 4 attendance sheet shall held signed among member individual director participating board meeting determines remuneration set duration chairman term office may exceed 5 internal regulation established board office director director may provide director participating board meeting videoconference accordance 2 person may appointed chairman applicable regulation deemed present board director age 75 purpose calculating quorum majority chairman office exceeds age shall deemed automatically resigned 164 supplementary information information legal nature provision shall apply adoption general management following decision mode operation appointment remuneration removal chairman ceo vice ceo accordance article l 225 51 1 commercial code company general closing annual account consolidated account management ensured responsibility preparation management report report either chairman board director management group individual appointed board director title ceo 6 board director deliberation recorded minute held accordance applicable law choice two mode operation minute signed acting chairman general management made board one two director director board decision concerning choice mode operation general management taken copy excerpt minute board majority vote director present director deliberation shall validly certified represented shareholder third party chairman ceo informed choice made board director condition set forth applicable power board director regulation 1 board director determines company board director may modify option chosen business guideline ensures time implemented subject power expressly granted law shareholder meeting within limit change mode operation general corporate object deal matter management shall entail modification relating proper running company article association deliberation governs affair company general management dealing third party company bound even act board director depending mode exercise chosen outside corporate purpose unless prove board director chairman ceo shall ensure third party knew act ultra vires responsibility general management could reasonably unaware thereof company view circumstance specified mere publication article association ceo appointed board director suffice establish proof thereof set duration term office determines remuneration applicable restriction 2 board director shall carry control power verification deems appropriate performance duty ceo must director shall receive information necessary age 75 age limit exceeded performance duty may obtain course term office ceo shall document considers useful general deemed automatically resigned new management ceo shall appointed 3 board director may give delegation ceo may removed office time authority representative choice within board director removal ceo limit authority law also chairman may give rise damage decided article association without valid cause board may decide creation review power ceo committee charge studying issue board chairman submits ceo vested broadest power act circumstance name company ceo shall exercise power within limit supplementary information information legal nature 165 corporate object subject power expressly event postal voting form received granted law shareholder meeting company prior meeting board director considered calculating quorum condition timeframe set decree ceo represents company dealing third party company bound even act right vote conferred share proportional ceo outside corporate object capital represent equal par value unless prove third party knew every share capital income right carry right act ultra vires could reasonably one vote unaware thereof view circumstance specified mere publication article event share pledged voting association suffice establish proof thereof right exercised holder security issuing company may validly vote share vice ceo subscribed acquired taken pledge share taken account calculate upon motion ceo whether position quorum filled chairman board director another person board director may name one voting take place vote cast show individual responsibility assisting hand sitting standing roll ceo title vice ceo call decided officer meeting maximum number vice ceo may exceed information voting right five limit bylaw voting right agreement ceo board director event conversion bearer form converted shall determine scope extent share immediately forfeit double voting right power granted vice ceo set event capital increase incorporation remuneration reserve profit share premium double voting right applies new share issued allocated free regard third party vice ceo vice ceo charge shareholder basis existing share power ceo already carry right heading 2 article 3 company bylaw revision bylaw upon cessation duty case unanimously passed general shareholder impediment affecting ceo vice ceo shall meeting extraordinary session august 24 retain unless otherwise decided board 1994 may cancelled general shareholder director office authority meeting convened extraordinary session appointment new ceo ratification special meeting beneficiary shareholder ceo may removed office time board director removal ceo december 31 2013 11623579 also chairman may give rise damage decided share double voting right total without valid cause 17042306 share thus total voting right 28664315 deduction buyback value condition exercise voting right treasury share repurchased fiscal 2010 majority quorum heading 3 article 15 bylaw 1698710 total voting right 26980175 annual extraordinary general meeting excerpt bylaw heading 3 article 16 quorum calculated basis share comprising share capital special meeting annual general shareholder meeting held basis share class concerned least year within six month year end net share entitled voting right virtue consider financial statement year subject law extension timeframe legal decision annual general shareholder meeting may double voting right conferred holder validly deliberate upon first convocation registered share fully paid shareholder present represented voting post registered name holder hold least one quarter share right least four year vote quorum required upon second 166 supplementary information information legal nature convocation meeting decides basis company acquisition share majority vote held shareholder present represented including shareholder voting post element share buyback program implemented accordance provision article l 225 209 crossing legal threshold et seq french commercial code modified ordinance issued january 30 2009 shareholder whose shareholding cross legal threshold defined french law either upwards agm april 19 2010 granted authorization downwards must declare said crossing notification board director maximum period autorité de marchés financier pursuant 18 month accordance provision article law force bylaw company l 225 209 seq provision provide additional threshold declaration european regulation 22732003 december 22 2003 company buy treasury share identification shareholder handle secondary market liquidity share company said handling shall within legal regulatory framework investment service provider acting company authorized seek identity bearer scope liquidity agreement compliant shareholder deontology charter approved autorité de marchés financier payment dividend ii deliver share case exercise right attached security giving access annual general shareholder meeting mean immediately certain future date power give every shareholder part capital company refund conversion dividend payable option receiving dividend exchange exercise warrant way share provided french law cash well perform hedging transaction related issuing security according regulation term payment dividend cash determined competent authority set general meeting default board time board director person acting director cash dividend must paid within pursuant delegation authority board maximum nine month end director deems appropriate reporting year unless timeframe extended legal authorization however profit may iii allocate repurchased share bought distributed interim dividend prior company officer employee approval annual financial statement company andor company group according balance sheet prepared end applicable law regulation especially within financial year certified independent scope participation profit auditor discloses company realized company expansion stockoption plan profit since close previous financial year employee stock ownership program employee recognition necessary amortization saving plan capital forming benefit depreciation provision well deduction free granting share well carry relevant prior loss amount hedging operation related operation transferred reserve required french law according regulation determined competent company bylaw interim dividend may authority time board director exceed profit thus defined reimbursement person acting pursuant delegation dividend may required shareholder unless authority board director deems appropriate distribution made violation legal provision company determines iv retain company share beneficiary aware illegality purchased order return exchange distribution time occurred could ignore payment within scope potential external nature dividend occurs project provided maximum number share share reimbursement timebarred three may purchased end shall exceed year payment dividend dividend five percent 5 total number share collected within five year payment constituting share capital company timebarred supplementary information information legal nature 167 v cancel repurchased share liquidity contract decrease company capital liquidity contract concluded vi pursue objective subsequently sartorius stedim biotech sa stockbroker permitted applicable law regulation gilbert dupont following asset appeared market practice subsequently recognized liquidity account december 31 2013 autorités de marchés financier provided case company would inform shareholder number share 715 press release liquidity account cash balance 42555747 2010 financial year company information following asset appeared purchased 1698710 share total price liquidity account date notification 6132719007 ie average price 3610 contract implementation issued total amount negotiation fee excluding vat amounted 6 k 2010 number share 0 liquidity account cash balance 421860 owned share split following objective 5 return share exchange payment within major contract scope potential external project several service agreement entered 5 deliver share case exercise entity division sartorius group right attached security giving access sartorius stedim biotech group order enable mean immediately certain future date entity division benefit certain capital company general administrative service term share bought back company among service agreement service agreement 2012 2013 financial year highest volume importance place sartorius stedim biotech gmbh sartorius december 31 2013 operation corporate administration gmbh 100 subsidiary company directly controlled 1698710 share sartorius ag sartorius corporate administration gmbh representing 997 share capital allocated provides general administrative service sartorius purpose use exchange payment stedim biotech entity sartorius event external expansion operation 849969 group service include among others accounting share transferring share right related treasury management payroll accounting human financial instrument 848741 share exercised resource system legal service sartorius corporate administration gmbh invoice service board director decided propose basis internal external cost incurred plus resolution 8 april 2014 ordinary annual margin 3 service invoiced sartorius shareholder meeting order modify corporate administration gmbh sartorius stedim allocation treasury share knowing biotech gmbh 2013 totaled million 189 maximum purchase price paid company share shall exceed fortyfive euro 45 per apart abovementioned service agreement share specified informative purpose contract material obligation 16994388 share constitute share capital commitment concluded outside company maximum sum allocated ordinary course company business share buyback plan amount seventysix million member sartorius stedim biotech group party four hundred seventyfour thousand seven hundred ten euro 76474710 strategy sale marketing organization within sartorius stedim biotech group towards customer create valuable longterm relationship therefore example key account management endeavor conclude longterm framework contract customer total solution provider sartorius stedim biotech strives use contract cover entire product portfolio sartorius stedim biotech fit validated process customer 168 supplementary information information legal nature registered trademark trademark application international registration name eu germany france country designated usa australia brazil mexico uk canada 14012008 16112007 application 962279 filed sartorius 13082007 16112017 17082007 13 different 09112007 stedim 006228019 au ch kr ru sg 3709002 class 1371410 biotech 13082017 tr vn 10112019 reg progress reg progress 26061985 494574 04101968 26062015 22071988 16071988 873661 bx ch de e 1572999 1246230 biostat 31102018 fr pt 26122019 16072016 12112001 07041983 10122001 28112001 002458461 1065357 2677224 609610 hydrosart 12112021 07042023 21012023 06052019 04101999 15111999 001330885 2450203 maxicaps 04102019 08052021 15022005 16022005 004289724 3195052 midicaps 15022015 02012017 18011979 1107904 09082019 __________ 09081978 26101988 07021979 18011979 980370 1495753 1144895 1107903 minisart 09082018 26102018 30122020 18012020 13061979 17101989 05121979 20121986 987883 1555685 1200237 1125952 sartocheck 13062019 17102019 06072022 20122020 06061979 17101989 15061982 20121986 988000 1555684 1197792 1125951 sartocon 06062019 17102019 15062022 20122020 02112004 28072004 10112004 004103701 30443764 3178067 virosart 02112014 31072014 28112016 06031985 494396 06032015 bx ch de dz 03061983 eg e fr hu kp 08082007 25101984 1057870 li mc pt ro r 3689721 1228900 sartoflow 30062023 ru sd vn 09292019 25102015 10012000 15022000 001454461 2429825 sartopore 10012020 20022021 24011995 630378 24012015 de bx ch 31082005 19041993 ___________________ 31081993 31011995 03092003 31011995 004614038 93465632 27022006 879252 2041550 651778 810249 2009384 flexboy 31082015 19042023 27022016 jp 04032017 31012015 03092023 31012015 20021998 02091997 27021998 03092003 000753202 97693975 2414947 810250 flexel 20022018 02092017 26122020 03092023 01071998 000865865 palletank 01072018 31082005 004614046 raft 31082015 15101999 001344266 evam 15102019 09102006 08082005 904339 30031984 004582037 09102016 1366524 stedim 08082015 jp 22102015 19071989 1627260 nutribag 19072019 05061989 1535354 nutrikit 05062019 05061989 1535353 nutrimix 05062019 05061989 1535352 nutripoche 05062019 22022001 01021995 758706 95556118 22022021 biosafe 01022015 de dk gb ch 01082005 053373523 biosteam 01082015 03111994 94543057 fluxbulle 03112014 apart trademark mentioned sartorius stedim biotech group owner applicant 327 different trademark various country date indicated daymonthyear supplementary information information legal nature 169 registered trademark trademark application name japan denmark finland ireland malaysia norway sweden china switzerland india taiwan 14012008 19112007 18012008 sartorius 08112007 11 trademark 10 trademark 12 trademark stedim 5170560 28112007 2 trademark 3 trademark 1 trademark biotech 03102018 12 trademark application application application 22021988 2021770 22022018 __________ 27081986 28061985 05011988 01071985 11071985 27051987 31031988 1880889 233586 100350 116688 8502982 128877 209760 biostat 27082016 29082016 05012018 30062016 11072022 27052017 31032018 21112001 4663672 hydrosart 18042023 15101999 4535058 maxicaps 11012022 25022005 4906540 midicaps 04112015 09021979 1583197 minisart 26042023 29091983 1618759 sartocheck 29092023 sartocon 28012005 24112004 20012005 5040228 4379959 533632 virosart 13042017 21062018 20012015 sartoflow 02022000 4495393 sartopore 03082021 19011995 323347 flexboy 16052017 02031998 4470133 flexel 27042021 28022006 5005301 palletank 24112016 raft evam stedim nutribag nutrikit nutrimix nutripoche biosafe biosteam fluxbulle apart trademark mentioned sartorius stedim biotech group owner applicant 327 different trademark various country date indicated daymonthyear 170 supplementary information special report statutory auditor related party agreement commitment special report statutory auditor related party agreement commitment free translation english report issued french provided solely convenience english speaking user report read conjunction construed french law professional standard applicable france year ended december 31 2013 shareholder capacity statutory auditor company agreement commitment submitted hereby report certain related party agreement approval general meeting commitment shareholder required inform basis hereby inform advised information provided u term agreement commitment authorized condition agreement commitment course year submitted general indicated u may identified meeting shareholder approval accordance performance engagement required article l 225 38 french commercial code comment whether beneficial code de commerce appropriate ascertain existence agreement commitment responsibility accordance article r 225 31 french agreement commitment already approved commercial code code de commerce evaluate general meeting shareholder benefit resulting agreement commitment prior approval hereby inform advised agreement commitment already approved addition required applicable general meeting shareholder whose inform accordance article r 225 31 implementation continued year french commercial code code de commerce concerning implementation year agreement commitment already approved general meeting shareholder marseille 24 february 2014 performed procedure considered ernst young deloitte associés necessary comply professional guidance issued national auditing body compagnie nationale xavier senent christophe perrau de commissaires aux comptes relating type engagement procedure consisted verifying information provided u consistent documentation extracted supplementary information resolution submitted annual combined shareholder meeting april 8 2014 171 resolution submitted annual combined shareholder meeting april 8 2014 resolution submitted annual total amount dividend disbursed ordinary shareholder meeting shareholder 1841231520 balance resulting disbursement 3143116213 first resolution remaining amount 3143116213 annual shareholder meeting asm carried forward next year considered report board director general report independent auditor therefore considering company hold special report chairman pursuant article treasury share net dividend 120 paid l 225 37 french commercial code approves every share par value 061 financial statement year ended 31 december 2013 disclosed net profit asm acknowledges informed 2087498653 presented transaction new tax regulation dividend according reflected financial statement summarized 2013 finance law abolished right choose report withholding tax 21 submitting dividend distribution progressive scale asm considered report tax income application 40 independent auditor consolidated financial allowance retained without modification statement said reporting year approves accordance article 158 3 2 4of french financial statement year ended 31 december general code 2013 disclose net profit 66276 thousand transaction included therein summarized dividend paid 15 april 2014 group management report amount distributed 1 january 2011 result asm grant full unreserved eligible tax rebate follows discharge director execution management duty said reporting year income eligible tax rebate income asm also approves overall amount 0 year ended dividend distributed excess amortization amortization 31 déc 2012 1687685560 0 deductible profit subject corporate income 31 déc 2011 15327238 0 tax well corresponding tax 31 déc 2010 13783264 0 second resolution third resolution asm approves appropriation net profit asm considered special report 2087498653 2013 follows independent auditor agreement subject article l 225 38 following french legal reserve 61 commercial code approves conclusion said report agreement contained therein balance resulting deduction legal reserve 2087492553 following added balance yearearlier profit carried forward 2896855180 would yield distributable profit 4984347733 172 supplementary information resolution submitted annual combined shareholder meeting april 8 2014 fourth resolution resolution submitted annual extraordinary shareholder meeting asm approve amount director fee allocated 2013 set aggregate amount director fee paid board director ninth resolution 197600 shareholder fulfilled quorum majority requirement pertaining extraordinary fifth resolution general shareholder meeting considered board director report decide amend article shareholder meeting complying 243 4 company purpose title 1 bylaw since recommendation afepmedef code updated doesnt exercise operating activity following june 2013 deliberating accordance quorum complete realization partial asset contribution majority requirement ordinary shareholder related transfer activity management meeting give favorable opinion element fluid benefit subsidiary sartorius stedim compensation due granted 2013 financial fmt follow year joachim kreuzburg chairman chief executive officer described 577 thousand company purpose france abroad purchase develop administrate manage sixth resolution portfolio equity security security voting right social right company regardless shareholder meeting complying 243 activity mean including way recommendation afepmedef code updated setting new company contribution kind june 2013 deliberating accordance quorum type social right subscription right majority requirement ordinary shareholder merger purchase social right meeting give favorable opinion element incorporation company compensation due granted 2013 financial year reinhard vogt executive vice president manage conduct coordinate activity described 650 thousand subsidiary affiliate applicable provide said company service administrative financial accounting legal seventh resolution nature opinion advise order study research necessary shareholder meeting complying 243 development growth recommendation afepmedef code updated june 2013 deliberating accordance quorum generally financial commercial majority requirement ordinary shareholder industrial personal real property operation meeting give favorable opinion element linked directly indirectly abovementioned compensation due granted 2013 financial corporate purpose complementary year volker niebel executive vice president related similar purpose may promote described 312 thousand development accomplishment thereof eighth resolution shareholder meeting complying 243 recommendation afepmedef code updated june 2013 deliberating accordance quorum majority requirement ordinary shareholder meeting give favorable opinion element compensation due granted 2013 financial year oscarwerner reif executive vice president described 429 thousand supplementary information resolution submitted annual combined shareholder meeting april 8 2014 173 tenth resolution voting right shareholder legal entity company controlling within meaning shareholder fulfilled quorum article l 233 3 commercial code requires majority requirement pertaining extraordinary prior authorisation board director general shareholder meeting considered board director report considering applies agreement one opportunity amending article 85 title iii person listed indirect interest bylaw decide amend said article follow agreement concluded company article 85 title iii bylaw undertaking also subject board director prior authorisation ceo one vice ceo internal regulation established board one director company owner director may provide director participating unlimited liability partner manager director member board meeting videoconference teleconference supervisory board generally corporate others mean telecommunication allowing officer undertaking identification participant ensuring effective participation accordance agreement must authorised approved applicable regulation deemed present condition set forth article l 225 40 purpose calculating quorum majority commercial code provision shall apply adoption following decision 3 agreement involving daytoday transaction concluded arm length shall subject appointment remuneration removal authorisation approval procedure set forth chairman ceo vice ceo article l 225 38 et seq commercial code closing annual account consolidated account preparation management report report twelfth resolution management group shareholder fulfilled quorum majority rest article 8 remains unchanged requirement pertaining ordinary general shareholder meeting considered board director report accordance provision article l 225 129 eleventh resolution et seq article l 225 130 french commercial code shareholder fulfilled quorum majority requirement pertaining extraordinary 1 decide increase share capital company general shareholder meeting considered maximum nominal amount eur six million six board director report considering hundred forty six thousand four hundred ninety nine opportunity amending article 85 title iii thirty four cent 664649934 bylaw decide amend said article follow specified maximum nominal amount calculated based number share existing date article 11 title iii bylaw meeting increasing nominal value existing share currently amounting eur sixty one cent 061 1 director legal entity ceo eur one 1 vice ceo prohibited contracting form borrowing company obtaining 2 decide increase share capital current account overdraft facility company carried capitalization endorsement guarantee commitment available sum item issue premium third party prohibition also applies indicated company annual account permanent representative director legal fiscal year preceding date decision entity spouse ascendant descendant board director complete share capital person listed well intermediary increase 2 agreement concluded directly indirectly 3 authorize board director implement via intermediary company decision increase share capital consequently ceo one vice ceo one director one determine definitive nominal amount share shareholder holding 10 capital increase decided shareholder pursuant 174 supplementary information resolution submitted annual combined shareholder meeting april 8 2014 resolution based number share existing thirteenth resolution date decision board director complete share capital increase authorization granted board director reduce share capital cancellation shareholder grant board director share purchased share buyback program right subdelegate accordance applicable law regulation power shareholder fulfilled quorum implement delegation power particular majority requirement pertaining extraordinary general shareholder meeting considered determine date completion share capi board director report statutory auditor tal decide date increase special report accordance provision nominal value existing share take article l 225 209 et seq article l 225 213 effect french commercial code make adjustment take account impact transaction involving share capital 1 authorize board director cancel one company set term enabling several time sole initiative portion necessary right holder security giving share purchased company share access share capital company buyback program limit ten per cent 10 preserved company share capital twentyfour discretion charge cost capital month period provided ten per cent 10 increase premium arising thereon limit applied company share capital deduct premium sum necessary necessary adjusted take increase legal reserve account transaction affecting share capital duly record completion capital increase decid company occur subsequently shareholder ed shareholder pursuant resolution meeting definitive nominal amount share capi tal increase make necessary amendment 2 authorize board director reduce share article association company capital company accordingly complete necessary formality provide decla ration disclosure authority particu 3 shareholder grant board director larly autorité de marchés financier right subdelegate accordance generally take appropriate measure applicable law regulation power implement authorization particular delegation power granted period five 5 year date shareholder meeting establish definitive amount capital reduction determine term condition reduction duly record reduction charge difference purchase price cancelled share nominal value available premium reserve amend article association company accordingly complete necessary formality provide declaration disclosure authority particularly autorité de marchés financier generally take appropriate measure authorization granted period twentysix 26 month date shareholder meeting supplementary information resolution submitted annual combined shareholder meeting april 8 2014 175 fourteenth resolution 3 set following limit amount issuance may carried pursuant delegation authority granted board delegation authority director issue share andor security giving access share capital company andor security nominal amount capital increase giving right allotment debt instrument capital increase may carried immediately preferential subscription right future pursuant delegation shareholder authority shall exceed maximum amount two million euro 2000000 equivalent value shareholder fulfilled quorum amount date issuance decision majority requirement pertaining extraordinary including nominal value share general shareholder meeting considered issued applicable pursuant adjustment board director report statutory auditor made order protect right holder special report noted share capital security giving access company share capital fully paidup accordance accordance applicable law regulation provision article l 225 129 trough l 225 129 6 well contractual provision specified l 225 132 trough l 225 134 l 228 91 limit nominal amount capital l 228 93 french commercial code increase without preferential subscription right shareholder set 15th 16th 17th 1 delegate board director right 18th 19th 20th resolution submitted subdelegate accordance applicable law shareholder meeting shall deducted regulation authority proceed one overall limit several time france abroad proportion time considers appropriate euro b nominal value debt instrument currency monetary unit established may issued pursuant delegation reference basket currency preferential authority shall exceed maximum amount subscription right shareholder maintained two million euro 2000000 equivalent value issuance share preference share amount date issuance decision andor security kind whatsoever specified amount include security giving right issuance abovepar reimbursement premium preference share giving access share capital provided ii limit issuance debt company new existing share andor ii instrument set 15th 16th 17th 18th 19th 20th issuance security giving right allotment resolution submitted shareholder meeting debt instrument valuable consideration free shall deducted overall limit consideration governed article l 228 91 et seq french commercial code specified 4 shareholder share security referred ii may subscribed either cash offset resolve shareholder company debt company preferential right subscribe issuance issuance share andor security board 2 delegate board director right director may decide pursuant delegation subdelegate accordance applicable law authority irreducible basis proportion regulation authority proceed one number share owned several time france abroad proportion time considers appropriate euro note board director may grant currency monetary unit established shareholder additional preferential right reference basket currency preferential introducing reducible subscription right exercisable subscription right shareholder maintained proportion shareholder existing preferential issuance security giving access share right within limit request capital company company hold directly indirectly half share note delegation authority automatically capital andor ii issuance security giving entail benefit holder security access share capital company may issued pursuant delegation directly indirectly hold half authority express waiver shareholder company share capital subject authorization preferential subscription right respect competent body company referred share security may give access ii immediately future 176 supplementary information resolution submitted annual combined shareholder meeting april 8 2014 note pursuant article l 225 134 subordination accordance provision french commercial code irreducible article l 228 97 french commercial code set applicable reducible subscription absorb interest rate interest rate may fixed entirety issuance share variable zerocoupon indexed specify security giving access share capital circumstance compulsory optional suspension company board director may use cancellation interest payment stipulate condition provided law order term fixed perpetual possibility shall determine option listed reduction increase nominal value set term issuance including granting guarantee security interest limit capital increase amount amortization including possibility redemption subscription provided said amount equal delivery company asset necessary least three quarter amount issuance security may accompanied warrant entitling decided upon holder allotment acquisition subscription bond debt instrument freely allocate unsubscribed share defined market authority example due security giving access share capital redemption remuneration term company right indexation option right amend term share andor offer part unsubscribed share security question term security giving access share capital compliance applicable formality company public french international market abroad determine mean payment share andor security giving access share resolve issuance warrant giving entitlement capital company issued immediately subscribe company share may also future made way free allocation owner existing share stipulated board set necessary term exercise director may decide fractional allotment right right right conversion exchange neither negotiable transferable redemption case may including delivery corresponding security sold company asset share security already issued company attached acknowledge board director shall report share andor security giving access share use made delegation capital company issued immediately authority next ordinary shareholder meeting future particular period accordance applicable law regulation may retrospective dividend payable new share well term 5 shareholder grant board director condition completion share right subdelegate accordance capital increase applicable law regulation power implement delegation authority set term company particular necessary time fixed period right purchase exchange stock exchange decide increase share capital company security giving access share capital determine nature share andor company issued issued immediately security issued future purpose canceling security taking account applicable decide amount share capital increase legal provision issuance price share andor security issued applicable amount issuance determine condition accordance premium applicable law allotment right holder security giving access share may determine date term capital temporarily suspended increase characteristic share andor security issued addition case discretion charge cost capital bond debt instrument determine whether increase premium arising thereon subordinated level supplementary information resolution submitted annual combined shareholder meeting april 8 2014 177 deduct premium sum necessary fifteenth resolution increase legal reserve delegation authority granted board determine make adjustment take account director issue share andor security giving access impact transaction involving share share capital company andor security capital company particular change giving right allotment debt instrument nominal value share increase share capital without preferential subscription right incorporation reserve free allocation shareholder public offering share stock split reverse stock split distribution dividend reserve premium shareholder fulfilled quorum asset redemption capital majority requirement pertaining extraordinary transaction affecting shareholder equity general shareholder meeting considered share capital set term enabling board director report statutory auditor necessary right holder security giving special report noted share capital access share capital company fully paidup accordance preserved provision article l 225 129 trough l 225 129 6 l 225 134 trough l 225 136 l 228 91 trough duly record completion capital increase l 228 93 french commercial code carried pursuant delegation authority make necessary amendment article 1 delegate board director right association company subdelegate accordance applicable law regulation authority proceed generally enter agreement particular public offering one several time france ensure completion proposed issue take abroad proportion time considers measure accomplish formality required appropriate euro currency issuance listing financial administration monetary unit established reference basket share andor security issued delegation currency issuance share authority exercise right attached preference share andor security kind thereto whatsoever security giving right issuance preference share giving access delegation authority granted period share capital company new existing twentysix 26 month date share andor ii issuance security giving shareholder meeting right allotment debt instrument valuable consideration free consideration governed article l 228 91 et seq french commercial code specified share security referred ii may subscribed either cash offset debt company 2 delegate board director right subdelegate accordance applicable law regulation authority proceed public offering one several time france abroad proportion time considers appropriate euro currency monetary unit established reference basket currency issuance share andor security giving access share capital company following issuance company company hold directly indirectly half share capital company directly indirectly hold half company share capital security giving access share capital company delegation authority automatically entail express waiver shareholder preferential subscription right 178 supplementary information resolution submitted annual combined shareholder meeting april 8 2014 respect share andor security giving 5 resolve waive shareholder preferential access share capital company subscription right share andor security security may give access giving access share capital company may issued pursuant delegation 3 delegate board director right authority specified board director subdelegate accordance applicable law may grant shareholder priority subscription period regulation authority proceed respect part issuance share public offering one several time france andor security giving access share capital abroad proportion time considers company period term appropriate euro currency shall determine accordance provision monetary unit established reference basket article l 225 135 5 french commercial code currency issuance security giving access priority subscription period shall give rise share capital company creation negotiable right shall exercised company hold directly indirectly half proportion number share owned share capital andor ii issuance security shareholder may exercised board giving access share capital company director considers appropriate reducible directly indirectly hold half irreducible basis specified share andor company share capital subject security subscribed said manner authorization competent body subject public offering france abroad company referred ii 6 public offering share andor security 4 set following limit amount decided pursuant delegation authority may issuance may carried pursuant carried one offering issued delegation authority simultaneously private placement set forth article l411 2 ii french monetary nominal amount capital increase financial code decided pursuant delegation capital increase may carried immediately authority 16th resolution submitted future pursuant delegation shareholder meeting authority shall exceed maximum amount two million euro 2000000 equivalent value 7 shareholder amount date issuance decision including nominal value share note delegation authority automatically issued applicable pursuant adjustment entail benefit holder security made order protect right holder may issued pursuant delegation security giving access company share capital authority express waiver shareholder accordance applicable law regulation preferential subscription right respect well contractual provision specified share security may give access nominal amount capital increase carried immediately future pursuant delegation authority shall deducted overall limit set paragraph 3a note pursuant article l 225 134 14th resolution submitted shareholder french commercial code irreducible meeting applicable reducible subscription absorb entirety issuance share b nominal value debt instrument security giving access share capital may issued pursuant delegation company board director may use authority shall exceed maximum amount condition provided law order two million euro 2000000 equivalent value shall determine option listed amount date issuance decision specified amount include abovepar reimbursement premium limit capital increase amount provided ii nominal amount debt subscription provided said amount instrument shall deducted overall limit equal least three quarter amount set paragraph 3b 14th resolution submitted issuance decided upon shareholder meeting freely allocate unsubscribed share security supplementary information resolution submitted annual combined shareholder meeting april 8 2014 179 note pursuant article l 225 136 subscription bond debt instrument french commercial code defined market authority example due redemption remuneration term issuance price share issued right indexation option right shall least equal minimum set forth amend term share andor applicable law regulation date security question term issuance decision compliance applicable formality issuance price security giving determine mean payment share access share capital company andor security giving access share issued share shall amount capital company issued immediately collected company immediately future increased applicable amount could collected later company set necessary term exercise shall share issued consequently right right conversion exchange issue security least equal redemption case may including delivery amount set forth paragraph company asset share security already issued company attached acknowledge board director shall report share andor security giving access share use made delegation capital company issued immediately authority next ordinary shareholder meeting future particular period accordance applicable law regulation may retrospective dividend payable new share well term 8 shareholder grant board director condition completion share right subdelegate accordance capital increase applicable law regulation power implement delegation authority set term company particular necessary time fixed period right purchase exchange stock exchange decide increase share capital company security giving access share capital determine nature share andor company issued issued immediately security issued future purpose canceling security taking account applicable decide amount capital increase legal provision issuance price share andor security issued applicable amount issuance determine condition accordance premium applicable law allotment right holder security giving access share may determine date term capital temporarily suspended increase characteristic share andor security issued addition case discretion charge cost capital bond debt instrument determine whether increase premium arising thereon subordinated level deduct premium sum necessary subordination accordance provision increase legal reserve article l 228 97 french commercial code set interest rate interest rate may fixed determine make adjustment take account variable zerocoupon indexed specify impact transaction involving share circumstance compulsory optional suspension capital company particular change cancellation interest payment stipulate nominal value share increase share capital term fixed perpetual possibility incorporation reserve free allocation reduction increase nominal value set share stock split reverse stock split distribution term issuance including granting dividend reserve premium guarantee security interest asset redemption capital amortization including possibility redemption transaction affecting shareholder equity delivery company asset necessary share capital set term enabling security may accompanied warrant entitling necessary right holder security giving holder allotment acquisition 180 supplementary information resolution submitted annual combined shareholder meeting april 8 2014 access share capital company sixteenth resolution preserved delegation authority granted board duly record completion capital increase director issue share andor security giving access carried pursuant delegation authority share capital company andor security make necessary amendment article giving right allotment debt instrument association company without preferential subscription right shareholder private placement set forth generally enter agreement particular article l411 2 ii french monetary ensure completion proposed issue take financial code measure accomplish formality required issuance listing financial administration shareholder fulfilled quorum share andor security issued delegation majority requirement pertaining extraordinary authority exercise right attached general shareholder meeting considered thereto board director report statutory auditor special report noted share delegation authority granted period capital fully paidup accordance twentysix 26 month date provision article l 225 129 l 225 129 2 shareholder meeting l 225 134 l 225 136 l 228 91 l 228 93 french commercial code article l 411 2 ii french commercial code 1 delegate board director right subdelegate accordance applicable law regulation authority proceed private placement set forth article l411 2 ii french monetary financial code one several time france abroad proportion time considers appropriate condition limit set forth applicable law regulation euro currency monetary unit established reference basket currency issuance share preference share andor security kind whatsoever security giving right issuance preference share giving access share capital company new existing share andor ii issuance security giving right allotment debt instrument valuable consideration free consideration governed article l 228 91 et seq french commercial code specified share security referred ii may subscribed either cash offset debt company 2 delegate board director right subdelegate accordance applicable law regulation authority proceed private placement set forth article l411 2 ii french monetary financial code one several time france abroad proportion time considers appropriate condition limit set forth applicable law regulation euro currency monetary unit established reference basket currency issuance share andor security supplementary information resolution submitted annual combined shareholder meeting april 8 2014 181 giving access share capital company b nominal value debt instrument following issuance company may issued pursuant delegation company hold directly indirectly half authority shall exceed maximum amount two share capital company directly million euro 2000000 equivalent value indirectly hold half company share amount date issuance decision capital security giving access share capital specified limit mutual limit company delegation authority set paragraph 4b 15th resolution automatically entail express waiver amount include abovepar shareholder preferential subscription right reimbursement premium provided respect share security giving access ii nominal amount debt instrument shall share capital company deducted overall limit set paragraph security may give access 3b 14th resolution submitted shareholder meeting 3 delegate board director right subdelegate accordance applicable law 5 resolve waive shareholder preferential regulation authority proceed subscription right share andor security private placement set forth article l411 2 ii giving access share capital company french monetary financial code one may issued pursuant delegation several time france abroad proportion authority time considers appropriate condition limit set forth applicable law 6 private placement set forth article l411 regulation euro currency 2 ii french monetary financial code monetary unit established reference basket share andor security decided pursuant currency issuance security giving access delegation authority may carried one share capital company offering issued simultaneously public company hold directly indirectly half offering decided pursuant delegation share capital andor ii issuance security authority 15th resolution submitted giving access share capital company shareholder meeting directly indirectly hold half company share capital subject 7 shareholder authorization competent body company referred ii note delegation authority automatically entail benefit holder security 4 set following limit amount may issued pursuant delegation issuance may carried pursuant authority express waiver shareholder delegation authority preferential subscription right respect share security may give access nominal amount capital increase immediately future capital increase may carried immediately future pursuant delegation note pursuant article l 225 134 authority shall exceed maximum amount two french commercial code irreducible million euro 2000000 equivalent value applicable reducible subscription absorb amount date issuance decision entirety issuance share including nominal value share security giving access share capital issued applicable pursuant adjustment company board director may use made order protect right holder condition provided law order security giving access company share capital shall determine option listed accordance applicable law regulation well contractual provision specified limit mutual limit set paragraph limit capital increase amount 4a 15th resolution nominal subscription provided said amount amount capital increase carried pursuant equal least three quarter amount delegation authority shall deducted issuance decided upon overall limit set paragraph 3a 14th resolution submitted shareholder meeting freely allocate unsubscribed share security 182 supplementary information resolution submitted annual combined shareholder meeting april 8 2014 note pursuant article l 225 136 subscription bond debt instrument french commercial code defined market authority example due redemption remuneration term issuance price share issued right indexation option right shall least equal minimum set forth amend term share andor applicable law regulation date security question term issuance decision compliance applicable formality issuance price security giving determine mean payment share access share capital company andor security giving access share issued share shall amount capital company issued immediately collected company immediately future increased applicable amount could collected later company set necessary term exercise shall share issued consequently right right conversion exchange issue security least equal redemption case may including delivery amount set forth paragraph company asset share security already issued company attached acknowledge board director shall report share andor security giving access share use made delegation capital company issued immediately authority next ordinary shareholder meeting future particular period accordance applicable law regulation may retrospective dividend payable new share well term 8 shareholder grant board director condition completion share right subdelegate accordance capital increase applicable law regulation power implement delegation authority set term company particular necessary time fixed period right purchase exchange stock exchange decide increase share capital company security giving access share capital determine nature share andor company issued issued immediately security issued future purpose canceling security taking account applicable decide amount capital increase legal provision issuance price share andor security issued applicable amount issuance determine condition accordance premium applicable law allotment right holder security giving access share may determine date term capital temporarily suspended increase characteristic share andor security issued addition case discretion charge cost capital bond debt instrument determine whether increase premium arising thereon subordinated level deduct premium sum necessary subordination accordance provision increase legal reserve article l 228 97 french commercial code set interest rate interest rate may fixed determine make adjustment take account variable zerocoupon indexed specify impact transaction involving share circumstance compulsory optional suspension capital company particular change cancellation interest payment stipulate nominal value share increase share capital term fixed perpetual possibility incorporation reserve free allocation share reduction increase nominal value set stock split reverse stock split distribution term issuance including granting dividend reserve premium asset guarantee security interest redemption capital transaction amortization including possibility redemption affecting shareholder equity share capital delivery company asset necessary set term enabling necessary security may accompanied warrant entitling right holder security giving access holder allotment acquisition share capital company preserved supplementary information resolution submitted annual combined shareholder meeting april 8 2014 183 duly record completion capital increase seventeenth resolution carried pursuant delegation authority make necessary amendment article authorization granted board director association company event issuance share andor security giving access share capital company generally enter agreement particular public offering private placement set forth ensure completion proposed issue take article l411 2 ii french monetary measure accomplish formality required financial code without preferential subscription issuance listing financial administration right shareholder set issuance price share andor security issued delegation condition defined shareholder authority exercise right attached meeting maximum ten per cent 10 thereto share capital per year delegation authority granted period shareholder fulfilled quorum twentysix 26 month date majority requirement pertaining extraordinary shareholder meeting general shareholder meeting considered board director report statutory auditor special report accordance provision article l 225 136 french commercial code 1 authorize board director right subdelegate accordance applicable law regulation issuance decided 15th 16th resolution depart pricing term set forth applicable law regulation date issuance decision ie day article r 225 119 french commercial code set price share andor security giving access share capital company issued public offering private placement set forth article l 411 2 ii french monetary financial code accordance following provision issuance price equal discretion board director arithmetic average closing price observed maximum period three 3 month preceding date issuance decision b volumeweighted average price market three 3 latest trading day preceding date issuance decision potential maximum discount twenty per cent 20 issuance price security giving access share capital company shall amount collected company immediately increased applicable amount could collected later company shall share issued consequently issuance security least equal amount set forth paragraph 184 supplementary information resolution submitted annual combined shareholder meeting april 8 2014 2 resolve nominal amount capital eighteenth resolution increase capital increase may carried pursuant authorization shall exceed delegation authority granted board limit ten per cent 10 share capital director increase number share andor company based share capital date security giving access share capital issuance decision period twelve 12 company issued event share capital month specified nominal amount increase without preferential subscription capital increase capital increase may right shareholder carried pursuant authorization deducted amount limit set forth either shareholder fulfilled quorum paragraph 4a 15th resolution majority requirement pertaining extraordinary inparagraph 4a 16th resolution case general shareholder meeting considered may board director report statutory auditor special report pursuant provision 3 shareholder note board director article l 225 135 1 r 225 118 french must provide additional report duly certified commercial code statutory auditor setting definitive condition transaction providing 1 delegate board director right assessment method tool used evaluate subdelegate accordance applicable law impact transaction situation regulation authority decide shareholder issuance carried 14th 16th resolution increase number share andor security authorization granted period twentysix giving access share capital company 26 month date shareholder issued event share capital increase meeting without preferential subscription right shareholder price used initial issuance within limit time quantity term set forth applicable law regulation well market practice date issuance decision ie day period thirty 30 day closing subscription limit fifteen per cent 15 initial issuance particular view granting oversubscription option specified share andor security may issued pursuant delegation authority may subscribed either cash offset debt company 2 resolve nominal amount capital increase capital increase may carried pursuant delegation authority deducted amount limit set forth resolution pursuant issuance decided delegation authority granted period twentysix 26 month date shareholder meeting supplementary information resolution submitted annual combined shareholder meeting april 8 2014 185 nineteenth resolution 3 resolve security giving access share capital company issued pursuant delegation authority granted board delegation authority may particular consist director issue share andor security giving access debt instrument combined issuance share capital company consideration debt instrument enable issuance contribution kind consisting company debt instrument intermediate security share andor security giving access share specified one hand nominal amount capital maximum ten per cent 10 debt instrument may issued pursuant share capital outside public exchange offer initiated delegation authority shall exceed maximum company amount two million euro 2000000 equivalent value amount date shareholder fulfilled quorum issuance decision hand majority requirement pertaining extraordinary limit mutual limit set paragraph 4b general shareholder meeting considered 15th resolution amount board director report statutory auditor include abovepar reimbursement premium special report accordance provision provided ii nominal amount article l 225 129 et seq article l 225 147 debt instrument shall deducted overall l 228 91 trough l 228 93 french limit set paragraph 3b 14th resolution commercial code submitted shareholder meeting 1 delegate board director right 4 resolve cancel preferential subscription right subdelegate accordance applicable law given shareholder company share regulation authority proceed one andor security may issued several time france abroad proportion delegation authority holder share time considers appropriate issuance andor security subject contribution kind share preference share andor refered security kind whatsoever security giving right issuance preference share 5 note delegation authority automatically giving access share capital company entail benefit holder security new existing share based report giving access share capital company expert appraiser referred article l 225 147 may issued pursuant delegation french commercial code consideration authority express waiver shareholder contribution kind consisting share andor preferential subscription right respect security giving access share capital case share security may give access immediately article l 225 148 french commercial future code applicable 6 shareholder grant board director 2 resolve nominal amount capital right subdelegate accordance increase capital increase may carried applicable law regulation power pursuant delegation authority shall implement delegation authority exceed limit ten per cent 10 share particular capital company specified limit mutual limit set paragraph 4a decide increase share capital company 15th resolution nominal amount consideration asset transferred capital increase carried pursuant company determine nature share delegation authority shall deducted andor security issued overall limit set paragraph 3a 14th resolution submitted shareholder meeting establish list share andor security transferred company approve valuation contribution kind set term issuance share andor security made consideration said contribution amount cash portion paid approve granting specific benefit reduce subject transferor consent valuation contribution consideration specific benefit 186 supplementary information resolution submitted annual combined shareholder meeting april 8 2014 determine characteristic security giving access share capital company issued consideration contribution kind new existing share andor ii issuance set term right holder security giving right allotment debt security giving access company capital instrument valuable consideration free preserved consideration governed article l 228 91 et seq french commercial code consideration discretion charge cost capital security tendered public exchange offer made increase premium arising thereon company france abroad accordance deduct premium sum necessary local regulation respect security increase legal reserve company whose share admitted trading regulated market referred article l 225 148 duly record completion capital increase french commercial code carried pursuant delegation authority make necessary amendment article 2 resolve nominal amount capital association company increase capital increase may carried immediately future pursuant generally enter agreement particular delegation authority shall exceed maximum ensure completion proposed issue take amount two million euro 2000000 measure accomplish formality required equivalent value amount date issuance listing financial administration issuance decision including nominal value share andor security issued delegation share issued applicable pursuant authority exercise right attached adjustment made order protect right thereto holder security giving access company share capital accordance applicable law delegation authority granted period regulation well contractual provision twentysix 26 month date specified limit mutual limit set shareholder meeting paragraph 4a 15th resolution nominal amount capital increase carried pursuant delegation authority shall twentieth resolution deducted overall limit set paragraph 3a 14th resolution submitted shareholder delegation authority granted board meeting director issue share andor security giving access share capital company consideration 3 resolve security giving access share security tendered public exchange offer capital company issued pursuant initiated company without preferential delegation authority may particular consist subscription right shareholder debt instrument combined issuance debt instrument enable issuance shareholder fulfilled quorum debt instrument intermediate security majority requirement pertaining extraordinary specified one hand nominal amount general shareholder meeting considered debt instrument may issued pursuant board director report statutory auditor delegation authority shall exceed maximum special report accordance provision amount two million euro 2000000 article l 225 129 trough l 225 129 6 l 225 equivalent value amount date 135 l 225 148 l 228 91 trough l 228 93 issuance decision hand french commercial code limit mutual limit set paragraph 4b 15th resolution amount 1 delegate board director right include abovepar reimbursement premium subdelegate accordance applicable law provided ii nominal amount regulation authority proceed one debt instrument shall deducted overall several time france abroad proportion limit set paragraph 3b 14th resolution time considers appropriate euro submitted shareholder meeting currency monetary unit established reference basket currency issuance share preference share andor security kind whatsoever security giving right issuance preference share supplementary information resolution submitted annual combined shareholder meeting april 8 2014 187 4 resolve waive preferential subscription right company particular change nominal shareholder respect share andor value share increase share capital security may issued pursuant incorporation reserve free allocation share delegation authority favor holder stock split reverse stock split distribution security mentioned dividend reserve premium asset redemption capital 5 note delegation authority automatically transaction affecting shareholder equity entail benefit holder security capital set term enabling giving access share capital company necessary right holder security giving may issued pursuant delegation access share capital company authority express waiver shareholder preserved preferential subscription right respect share security may give access immediately duly record completion capital increase future carried pursuant delegation authority make necessary amendment article 6 shareholder grant board director association company right subdelegate accordance applicable law regulation power generally enter agreement particular implement delegation authority ensure completion proposed issue take particular measure accomplish formality required issuance listing financial administration decide increase share capital company share andor security issued delegation consideration security mentioned authority exercise right attached determine nature share andor thereto security issued delegation authority granted period set exchange ratio applicable cash twentysix 26 month date balance consideration paid shareholder meeting confirm number security tendered exchange determine date term condition issuance characteristic share andor security may issued pursuant delegation authority particular price date first entitlement dividend new share andor security giving access share capital company record contribution premium account shareholder shall right balance sheet liability difference issuance price new share nominal value determine condition accordance applicable law allotment right holder security giving access share may temporarily suspended discretion charge share premium expense related completion share capital increase well sum required order constitute legal reserve determine make adjustment take account impact transaction involving capital 188 supplementary information resolution submitted annual combined shareholder meeting april 8 2014 twentyfirst resolution decide event share issued delegation authority granted board fractional right negotiable director increase share capital corresponding share sold proceeds capitalization reserve earnings premium sale allocated holder sum upon capitalization would right term specified law regulation permitted make adjustment take account impact shareholder fulfilled quorum transaction involving share capital majority requirement pertaining ordinary general company particular change nominal shareholder meeting considered board value share increase share capital director report statutory auditor special incorporation reserve free allocation share report accordance provision stock split reverse stock split distribution article l 225 129 l 225 129 6 dividend reserve premium l 225 130 french commercial code asset redemption capital transaction affecting shareholder equity 1 delegate board director right share capital set term enabling subdelegate accordance applicable law necessary right holder security giving regulation authority proceed one access share capital company several time france abroad proportion preserved time considers appropriate increase share capital company discretion charge cost capital incorporation share premium reserve earnings increase premium arising thereon amount may converted capital deduct premium sum necessary successively simultaneously accordance increase legal reserve applicable law article association freely allocating new share andor increasing duly record completion capital increase nominal value existing share carried pursuant delegation authority combination two procedure make necessary amendment article association company 2 resolve nominal amount capital increase capital increase may carried generally enter agreement particular immediately future pursuant ensure completion proposed issue take delegation authority shall exceed maximum measure accomplish formality required amount two million euro 2000000 issuance listing financial administration specified nominal amount limit separate share andor security issued delegation overall limit set paragraph 3a 14th authority exercise right attached resolution submitted shareholder meeting thereto 3 shareholder grant board director delegation authority granted period right subdelegate accordance twentysix 26 month date applicable law regulation power shareholder meeting implement delegation authority particular determine amount nature sum incorporated capital set number new share issued andor amount nominal value existing share increased decide date may retrospective new share rank dividend increase nominal value existing share take effect supplementary information resolution submitted annual combined shareholder meeting april 8 2014 189 twentysecond resolution 4 resolve issuance price share andor security giving access share capital delegation authority granted board company set accordance article director issue share andor security giving access l3332 18 et seq french labor code provided share capital company reserved pursuant abovementioned article member enrolled employersponsored company discount set shall exceed twenty per cent 20 saving plan without preferential subscription right average quoted price company share shareholder regulated market nyse euronext paris twenty 20 trading day preceding date shareholder fulfilled quorum decision setting opening date subscription majority requirement pertaining extraordinary period shareholder expressly authorize board general shareholder meeting considered director reduce cancel aforementioned board director report statutory auditor discount considers appropriate particular special report accordance provision order take consideration international article l 225 129 et seq article l 225 138 accounting standard inter alia locally applicable l 225 138 1 french commercial code legal accounting tax social provision article l 3332 1 et seq french labor country certain beneficiary board code director may also substitute part discount granting share andor security giving 1 delegate board director right access share capital company pursuant subdelegate accordance applicable law provision regulation authority proceed one several time france abroad proportion 5 authorize board director freely grant time considers appropriate issuance pursuant term delegation authority share preference share andor share security giving immediate deferred security kind whatsoever security claim share company substitute giving right issuance preference share part discount andor grant abondement giving access share capital company case may provided total benefit new existing share reserved member enrolled resulting discount andor grant employersponsored saving plan abondement may exceed applicable legal plan whose member capital increase may regulatory limit reserved equivalent term article l 3332 18 french labor code instituted within french 6 shareholder grant board director foreign entity group entity falling within right subdelegate accordance scope company consolidated combined applicable law regulation power financial statement pursuant article l 3344 1 implement delegation authority l 3344 2 french labor code particular specified share security referred ii may subscribed either cash establish accordance law list offset debt company company beneficiary indicated may subscribe share security 2 resolve nominal amount capital giving access capital thereby issued increase capital increase may carried may freely allotted share andor security giving immediately future pursuant access capital delegation authority shall exceed maximum amount two million euro 2000000 decide subscription may made directly specified limit limit separate beneficiary belonging entity group saving overall limit set paragraph 3a 14th plan similar plan via dedicated mutual fund resolution submitted shareholder meeting vehicle entity permitted applicable law regulation 3 resolve waive preferential subscription right shareholder respect share andor determine condition particular regard security giving access share capital length service must met company may issued pursuant beneficiary capital increase delegation authority favor beneficiary defined set opening closing date subscription 190 supplementary information resolution submitted annual combined shareholder meeting april 8 2014 set amount issuance made twentythird resolution present delegation authority particular determine issuance price date time limit asm give authority carrier term condition subscription payment original copy extract herewith asms delivery date entitlement dividend minute undertake formality may share andor security may necessary retrospective rule pro rating event oversubscription term condition issue subject applicable legal regulatory limit case issue new share charge amount required pay said share reserve profit share premium discretion charge cost capital increase premium arising thereon deduct premium sum necessary increase legal reserve duly record completion capital increase carried pursuant delegation authority make necessary amendment article association company generally enter agreement particular ensure completion proposed issue take measure accomplish formality required issuance listing financial administration share andor security issued delegation authority exercise right attached thereto delegation authority granted period twentysix 26 month date shareholder meeting supplementary information information reference document annual financial report 191 information reference document annual financial report declaration responsibility reference document 2013 annual financial report hereby certify taken reasonable received completion letter auditor measure effect information stating audited information contained present reference document contained reference document best knowledge accordance financial position financial statement fact make omission likely affect import read document entirety certify best knowledge historical financial information presented financial statement prepared accordance document discussed auditor report applicable accounting standard give fair found page 142 158 reference view asset liability financial position document profit loss company activity included consolidation february 27 2014 management report page 18 68 present fair review development performance business financial position company activity included consolidation well description main risk uncertainty exposed joachim kreuzburg chairman board ceo 192 supplementary information information reference document annual financial report table reconciliation order facilitate understanding present 8092004 april 29 2004 european document concerning presentation sartorius commission column right stedim biotech sa table left corresponding page present document heading note 1 european regulation heading part 1 european regulation n8092004 april 29 2004 page 1 person responsible 11 person responsible information 191 12 certification person responsible registering document 191 2 independent auditor 21 name address independent auditor issuer 94 3 selected financial information presentation selected historical financial information every year period covered 31 financial information 2 24 31 47 49 4 risk factor 50 56 5 information issuer 51 history development company 000 511 corporate name commercial name issuer 160 512 place registration number issuer 160 513 date establishment life issuer 160 514 registered office legal form issuer legislation governing operation country origin address 160 52 investment 47 49 521 principal investment including amount carried 29 114 6 overview operation 61 principal operation 18 31 62 principal market 22 23 63 dependence patent license contract 53 54 168 169 64 competition 22 53 7 organigram organizational chart 71 description group 113 114 72 list subsidiary 114 8 property plant equipment 81 significant existing planned property plant equipment 122 123 82 environmental issue 32 45 9 analysis financial situation result 91 financial position 47 49 99 101 92 operating profit 24 27 98 117 10 cash position capital 101 issuer capital short longterm 61 65 101 125 126 151 102 cash flow 49 100 103 borrowing condition financial structure 49 132 133 104 expected source financing 43 45 112 121 123 11 research development patent license 27 28 168 169 12 information trend 20 23 13 profit forecast estimate applicable 14 governing management supervisory executive body 141 composition governing management body nature family link amongst person 70 77 1411 conviction fraud within last five year least 75 1412 bankruptcy sequestration liquidation member governing body 75 1413 indictment andor official public sanction member governing body 75 142 conflict interest level governing management body 75 15 remuneration benefit 151 remuneration paid benefit kind 67 73 80 85 92 152 pension retirement benefit 57 73 77 84 supplementary information information reference document annual financial report 193 heading part 1 european regulation n8092004 april 29 2004 page 16 operation governing management body 161 expiration date current mandate term office 70 75 162 service agreement member 70 75 163 audit remuneration committee issuer 76 78 79 83 164 corporate governance 70 84 17 employee 171 workforce end period covered historical financial information 34 140 172 shareholding capital 65 138 139 173 employee shareholding capital 51 165 166 18 principal shareholder 181 crossing threshold 166 182 double voting right 166 183 control business 16 51 19 transaction related party 140 20 financial information issuer asset financial situation profit 201 historical financial information result last five year 68 202 20122013 consolidated financial result 24 26 203 2013 statement profit loss 98 20122013 consolidated financial statement statement financial position statement profit loss 204 statement cash flow statement change equity note consolidated financial statement 97 148 205 verification annual historical information independent auditor report 143 158 206 last financial information 3 207 dividend distribution policy 15 153 208 legal arbitration procedure 45 209 significant change financial commercial situation 47 49 21 additional information 211 share capital 61 amount issued capital number share authorized number share issued fully paid number share issued fully paid par value per share reconciliation number share 2111 outstanding beginning end year 61 62 125 151 2112 share representing capital applicable number book value face value share held behalf issuer subsidiary 2113 issuer 61 64 2114 amount convertible security exchangeable security security warrant applicable information term acquisition right obligation authorized unissued 2115 capital undertaking increase capital applicable information capital member group option agreed 2116 conditionally unconditionally put option applicable 2117 history share capital period covered historical financial information 61 64 212 memorandum article association 160 167 2121 object purpose issuer 160 2122 member administrative management supervisory body 160 166 2123 right preference restriction attaching class existing share 166 167 2124 action required change right shareholder applicable condition governing manner annual general meeting extraordinary general meeting 2125 shareholder called including condition admission 161 163 provision issuer article association statute charter bylaw would effect 2126 delaying deferring preventing change control issuer applicable provision article association statute charter bylaw governing ownership threshold 2127 shareholder ownership must disclosed 167 condition imposed memorandum article association statute charter bylaw 2128 governing change capital condition stringent required law applicable 22 major contract 167 23 information provided third party declaration expert declaration interest applicable 24 document accessible public 3 25 information shareholding 114 194 supplementary information glossary glossary industrial productspecific term bioreactor freezethaw technology englishspeaking country bioreactor used vessel technology used controlled freezing thawing cultivating animal human cell culture medium non biological liquid liquid biologics englishspeaking country term also used synonymously fermentor system microorganism membrane chromatography bacteria yeast fungi multiply case vessel selective separation mixture substance adsorption used obtain cell part one metabolite specifically modified membrane membrane adsorbers flowing system capsule readytouse filter unit consisting filter housing hose membrane filter connector incorporated filter cartridge connection thin film foil made polymer porous structure piping film used filtration application crossflow monoclonal antibody term taken filtration technology instead directly flowing synthetic antibody increasingly used medical filter static filtration liquid flow perpendicularly diagnosis treatment filter surface prevents filter blockage resulting longer inservice life filter purification important step downstream processing disposable product single use cf singleuse product recombinant protein protein manufactured using genetically modified organism example downstream processing include pharmaceutical protein insulin vaccine collective term various step follow fermentation cell cultivation production biopharmaceuticals example scaleup separation purification concentration transfer scale increase size term used denote progression process increase range lab fda food drug administration scale pilot scale process scale retaining u governmental agency responsible monitoring technology material construction geometry throughout food biotechnological medical veterinary pharmaceutical product singleuse product see disposable fermentation technical process used produce transform intra sterile filter sterilizinggrade filter extracellular substance help microorganism membrane filter whose pore size usually 02 μm smaller product processspecific validation test required fluid management technology confirm whether filter type selected delivers sterile filtrate technology system use handling sensitive biological liquid example transportation storage medium sterility test sterility testing test verify sample contains living viable substance validation systematic checking essential step facility research development production including testing pharmaceutical ensure product manufactured made reliably reproducibly desired quality supplementary information glossary 195 business economic term amortization ifrs international financial reporting standard amortization relates exclusively potential reduction internationally recognized accounting principle value goodwill allocation purchase price intangible asset acquired carried accordance ifrs 3 investment rate ratio capital expenditure sale revenue cash flow short longterm management liquid fund cash pro forma balance inflow outflow fund pro forma presentation used annual report mean figure include business generated stedim consolidated derivative financial instrument first time june 29 2007 full previous year instrument hedging risk change market business generated sartorius stedim plastic gmbh consolidated price foreign currency january 1 2007 full fiscal year 2007 preceding year ebit supply chain management earnings interest tax setup coordinated control integrated flow material information finance supply chain entire value ebit margin added process ratio ebit see ebit sale revenue tecdax ebita german stock index transaction service provider earnings interest tax amortization related marketplace organizer deutsche börse ag business combination amortization item refers amortization confirmed connection purchase price treasury allocation ppa intangible asset acquired specified short mediumterm liquidity management ifrs3 standard underlying ebita adjusted onetime item ebita margin ebita see ebita adjusted extraordinary item 2013 ratio ebita see ebita sale extraordinary item amounted 37 million previous year 59 million essentially cover onetime expense strategic ebitda group project integration acquisition related item earnings interest tax depreciation amortization underlying ebita margin ebitda margin ratio operating ebita see underlying ebita sale revenue ratio ebitda see ebitda sale revenue underlying ebitda fixed asset ebitda see ebitda adjusted extraordinary item 2013 sum intangible asset property plant equipment extraordinary item amounted 37 million previous year financial asset 59 million essentially cover onetime expense strategic group project integration acquisition related item free float share public company freely available underlying ebitda margin investing public ratio operating ebitda see underlying ebitda sale revenue goodwill underlying consolidated net profit represents difference price paid company profit figure yielded adjustment extraordinary business net asset goodwill form intangible asset item amortization business combination refers exclusively purchase price allocation ppa intangible ia international accounting standard asset acquired according revised ifrs 3 internationally recognized accounting principle 196 supplementary information adresses adresses europe france austria ireland sartorius stedim biotech sa sartorius stedim austria gmbh sartorius stedim ireland ltd zone industrielle le paluds franzosengraben 12 unit 41 business centre avenue de jouques c 91051 1030 vienna stadium business park 13781 aubagne cedex phone 43179657630 ballycoolin road phone 33442845600 fax 431796576344 dublin 11 fax 33442845619 separationaustriasartoriuscom phone 35318234394 infosartoriusstedimcom fax 35318089388 belgium infoirelandsartoriusstedimcom sartorius stedim france sa zone industrielle le paluds sartorius stedim belgium nv italy avenue de jouques c 71058 leuvensesteenweg 248b 13781 aubagne cedex 1800 vilvoorde sartorius stedim italy spa phone 33442845600 phone 3227560680 via dellantella 76a fax 33442846545 fax 3227560681 50012 antella bagno ripoli florence infobiotechfrancesartoriusstedimcom lindreymensartoriuscom phone 39055634041 fax 390556340526 sartorius stedim aseptics sa denmark infoitalysartoriuscom zone industrielle de saux 6 rue ampère 65100 lourdes sartorius stedim nordic netherlands phone 33562427373 lyskaer 3 fax 33 562420844 2730 herlev sartorius stedim nl infosartoriusstedimcom phone 4570234400 westblaak 89 fax 4546304030 3012 kg rotterdamm germany infodksartoriusstedimcom phone 31306025080 fax 31306025099 sartorius stedim biotech gmbh hungary officenlsartoriuscom augustspindlerstr 11 37079 goettingen sartorius stedim hungária kft poland phone 495513080 kagyló u 5 fax 495513083289 2092 budakeszi sartorius stedim poland sp zoo infosartoriusstedimcom phone 3623457227 ul wrzesinska 70 fax 3623457147 62 025 kostrzyn sartorius stedim plastic gmbh ssbsartoriushu phone 48616473840 karlarnoldstr 21 fax 48618792504 37079 goettingen biuroplsartoriuscom phone 49551504500 fax 495515045050 portugal infosartoriusstedimcom sartorius stedim spain sa sartorius stedim system gmbh cisabel colbrand 10 12 oficina 6970 robertboschstraße 5 7 polígono industrial de fuencarral 34302 guxhagen 28050 madrid phone 4956654070 phone 800855800 fax 4956654072200 fax 800855799 infosartoriusstedimcom biotech_spainsartoriusstedimcom supplementary information adresses 197 africa russia uk tunisia sartorius icr ooo saintpetersburg sartorius stedim uk ltd sartorius stedim bioprocess sarl rasstannaya str 2 building 2 letter longmead business centre km 24 route de zaghouan 192007 st petersburg blenheim road mhamdia bourbiâa 1145 phone 78123275327 epsom surrey kt19 9qq bp 87 ben arous fax 78123275323 phone 441372737159 phone 21679397014 russiasartoriuscom fax 441372726171 fax 21679397019 uksartoriussartoriusstedimcom infosartoriusstedimcom spain sartorius stedim lab ltd sartorius stedim biotech sarl sartorius stedim spain sa unit 6 km 24 route de zaghouan cisabel colbrand 10 12 oficina 6970 stonedale road mhamdia bourbiâa 1145 polígono industrial de fuencarral stonehouse gloucestershire gl10 3rq bp 87 ben arous 28050 madrid phone 441453821972 phone 21679397014 phone 34913586091 fax 441453827928 fax 21679397019 fax 34913589623 alanjohnsonsartoriusstedimcom infosartoriusstedimcom biotech_spainsartoriusstedimcom tab biosystems sartorius stedim integrated service sarl switzerland york way km 24 route de zaghouan royston herfordshire sg8 5wy mhamdia bourbiâa 1145 sartorius stedim switzerland ag phone 441763227200 bp 87 ben arous ringstrasse 24a fax 441763227201 phone 21679397014 8317 tagelswangen infotapbiosystemscom fax 21679397019 phone 41523543636 infosartoriusstedimcom fax 41523543646 biotechswitzerlandsartoriusstedimcom 198 supplementary information adresses north america latin america asia pacific usa argentina china sartorius stedim north america inc sartorius argentina sa sartorius stedim biotech beijing co ltd 5 orville drive int avalos 4251 33 yu road tianzhu airport bohemia new york 11716 b1605ecs munro industrial park zone b phone 16312544249 buenos aire shun yi district 101300 beijing fax 16312544264 phone 541147210505 phone 861080426516 infosartoriusstedimcom fax 541147622333 fax 861080426580 sartoriussartoriuscomar enquirycnsartoriusstedimcom tap biosystems 20 montchanin road brazil india greenville de 19807 phone 13024789060 sartorius brasil ltda sartorius stedim india pvt ltd fax 1 3024789575 avenida senador vergueiro 2962 692 693 jakkasandra infotapbiosystemscom são bernardo campo kunigal road cep 09600 004 sp nelamangala bangalore 562123 puerto rico phone 551143628900 phone 918043505250 fax 551143628901 fax 918043505255 sartorius stedim filter inc sartoriussartoriuscombr biotechindiasartoriuscom carretera 128 int 376 barriada arturo lluveras mexico japan po box 6 yauco puerto rico 00698 sartorius de méxico sa de cv sartorius stedim japan kk phone 17878565020 circuito circunvalación poniente 149 4th floor daiwa shinagawa north bldg fax 17878567945 ciudad satélite 1 8 11 kitashinagawa shinagawaku marcoslopezsartoriuscom 53100 naucalpan estado de méxico tokyo 140 0001 phone 525555621102 phone 81337405407 fax 525555622942 fax 81337405406 sartoriussartomexcommx infosartoriuscojp malaysia sartorius stedim malaysia sdn bhd lot l3 e 3b enterprise 4 technology park malaysia bukit jalil 57000 kuala lumpur phone 60389960622 fax 60389960755 ehtansartoriuscommy supplementary information adresses 199 singapore australia sartorius stedim singapore pte ltd sartorius stedim australia pty ltd 1 science park road unit 5 7 11 rodeo drive 05 08a capricorn dandenong south melbourne singapore science park ii victoria 3175 singapore 117528 phone 61387621800 phone 6568723966 fax 61387621828 fax 6567782494 infoaustraliasartoriusstedimcom chooleepangsartoriusstedimcom south korea sartorius korea biotech co ltd 8th floor solid space 220 pangyoyeokro bundanggu seongnamsi gyeonggido 463 400 phone 82316225700 fax 82316225798 infosartoriuscokr vietnam sartorius representative office unit c 17th floor tower big building 18 pham hung street dinh tu liem hanoi phone 84437955587 fax 84437955589 sartoriusvnhnvnnvn address visit website internet wwwsartoriuscom 200 supplementary information product highlight 2013 bioprocess solution sartorius stedim biotech concentrate bioprocess business pharmaceutical customer broad product portfolio company help biotech medication vaccine manufactured safely efficiently key mission optimize pharmaceutical manufacturing process primarily increasing usage singleuse product solution sartorius stedim biotech global leader filtration fermentation cell cultivation membrane chromatography fluid management biostat cultibag str cell culture medium sartopore platinum sartocheck 4 plus bag tester singleuse bioreactor system nutrient solution buffer new highly efficient filter test system checking cell culture process use production generation sterile filtration integrity singleuse bag scalable 2000 l active biopharmaceutical biopharmaceutical medium ingredient supplementary information product highlight 2012 201 local presence worldwide royston uk dublin ireland stonehouse uk epsom uk vilvoorde belgium rotterdam netherlands aubagne france lourdes france madrid spain bohemia ny usa wilmington nc usa mexico city mexico yauco puerto rico são paulo brazil buenos aire argentina sale production production sale herlev denmark goettingen germany poznan poland guxhagen germany vienna austria budapest hungary tagelswangen switzerland florence italy beijing china seoul south korea tokyo japan hanoi vietnam mohamdia tunisia bangalore india kuala lumpur malaysia singapore singapore melbourne australia financial schedule analyst conference sfaf paris france march 4 2014 annual general shareholder meeting aubagne france april 8 2014 payment dividends1 april 15 2014 publication firstquarter figure 2014 april 8 2014 publication firsthalf figure 2014 july 22 2014 publication ninemonth figure 2014 october 21 2014 publication preliminary figure fiscal 2014 january 2015 annual general shareholder meeting aubagne france april 7 2015 publication firstquarter figure 2015 april 2015 1 subject appro val annual general shareholder meeting contact petra kirchhoff andreas theisen vice president director corporate communication ir investor relation phone 495513081686 phone 495513081668 petrakirchhoffsartoriuscom andreastheisensartoriuscom publication published financial reporting system firesys sartorius stedim biotech sa michael konrad gmbh corporate communication frankfurt main germany c 91051 13781 aubagne cedex france photography peter ginter lohmar germany editorial deadline february 20 2014 published february 28 2014 translation original frenchlanguage document de référence 2013 sartorius stedim biotech sa zone industrielle le paluds avenue de jouques c 91051 13781 aubagne cedex france phone 33442845600 fax 33442845619 infosartoriusstedimcom wwwsartoriusstedimcom sartorius stedim biotech sa printed germany publication og0040e131201 order 8600000173